#BEGIN_DRUGCARD DB03461

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C21H28N7O17P3

# Chemical_IUPAC_Name:
1-[(2R,3R,4R,5S)-5-({[(S)-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxy-4-(phosphonooxy)oxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-1$l^{5}-pyridin-1-ylium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Nicotinamide adenine dinucleotide phosphate. A coenzyme composed of ribosylnicotinamide 5&#39;-phosphate (NMN) coupled by pyrophosphate linkage to the 5&#39;-phosphate adenosine 2&#39;,5&#39;-bisphosphate. It serves as an electron carrier in a number of reactions, being alternately oxidized (NADP+) and reduced (NADPH). (Dorland, 27th ed)

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2'-Monophosphoadenosine 5'-Diphosphoribose

# HET_ID:
NAP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C21H28N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1-4,7-8,10-11,13-16,20-21,29-31H,5-6H2,(H7-,22,23,24,25,32,33,34,35,36,37,38,39)/t10-,11-,13-,14-,15+,16+,20+,21+/m0/s1

# InChI_Key:
InChIKey=XJLXINKUBYWONI-XCSFTKGKSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3461

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
743.405

# Molecular_Weight_Mono:
743.075452041

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1DJL

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.81

# Predicted_LogS:
-2.2

# Predicted_Water_Solubility:
4.84e+00 g/l

# Primary_Accession_No:
DB03461

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936685

# PubChem_Substance_ID:
46507953

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02293

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=O)C1=CC=C[N+](=C1)[C@@H]1O[C@@H](CO[P@]([O-])(=O)O[P@@](O)(=O)OC[C@@H]2O[C@H]([C@H](OP(O)(O)=O)[C@H]2O)N2C=NC3=C2N=CN=C3N)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:17 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
M84991

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
fabG

# Drug_Target_10_Gene_Sequence:
Not Available

# Drug_Target_10_General_Function:
Lipid transport and metabolism

# Drug_Target_10_General_References:
1314802	Verwoert II, Verbree EC, van der Linden KH, Nijkamp HJ, Stuitje AR: Cloning, nucleotide sequence, and expression of the Escherichia coli fabD gene, encoding malonyl coenzyme A-acyl carrier protein transacylase. J Bacteriol. 1992 May;174(9):2851-7.
1556094	Rawlings M, Cronan JE Jr: The gene encoding Escherichia coli acyl carrier protein lies within a cluster of fatty acid biosynthetic genes. J Biol Chem. 1992 Mar 25;267(9):5751-4.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
3772

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
25561

# Drug_Target_10_Name:
3-oxoacyl-[acyl-carrier-protein] reductase

# Drug_Target_10_Number_of_Residues:
244

# Drug_Target_10_PDB_ID:
1Q7B

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_10_Protein_Sequence:
>3-oxoacyl-[acyl-carrier-protein] reductase
MNFEGKIALVTGASRGIGRAIAETLAARGAKVIGTATSENGAQAISDYLGANGKGLMLNV
TDPASIESVLEKIRAEFGEVDILVNNAGITRDNLLMRMKDEEWNDIIETNLSSVFRLSKA
VMRAMMKKRHGRIITIGSVVGTMGNGGQANYAAAKAGLIGFSKSLAREVASRGITVNVVA
PGFIETDMTRALSDDQRAGILAQVPAGRLGGAQEIANAVAFLASDEAAYITGETLHVNGG
MYMV

# Drug_Target_10_Reaction:
(3R)-3-hydroxyacyl-[acyl-carrier protein] + NADP+ = 3-oxoacyl-[acyl-carrier protein] + NADPH + H+

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
(3R)-3-hydroxyacyl-[acyl-carrier-protein] + NADP(+) = 3-oxoacyl-[acyl-carrier-protein] + NADPH

# Drug_Target_10_SwissProt_ID:
P0AEK2

# Drug_Target_10_SwissProt_Name:
FABG_ECOLI

# Drug_Target_10_Synonyms:
3-ketoacyl- acyl carrier protein reductase
EC 1.1.1.100

# Drug_Target_10_Theoretical_pI:
7.67

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Not Available

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
J02799

# Drug_Target_11_GenBank_ID_Protein:
146432

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
icd

# Drug_Target_11_Gene_Sequence:
>1251 bp
ATGGAAAGTAAAGTAGTTGTTCCGGCACAAGGCAAGAAGATCACCCTGCAAAACGGCAAA
CTCAACGTTCCTGAAAATCCGATTATCCCTTACATTGAAGGTGATGGAATCGGTGTAGAT
GTAACCCCAGCCATGCTGAAAGTGGTCGACGCTGCAGTCGAGAAAGCCTATAAAGGCGAG
CGTAAAATCTCCTGGATGGAAATTTACACCGGTGAAAAATCCACACAGGTTTATGGTCAG
GACGTCTGGCTGCCTGCTGAAACTCTTGATCTGATTCGTGAATATCGCGTTGCCATTAAA
GGTCCGCTGACCACTCCGGTTGGTGGCGGTATTCGCTCTCTGAACGTTGCCCTGCGCCAG
GAACTGGATCTCTACATCTGCCTGCGTCCGGTACGTTACTATCAGGGCACTCCAAGCCCG
GTTAAACACCCTGAACTGACCGATATGGTTATCTTCCGTGAAAACTCGGAAGACATTTAT
GCGGGTATCGAATGGAAAGCAGACTCTGCCGACGCCGAGAAAGTGATTAAATTCCTGCGT
GAAGAGATGGGGGTGAAGAAAATTCGCTTCCCGGAACATTGTGGTATCGGTATTAAGCCG
TGTTCGGAAGAAGGCACCAAACGTCTGGTTCGTGCAGCGATCGAATACGCAATTGCTAAC
GATCGTGACTCTGTGACTCTGGTGCACAAAGGCAACATCATGAAGTTCACCGAAGGAGCG
TTTAAAGACTGGGGCTACCAGCTGGCGCGTGAAGAGTTTGGCGGTGAACTGATCGACGGT
GGCCCGTGGCTGAAAGTTAAAAACCCGAACACTGGCAAAGAGATCGTCATTAAAGACGTG
ATTGCTGATGCATTCCTGCAACAGATCCTGCTGCGTCCGGCTGAATATGATGTTATCGCC
TGTATGAACCTGAACGGTGACTACATTTCTGACGCCCTGGCAGCGCAGGTTGGCGGTATC
GGTATCGCCCCTGGTGCAAACATCGGTGACGAATGCGCCCTGTTTGAAGCCACCCACGGT
ACTGCGCCGAAATATGCCGGTCAGGACAAAGTAAATCCTGGCTCTATTATTCTCTCCGCT
GAGATGATGCTGCGCCACATGGGTTGGACCGAAGCGGCTGACTTAATTGTTAAAGGTATG
GAAGGCGCAATCAACGCGAAAACCGTAACCTATGACTTCGAGCGTCTGATGGATGGCGCT
AAACTGCTGAAATGTTCAGAGTTTGGTGACGCGATCATCGAAAACATGTAA

# Drug_Target_11_General_Function:
Energy production and conversion

# Drug_Target_11_General_References:
10623532	Cherbavaz DB, Lee ME, Stroud RM, Koshland DE Jr: Active site water molecules revealed in the 2.1 A resolution structure of a site-directed mutant of isocitrate dehydrogenase. J Mol Biol. 2000 Jan 21;295(3):377-85.
2204109	Hurley JH, Dean AM, Sohl JL, Koshland DE Jr, Stroud RM: Regulation of an enzyme by phosphorylation at the active site. Science. 1990 Aug 31;249(4972):1012-6.
2682654	Hurley JH, Thorsness PE, Ramalingam V, Helmers NH, Koshland DE Jr, Stroud RM: Structure of a bacterial enzyme regulated by phosphorylation, isocitrate dehydrogenase. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8635-9.
3112144	Thorsness PE, Koshland DE Jr: Inactivation of isocitrate dehydrogenase by phosphorylation is mediated by the negative charge of the phosphate. J Biol Chem. 1987 Aug 5;262(22):10422-5.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.
9352899	Wang FS, Whittam TS, Selander RK: Evolutionary genetics of the isocitrate dehydrogenase gene (icd) in Escherichia coli and Salmonella enterica. J Bacteriol. 1997 Nov;179(21):6551-9.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
2302

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
45757

# Drug_Target_11_Name:
Isocitrate dehydrogenase [NADP]

# Drug_Target_11_Number_of_Residues:
416

# Drug_Target_11_PDB_ID:
1PB3

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00180	Iso_dh

# Drug_Target_11_Protein_Sequence:
>Isocitrate dehydrogenase [NADP]
MESKVVVPAQGKKITLQNGKLNVPENPIIPYIEGDGIGVDVTPAMLKVVDAAVEKAYKGE
RKISWMEIYTGEKSTQVYGQDVWLPAETLDLIREYRVAIKGPLTTPVGGGIRSLNVALRQ
ELDLYICLRPVRYYQGTPSPVKHPELTDMVIFRENSEDIYAGIEWKADSADAEKVIKFLR
EEMGVKKIRFPEHCGIGIKPCSEEGTKRLVRAAIEYAIANDRDSVTLVHKGNIMKFTEGA
FKDWGYQLAREEFGGELIDGGPWLKVKNPNTGKEIVIKDVIADAFLQQILLRPAEYDVIA
CMNLNGDYISDALAAQVGGIGIAPGANIGDECALFEATHGTAPKYAGQDKVNPGSIILSA
EMMLRHMGWTEAADLIVKGMEGAINAKTVTYDFERLMDGAKLLKCSEFGDAIIENM

# Drug_Target_11_Reaction:
(1) isocitrate + NADP+ = 2-oxoglutarate + CO2 + NADPH

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Isocitrate + NADP(+) = 2-oxoglutarate + CO(2) + NADPH

# Drug_Target_11_SwissProt_ID:
P08200

# Drug_Target_11_SwissProt_Name:
IDH_ECOLI

# Drug_Target_11_Synonyms:
EC 1.1.1.42
IDH
IDP
NADP(+)-specific ICDH
Oxalosuccinate decarboxylase

# Drug_Target_11_Theoretical_pI:
4.90

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Cytoplasm

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
AKR1B1

# Drug_Target_12_GenBank_ID_Gene:
J04795

# Drug_Target_12_GenBank_ID_Protein:
178487

# Drug_Target_12_GeneCard_ID:
AKR1B1

# Drug_Target_12_Gene_Name:
AKR1B1

# Drug_Target_12_Gene_Sequence:
>951 bp
ATGGCAAGCCGTCTCCTGCTCAACAACGGCGCCAAGATGCCCATCCTGGGGTTGGGTACC
TGGAAGTCCCCTCCAGGGCAGGTGACTGAGGCCGTGAAGGTGGCCATTGACGTCGGGTAC
CGCCACATCGACTGTGCCCATGTGTACCAGAATGAGAATGAGGTGGGGGTGGCCATTCAG
GAGAAGCTCAGGGAGCAGGTGGTGAAGCGTGAGGAGCTCTTCATCGTCAGCAAGCTGTGG
TGCACGTACCATGAGAAGGGCCTGGTGAAAGGAGCCTGCCAGAAGACACTCAGCGACCTG
AAGCTGGACTACCTGGACCTCTACCTTATTCACTGGCCGACTGGCTTTAAGCCTGGGAAG
GAATTTTTCCCATTGGATGAGTCGGGCAATGTGGTTCCCAGTGACACCAACATTCTGGAC
ACGTGGGCGGCCATGGAAGAGCTGGTGGATGAAGGGCTGGTGAAAGCTATTGGCATCTCC
AACTTCAACCATCTCCAGGTGGAGATGATCTTAAACAAACCTGGCTTGAAGTATAAGCCT
GCAGTTAACCAGATTGAGTGCCACCCATATCTCACTCAGGAGAAGTTAATCCAGTACTGC
CAGTCCAAAGGCATCGTGGTGACCGCCTACAGCCCCCTCGGCTCTCCTGACAGGCCCTGG
GCCAAGCCCGAGGACCCTTCTCTCCTGGAGGATCCCAGGATCAAGGCGATCGCAGCCAAG
CACAATAAAACTACAGCCCAGGTCCTGATCCGGTTCCCCATGCAGAGGAACTTGGTGGTG
ATCCCCAAGTCTGTGACACCAGAACGCATTGCTGAGAACTTTAAGGTCTTTGACTTTGAA
CTGAGCAGCCAGGATATGACCACCTTACTCAGCTACAACAGGAACTGGAGGGTCTGTGCC
TTGTTGAGCTGTACCTCCCACAAGGATTACCCCTTCCATGAAGAGTTTTGA

# Drug_Target_12_General_Function:
Involved in oxidoreductase activity

# Drug_Target_12_General_References:
1447221	Borhani DW, Harter TM, Petrash JM: The crystal structure of the aldose reductase.NADPH binary complex. J Biol Chem. 1992 Dec 5;267(34):24841-7.
1621098	Wilson DK, Bohren KM, Gabbay KH, Quiocho FA: An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science. 1992 Jul 3;257(5066):81-4.
1901857	Graham A, Brown L, Hedge PJ, Gammack AJ, Markham AF: Structure of the human aldose reductase gene. J Biol Chem. 1991 Apr 15;266(11):6872-7.
2111143	Grundmann U, Bohn H, Obermeier R, Amann E: Cloning and prokaryotic expression of a biologically active human placental aldose reductase. DNA Cell Biol. 1990 Apr;9(3):149-57.
2112546	Nishimura C, Matsuura Y, Kokai Y, Akera T, Carper D, Morjana N, Lyons C, Flynn TG: Cloning and expression of human aldose reductase. J Biol Chem. 1990 Jun 15;265(17):9788-92.
2492527	Morjana NA, Lyons C, Flynn TG: Aldose reductase from human psoas muscle. Affinity labeling of an active site lysine by pyridoxal 5'-phosphate and pyridoxal 5'-diphospho-5'-adenosine. J Biol Chem. 1989 Feb 15;264(5):2912-9.
2498333	Bohren KM, Bullock B, Wermuth B, Gabbay KH: The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem. 1989 Jun 5;264(16):9547-51.
2504709	Chung S, LaMendola J: Cloning and sequence determination of human placental aldose reductase gene. J Biol Chem. 1989 Sep 5;264(25):14775-7.
2510130	Graham A, Hedge PJ, Powell SJ, Riley J, Brown L, Gammack A, Carey F, Markham AF: Nucleotide sequence of cDNA for human aldose reductase. Nucleic Acids Res. 1989 Oct 25;17(20):8368.
8234324	Wilson DK, Tarle I, Petrash JM, Quiocho FA: Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9847-51.
8245005	Tarle I, Borhani DW, Wilson DK, Quiocho FA, Petrash JM: Probing the active site of human aldose reductase. Site-directed mutagenesis of Asp-43, Tyr-48, Lys-77, and His-110. J Biol Chem. 1993 Dec 5;268(34):25687-93.
8281941	Jaquinod M, Potier N, Klarskov K, Reymann JM, Sorokine O, Kieffer S, Barth P, Andriantomanga V, Biellmann JF, Van Dorsselaer A: Sequence of pig lens aldose reductase and electrospray mass spectrometry of non-covalent and covalent complexes. Eur J Biochem. 1993 Dec 15;218(3):893-903.
8343525	Liu SQ, Bhatnagar A, Ansari NH, Srivastava SK: Identification of the reactive cysteine residue in human placenta aldose reductase. Biochim Biophys Acta. 1993 Aug 7;1164(3):268-72.
8435445	Ferraretto A, Negri A, Giuliani A, De Grada L, Fuhrman Conti AM, Ronchi S: Aldose reductase is involved in long-term adaptation of EUE cells to hyperosmotic stress. Biochim Biophys Acta. 1993 Feb 17;1175(3):283-8.
9195951	Ko BC, Ruepp B, Bohren KM, Gabbay KH, Chung SS: Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J Biol Chem. 1997 Jun 27;272(26):16431-7.
9405046	Harrison DH, Bohren KM, Petsko GA, Ringe D, Gabbay KH: The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. Biochemistry. 1997 Dec 23;36(51):16134-40.

# Drug_Target_12_HGNC_ID:
HGNC:381

# Drug_Target_12_HPRD_ID:
00071

# Drug_Target_12_ID:
822

# Drug_Target_12_Locus:
7q35

# Drug_Target_12_Molecular_Weight:
35723

# Drug_Target_12_Name:
Aldose reductase

# Drug_Target_12_Number_of_Residues:
315

# Drug_Target_12_PDB_ID:
1T40

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_12_Protein_Sequence:
>Aldose reductase
ASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQE
KLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKE
FFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPA
VNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKH
NKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCAL
LSCTSHKDYPFHEEF

# Drug_Target_12_Reaction:
alditol + NAD(P)+ = aldose + NAD(P)H + H+

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies

# Drug_Target_12_SwissProt_ID:
P15121

# Drug_Target_12_SwissProt_Name:
ALDR_HUMAN

# Drug_Target_12_Synonyms:
AR
Aldehyde reductase
EC 1.1.1.21

# Drug_Target_12_Theoretical_pI:
6.99

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
M64446

# Drug_Target_13_GenBank_ID_Protein:
149631

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
zwf

# Drug_Target_13_Gene_Sequence:
>1461 bp
ATGGTTTCAGAAATCAAGACGTTAGTAACTTTCTTTGGTGGCACTGGTGACTTGGCCAAG
CGTAAGCTTTACCCATCAGTTTTCAATCTTTATAAAAAAGGCTACTTGCAAAAGCATTTT
GCCATTGTTGGAACGGCCCGTCAAGCCCTCAATGATGACGAATTCAAACAATTGGTTCGT
GATTCAATTAAAGATTTCACTGACGATCAAGCACAAGCTGAGGCGTTCATCGAACATTTC
TCATACCGTGCACACGACGTAACAGATGCTGCTTCATACGCTGTTTTAAAAGAGGCGATT
GAAGAAGCTGCCGACAAATTTGATATCGATGGCAACCGCATTTTCTATATGTCAGTTGCG
CCACGTTTCTTTGGTACAATTGCCAAATATCTTAAGTCAGAAGGCCTACTAGCTGACACT
GGTTACAACCGTTTGATGATTGAAAAGCCTTTCGGTACATCATATGACACAGCTGCCGAA
CTCCAAAATGACTTGGAAAACGCATTTGATGATAACCAACTATTCCGTATTGACCACTAC
CTTGGTAAGGAAATGGTTCAAAACATTGCTGCCCTTCGCTTTGGTAACCCAATTTTCGAT
GCTGCTTGGAACAAGGATTACATCAAGAACGTTCAAGTAACATTGTCAGAAGTCTTGGGT
GTCGAAGAACGTGCCGGCTACTATGACACAGCCGGTGCATTGCTTGACATGATTCAAAAC
CACACCATGCAAATTGTTGGTTGGTTAGCCATGGAAAAACCAGAATCATTCACTGACAAA
GACATTCGTGCCGCTAAAAACGCAGCCTTTAATGCTTTGAAGATCTATGATGAAGCAGAA
GTTAACAAATACTTTGTTCGTGCACAATATGGTGCCGGTGATTCAGCTGACTTCAAGCCA
TACCTTGAAGAATTAGACGTACCTGCTGATTCTAAAAACAATACCTTCATCGCCGGCGAA
TTGCAATTTGATTTGCCACGTTGGGAGGGTGTCCCATTCTATGTCCGTTCAGGTAAGCGC
TTAGCTGCTAAACAGACACGGGTTGATATCGTCTTTAAGGCTGGCACGTTTAACTTTGGT
TCAGAACAAGAAGCACAAGAAGCTGTCTTGTCAATTATCATTGATCCAAAGGGTGCTATC
GAATTGAAGTTGAACGCCAAGTCAGTTGAAGATGCTTTCAACACACGTACAATTGACTTA
GGTTGGACTGTATCTGACGAAGATAAGAAGAACACGCCAGAACCATACGAACGTATGATT
CACGACACTATGAATGGTGATGGCTCTAACTTCGCTGACTGGAATGGCGTTTCAATCGCT
TGGAAGTTCGTTGATGCTATTTCAGCCGTTTATACCGCAGATAAAGCACCACTTGAAACT
TACAAGTCGGGCTCAATGGGTCCTGAAGCATCCGATAAATTATTGGCTGCCAATGGTGAT
GCTTGGGTGTTTAAAGGTTAA

# Drug_Target_13_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_13_General_References:
11106478	Cosgrove MS, Gover S, Naylor CE, Vandeputte-Rutten L, Adams MJ, Levy HR: An examination of the role of asp-177 in the His-Asp catalytic dyad of Leuconostoc mesenteroides glucose 6-phosphate dehydrogenase: X-ray structure and pH dependence of kinetic parameters of the D177N mutant enzyme. Biochemistry. 2000 Dec 12;39(49):15002-11.
11106479	Vought V, Ciccone T, Davino MH, Fairbairn L, Lin Y, Cosgrove MS, Adams MJ, Levy HR: Delineation of the roles of amino acids involved in the catalytic functions of Leuconostoc mesenteroides glucose 6-phosphate dehydrogenase. Biochemistry. 2000 Dec 12;39(49):15012-21.
1304341	Lee WT, Levy HR: Lysine-21 of Leuconostoc mesenteroides glucose 6-phosphate dehydrogenase participates in substrate binding through charge-charge interaction. Protein Sci. 1992 Mar;1(3):329-34.
2071589	Lee WT, Flynn TG, Lyons C, Levy HR: Cloning of the gene and amino acid sequence for glucose 6-phosphate dehydrogenase from Leuconostoc mesenteroides. J Biol Chem. 1991 Jul 15;266(20):13028-34.
3100332	Bhadbhade MM, Adams MJ, Flynn TG, Levy HR: Sequence identity between a lysine-containing peptide from Leuconostoc mesenteroides glucose-6-phosphate dehydrogenase and an active site peptide from human erythrocyte glucose-6-phosphate dehydrogenase. FEBS Lett. 1987 Jan 26;211(2):243-6.
7881907	Rowland P, Basak AK, Gover S, Levy HR, Adams MJ: The three-dimensional structure of glucose 6-phosphate dehydrogenase from Leuconostoc mesenteroides refined at 2.0 A resolution. Structure. 1994 Nov 15;2(11):1073-87.
9485426	Cosgrove MS, Naylor C, Paludan S, Adams MJ, Levy HR: On the mechanism of the reaction catalyzed by glucose 6-phosphate dehydrogenase. Biochemistry. 1998 Mar 3;37(9):2759-67.

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
2630

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
54441

# Drug_Target_13_Name:
Glucose-6-phosphate 1-dehydrogenase

# Drug_Target_13_Number_of_Residues:
486

# Drug_Target_13_PDB_ID:
1H94

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00479	G6PD_N
PF02781	G6PD_C

# Drug_Target_13_Protein_Sequence:
>Glucose-6-phosphate 1-dehydrogenase
MVSEIKTLVTFFGGTGDLAKRKLYPSVFNLYKKGYLQKHFAIVGTARQALNDDEFKQLVR
DSIKDFTDDQAQAEAFIEHFSYRAHDVTDAASYAVLKEAIEEAADKFDIDGNRIFYMSVA
PRFFGTIAKYLKSEGLLADTGYNRLMIEKPFGTSYDTAAELQNDLENAFDDNQLFRIDHY
LGKEMVQNIAALRFGNPIFDAAWNKDYIKNVQVTLSEVLGVEERAGYYDTAGALLDMIQN
HTMQIVGWLAMEKPESFTDKDIRAAKNAAFNALKIYDEAEVNKYFVRAQYGAGDSADFKP
YLEELDVPADSKNNTFIAGELQFDLPRWEGVPFYVRSGKRLAAKQTRVDIVFKAGTFNFG
SEQEAQEAVLSIIIDPKGAIELKLNAKSVEDAFNTRTIDLGWTVSDEDKKNTPEPYERMI
HDTMNGDGSNFADWNGVSIAWKFVDAISAVYTADKAPLETYKSGSMGPEASDKLLAANGD
AWVFKG

# Drug_Target_13_Reaction:
D-glucose 6-phosphate + NADP+ = D-glucono-1,5-lactone 6-phosphate + NADPH + H+

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
D-glucose 6-phosphate + NADP(+) = D-glucono- 1,5-lactone 6-phosphate + NADPH

# Drug_Target_13_SwissProt_ID:
P11411

# Drug_Target_13_SwissProt_Name:
G6PD_LEUME

# Drug_Target_13_Synonyms:
EC 1.1.1.49
G6PD

# Drug_Target_13_Theoretical_pI:
4.57

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
AKR1C2

# Drug_Target_14_GenBank_ID_Gene:
U05598

# Drug_Target_14_GenBank_ID_Protein:
531160

# Drug_Target_14_GeneCard_ID:
AKR1C2

# Drug_Target_14_Gene_Name:
AKR1C2

# Drug_Target_14_Gene_Sequence:
>972 bp
ATGGATTCGAAATACCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGA
TTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTCTAGAGGCCGTCAAATTG
GCAATAGAAGCCGGGTTCCACCATATTGATTCTGCACATGTTTACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGAGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AGGTCACTGAAAAATCTTCAATTGGACTATGTTGACCTCTATCTTATTCATTTTCCAGTG
TCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGAC
ACAGTGGATCTCTGTGCCACGTGGGAGGCCATGGAGAAGTGTAAAGATGCAGGATTGGCC
AAGTCCATCGGGGTGTCCAACTTCAACCACAGGCTGCTGGAGATGATCCTCAACAAGCCA
GGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGA
AAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGA
TCCCATCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC
CTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC
GTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAAC
AGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCT
GATGAATATTAA

# Drug_Target_14_General_Function:
Involved in oxidoreductase activity

# Drug_Target_14_General_References:
10672042	Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S: Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000 Feb;5(2):111-25.
7959017	Qin KN, Khanna M, Cheng KC: Structure of a gene coding for human dihydrodiol dehydrogenase/bile acid-binding protein. Gene. 1994 Nov 18;149(2):357-61.
8011662	Ciaccio PJ, Tew KD: cDNA and deduced amino acid sequences of a human colon dihydrodiol dehydrogenase. Biochim Biophys Acta. 1994 Jun 28;1186(1-2):129-32.
8274401	Qin KN, New MI, Cheng KC: Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 1993 Dec;46(6):673-9.
9716498	Shiraishi H, Ishikura S, Matsuura K, Deyashiki Y, Ninomiya M, Sakai S, Hara A: Sequence of the cDNA of a human dihydrodiol dehydrogenase isoform (AKR1C2) and tissue distribution of its mRNA. Biochem J. 1998 Sep 1;334 ( Pt 2):399-405.

# Drug_Target_14_HGNC_ID:
HGNC:385

# Drug_Target_14_HPRD_ID:
11857

# Drug_Target_14_ID:
686

# Drug_Target_14_Locus:
10p15-p14

# Drug_Target_14_Molecular_Weight:
36736

# Drug_Target_14_Name:
Aldo-keto reductase family 1 member C2

# Drug_Target_14_Number_of_Residues:
323

# Drug_Target_14_PDB_ID:
1IHI

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_14_Protein_Sequence:
>Aldo-keto reductase family 1 member C2
MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHIDSAHVYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLDYVDLYLIHFPV
SVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNHRLLEMILNKP
GLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLN
RNVRYLTLDIFAGPPNYPFSDEY

# Drug_Target_14_Reaction:
androsterone + NAD(P)+ = 5alpha-androstane-3,17-dione + NAD(P)H + H+

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Works in concert with the 5alpha/5beta-steroid reductases to convert steroid hormones into the 3alpha/5alpha and 3alpha/5beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5alpha-DHT) to 5-alpha-androstane-3alpha,17beta-diol (3-alpha-diol)

# Drug_Target_14_SwissProt_ID:
P52895

# Drug_Target_14_SwissProt_Name:
AK1C2_HUMAN

# Drug_Target_14_Synonyms:
3-alpha-HSD3
Chlordecone reductase homolog HAKRD
DD/BABP
DD2
Dihydrodiol dehydrogenase 2
Dihydrodiol dehydrogenase/bile acid-binding protein
EC 1.-.-.-
EC 1.1.1.213
EC 1.3.1.20
Trans-1,2- dihydrobenzene-1,2-diol dehydrogenase
Type III 3- alpha-hydroxysteroid dehydrogenase

# Drug_Target_14_Theoretical_pI:
7.55

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Cytoplasm

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
HSD17B1

# Drug_Target_15_GenBank_ID_Gene:
X13440

# Drug_Target_15_GenBank_ID_Protein:
23365

# Drug_Target_15_GeneCard_ID:
HSD17B1

# Drug_Target_15_Gene_Name:
HSD17B1

# Drug_Target_15_Gene_Sequence:
>987 bp
ATGGCCCGCACCGTGGTGCTCATCACCGGCTGTTCCTCGGGCATCGGCCTGCACTTGGCC
GTACGTCTGGCTTCAGATCCATCCCAGAGCTTCAAAGTGTATGCCACGTTGAGGGACCTG
AAAACACAGGGCCGGCTGTGGGAGGCGGCCCGGGCCCTGGCATGCCCTCCGGGATCCCTG
GAGACGTTGCAGCTGGACGTAAGGGACTCAAAATCCGTGGCCGCTGCCCGGGAACGCGTG
ACTGAGGGCCGCGTGGACGTGCTGGTGTGTAACGCAGGCCTGGGCCTGCTGGGGCCGCTG
GAGGCGCTGGGGGAGGACGCCGTGGCCTCTGTGCTGGACGTGAATGTAGTAGGGACTGTG
CGGATGCTGCAGGCCTTCCTGCCAGACATGAAGAGGCGCGGTTCGGGACGCGTGTTGGTG
ACCGGGAGCGTGGGAGGATTGATGGGGCTGCCTTTCAATGACGTTTATTGCGCCAGCAAG
TTCGCGCTCGAAGGCTTATGCGAGAGTCTGGCGGTTCTGCTGCTGCCCTTTGGGGTCCAC
TTGAGCCTGATCGAGTGCGGCCCAGTGCACACCGCCTTCATGGAGAAGGTGTTGGGCAGC
CCAGAGGAGGTGCTGGACCGCACGGACATCCACACCTTCCACCGCTTCTACCAATACCTC
GCCCACAGCAAGCAAGTCTTTCGCGAGGCGGCGCAGAACCCTGAGGAGGTGGCGGAGGTC
TTCCTCACCGCTTTGCGCGCCCCGAAGCCGACCCTGCGCTACTTCACCACCGAGCGCTTC
CTGCCCCTGCTGCGGATGCGCCTGGACGACCCCAGCGGCTCCAACTACGTCACCGCCATG
CACCGGGAAGTGTTCGGCGACGTTCCGGCAAAGGCCGAGGCTGGGGCCGAGGCTGGGGGC
GGGGCCGGGCCTGGGGCAGAGGACGAGGCCGGGCGCAGTGCGGTGGGGGACCCTGAGCTC
GGCGATCCTCCGGCCGCCCCGCAGTAA

# Drug_Target_15_General_Function:
Lipid transport and metabolism

# Drug_Target_15_General_References:
10625652	Han Q, Campbell RL, Gangloff A, Huang YW, Lin SX: Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/c-19 steroid discrimination and enzyme-induced strain. J Biol Chem. 2000 Jan 14;275(2):1105-11.
1327779	Peltoketo H, Isomaa V, Vihko R: Genomic organization and DNA sequences of human 17 beta-hydroxysteroid dehydrogenase genes and flanking regions. Localization of multiple Alu sequences and putative cis-acting elements. Eur J Biochem. 1992 Oct 1;209(1):459-66.
2197970	Luu-The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Cote J, Leblanc G, Lagace L, Berube D, et al.: Purification, cloning, complementary DNA structure, and predicted amino acid sequence of human estradiol 17 beta-dehydrogenase. Ann N Y Acad Sci. 1990;595:40-52.
2330005	Luu-The V, Labrie C, Simard J, Lachance Y, Zhao HF, Couet J, Leblanc G, Labrie F: Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes. Mol Endocrinol. 1990 Feb;4(2):268-75.
2547159	Baker ME: Human placental 17 beta-hydroxysteroid dehydrogenase is homologous to NodG protein of Rhizobium meliloti. Mol Endocrinol. 1989 May;3(5):881-4.
2779584	Luu The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Leblanc G, Cote J, Berube D, Gagne R, et al.: Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta. Mol Endocrinol. 1989 Aug;3(8):1301-9.
2846351	Peltoketo H, Isomaa V, Maentausta O, Vihko R: Complete amino acid sequence of human placental 17 beta-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Lett. 1988 Oct 24;239(1):73-7.
3955020	Galdes A, Auld DS, Vallee BL: Elucidation of the chemical nature of the steady-state intermediates in the mechanism of carboxypeptidase A. Biochemistry. 1986 Feb 11;25(3):646-51.
4719204	Nicolas JC, Harris JI: Human placental 17 -oestradiol dehydrogenase. Sequence of a tryptic peptide containing an essential cysteine. FEBS Lett. 1973 Jan 15;29(2):173-6.
5045524	Burns DJ, Engel LL, Bethune JL: Amino acid composition and subunit structure. Human placental 17 -estradiol dehydrogenase. Biochemistry. 1972 Jul 4;11(14):2699-703.
6578212	Murdock GL, Chin CC, Offord RE, Bradshaw RA, Warren JC: Human placental estradiol 17 beta-dehydrogenase. Identification of a single histidine residue affinity-labeled by both 3-bromoacetoxyestrone and 12 beta-bromoacetoxy-4-estrene-3,17-dione. J Biol Chem. 1983 Oct 10;258(19):11460-4.
7663947	Ghosh D, Pletnev VZ, Zhu DW, Wawrzak Z, Duax WL, Pangborn W, Labrie F, Lin SX: Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution. Structure. 1995 May 15;3(5):503-13.
8389226	Normand T, Narod S, Labrie F, Simard J: Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. Hum Mol Genet. 1993 Apr;2(4):479-83.
8805577	Breton R, Housset D, Mazza C, Fontecilla-Camps JC: The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Structure. 1996 Aug 15;4(8):905-15.
9525918	Mazza C, Breton R, Housset D, Fontecilla-Camps JC: Unusual charge stabilization of NADP+ in 17beta-hydroxysteroid dehydrogenase. J Biol Chem. 1998 Apr 3;273(14):8145-52.

# Drug_Target_15_HGNC_ID:
HGNC:5210

# Drug_Target_15_HPRD_ID:
00185

# Drug_Target_15_ID:
217

# Drug_Target_15_Locus:
17q11-q21

# Drug_Target_15_Molecular_Weight:
34849

# Drug_Target_15_Name:
Estradiol 17-beta-dehydrogenase 1

# Drug_Target_15_Number_of_Residues:
327

# Drug_Target_15_PDB_ID:
1QYX

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_15_Protein_Sequence:
>Estradiol 17-beta-dehydrogenase 1
ARTVVLITGCSSGIGLHLAVRLASDPSQSFKVYATLRDLKTQGRLWEAARALACPPGSLE
TLQLDVRDSKSVAAARERVTEGRVDVLVCNAGLGLLGPLEALGEDAVASVLDVNVVGTVR
MLQAFLPDMKRRGSGRVLVTGSVGGLMGLPFNDVYCASKFALEGLCESLAVLLLPFGVHL
SLIECGPVHTAFMEKVLGSPEEVLDRTDIHTFHRFYQYLAHSKQVFREAAQNPEEVAEVF
LTALRAPKPTLRYFTTERFLPLLRMRLDDPSGSNYVTAMHREVFGDVPAKAEAGAEAGGG
AGPGAEDEAGRSAVGDPELGDPPAAPQ

# Drug_Target_15_Reaction:
estradiol-17beta + NAD(P)+ = estrone + NAD(P)H + H+

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH

# Drug_Target_15_SwissProt_ID:
P14061

# Drug_Target_15_SwissProt_Name:
DHB1_HUMAN

# Drug_Target_15_Synonyms:
17-beta- hydroxysteroid dehydrogenase type 1
17-beta-HSD 1
20 alpha-hydroxysteroid dehydrogenase
20-alpha-HSD
E2DH
EC 1.1.1.62
Placental 17- beta-hydroxysteroid dehydrogenase

# Drug_Target_15_Theoretical_pI:
5.42

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Mitochondrion
matrix side (Potential)
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
NNT

# Drug_Target_16_GenBank_ID_Gene:
U40490

# Drug_Target_16_GenBank_ID_Protein:
1110520

# Drug_Target_16_GeneCard_ID:
NNT

# Drug_Target_16_Gene_Name:
NNT

# Drug_Target_16_Gene_Sequence:
>3261 bp
ATGGCAAACCTATTGAAAACAGTGGTGACTGGCTGCTCGTGTCCTCTACTTAGCAATTTG
GGGTCCTGTAAGGGTCTACGTGTGAAGAAGGATTTTTTACGAACATTTTATACTCACCAA
GAACTGTGGTGTAAAGCGCCTGTAAAACCAGGAATTCCATATAAGCAACTGACTGTTGGA
GTCCCCAAAGAGATATTCCAAAATGAGAAGCGAGTGGCATTGTCTCCTGCTGGTGTTCAG
AACTTGGTCAAGCAGGGTTTTAATGTTGTCGTGGAATCGGGTGCGGGCGAAGCTTCCAAG
TTCTCAGATGATCACTATAGAGTGGCAGGTGCCCAAATCCAAGGGGCAAAGGAAGTGCTG
GCTTCTGATTTGGTGGTCAAAGTGCGAGCCCCTATGGTTAATCCAACATTAGGTGTTCAT
GAAGCTGACCTTTTAAAGACATCAGGAACGCTGATTAGTTTTATTTACCCAGCCCAAAAT
CCAGAGTTGCTAAATAAACTTTCCCAAAGAAAAACTACAGTTCTGGCAATGGACCAGGTT
CCAAGAGTCACAATTGCTCAGGGATATGATGCGCTAAGCTCCATGGCCAACATTGCGGGT
TATAAGGCTGTTGTCCTAGCAGCAAATCATTTTGGACGTTTTTTTACTGGTCAGATCACA
GCTGCTGGAAAAGTTCCTCCAGCTAAGATTCTGATAGTTGGTGGTGGTGTTGCTGGGCTT
GCTTCTGCAGGCGCCGAAAAGTCGATGGGTGCAATTGTTCGAGGATTTGACACAAGAGCT
GCCAGTTTGGAACAGTTCAAGTCTCTTGGTGCTGAGCCCTTGGAGGTGGACTTGAAGGAA
TCTGGTGAGGGACAAGGAGGATATGCAAAAGAGATGTCCAAAGAGTTCATTGAAGCTGAA
ATGAAACTCTTTGCTCAACAATGCAAGGAGGTAGACATCCTTATCAGCACAGCACTTATT
CCAGGTAAAAAAGCTCCAGTTTTATTTAATAAAGAAATGATTGAGTCAATGAAGGAAGGT
TCAGTTGTTGTGGATTTAGCTGCTGAGGCTGGTGGAAACTTTGAAACCACTAAGCCAGGA
GAACTCTACATTCATAAGGGAATTACTCACATAGGCTACACAGACCTGCCCAGCCGAATG
GCCACTCAGGCCAGCACCCTATATTCCAACAACATCACCAAACTCCTGAAGGCCATCAGC
CCGGACAAAGATAATTTTTATTTTGATGTGAAAGATGACTTTGACTTTGGTACGATGGGT
CATGTCATTAGAGGAACTGTAGTGATGAAAGATGGTAAAGTGATTTTCCCAGCTCCCACA
CCGAAAAATATTCCTCAAGGTGCCCCAGTAAAACAGAAGACAGTGGCTGAGCTGGAAGCT
GAAAAAGCAGCTACCATTACACCCTTCAGGAAGACAATGTCAACGGCTTCTGCATATACA
GCAGGTCTCACAGGGATACTGGGTTTGGGCATTGCGGCTCCCAATCTAGCCTTTTCTCAG
ATGGTGACCACTTTTGGCTTGGCTGGCATTGTGGGGTATCATACCGTCTGGGGAGTGACC
CCTGCTCTCCACTCACCACTGATGTCTGTGACAAATGCAATCTCAGGGCTGACTGCAGTT
GGTGGGTTGGCACTGATGGGAGGACATTTGTATCCTTCCACAACTTCTCAGGGCCTTGCT
GCTCTTGCTGCATTCATATCCTCTGTCAACATTGCAGGTGGCTTTCTGGTGACTCAGAGA
ATGCTGGACATGTTCAAGCGTCCCACTGACCCCCCAGAATACAACTACCTGTACCTGCTC
CCTGCCGGCACCTTTGTTGGTGGATATTTAGCTGCCCTCTACAGTGGTTATAACATTGAA
CAGATCATGTACCTAGGCTCGGGTTTGTGCTGTGTCGGTGCCTTGGCTGGCCTCTCCACC
CAGGGAACAGCACGTCTTGGCAATGCACTGGGCATGATTGGGGTTGCTGGAGGACTGGCA
GCCACCCTCGGAGTCCTAAAACCGGGCCCAGAATTACTAGCTCAGATGTCTGGAGCGATG
GCTTTGGGTGGTACCATTGGATTGACAATTGCCAAACGCATCCAGATTTCTGATTTACCT
CAATTAGTTGCTGCTTCACACAGTTTAGTGGGTTTGGCAGCTGTACTTACTTGCATAGCT
GAGTACATTATAGAATATCCACATTTTGCTCCGGATGCAGCAGCAAATCTCACCAAGATT
GTGGCCTACCTCGGCACTTACATTGGTGGCGTCACCTTTAGTGGGTCTCTCATTGCCTAT
GGAAAATTGCAGGGTCTCCTGAAATCTGCCCCTCTCCTACTGCCTGGAAGGCACTTACTC
AATGCAGGCTTACTGGCTGCTAGTGTGGGCGGGATAATCCCATTCATGGTGGACCCAAGC
TTTACTACTGGCATCACCTGTCTGGGTTCAGTGTCTGCTCTCTCTGCTGTCATGGGTGTG
ACTTTGACAGCTGCTATTGGGGGTGCTGACATGCCCGTCGTTATCACTGTGCTGAACAGC
TACTCAGGCTGGGCCCTGTGTGCAGAGGGCTTCCTGCTCAACAACAATCTGCTGACCATC
GTGGGTGCACTCATAGGCTCGTCTGGTGCTCCCCTGTCATACATCATGTGTGTGGCAATG
AATCGCTCCCTGGCTAATGTGATTCTTGGAGGCTATGGCACCACTTCAACAGCTGGTGGA
AAACCCATGGAAATTTCTGGCACACATACGGAAATCAACCTTGACAATGCAATTGACATG
ATTCGAGAAGCTAATAGCATTATTTTTACACCAGGCTATGGTCTCTGTGCAGCCAAAGCT
CAATACCCCATTGCTGATTTGGTAAAGATGCTCACTGAGCAAGGCAAAAAAGTCAGGTTT
GGAATTCACCCAGTTGCAGGCCGAATGCCTGGTCAGCTTAATGTGCTGCTGGCTGAGGCT
GGTGTGCCATATGACATTGTGTTGGAAATGGATGAGATCAACCATGATTTTCCAGATACT
GATTTGGTCCTTGTAATTGGAGCTAATGACACTGTTAATTCAGCAGCTCAAGAAGATCCC
AACTCTATTATTGCAGGCATGCCAGTCCTTGAGGTCTGGAAATCAAAGCAGGTGATTGTT
ATGAAGAGGTCTTTGGGTGTTGGCTATGCTGCAGTGGACAATCCAATCTTCTACAAACCT
AACACGGCCATGCTTCTAGGTGATGCCAAGAAAACATGTGACGCGCTCCAGGCGAAAGTT
AGAGAATCCTATCAGAAGTAA

# Drug_Target_16_General_Function:
Energy production and conversion

# Drug_Target_16_General_References:
10673423	White SA, Peake SJ, McSweeney S, Leonard G, Cotton NP, Jackson JB: The high-resolution structure of the NADP(H)-binding component (dIII) of proton-translocating transhydrogenase from human heart mitochondria. Structure. 2000 Jan 15;8(1):1-12.
8616157	Arkblad EL, Betsholtz C, Rydstrom J: The cDNA sequence of proton-pumping nicotinamide nucleotide transhydrogenase from man and mouse. Biochim Biophys Acta. 1996 Mar 28;1273(3):203-5.
9524818	Zieger B, Ware J: Cloning and deduced amino acid sequence of human nicotinamide nucleotide transhydrogenase. DNA Seq. 1997;7(6):369-73.

# Drug_Target_16_HGNC_ID:
HGNC:7863

# Drug_Target_16_HPRD_ID:
09715

# Drug_Target_16_ID:
11

# Drug_Target_16_Locus:
5p13.1-5cen

# Drug_Target_16_Molecular_Weight:
113897

# Drug_Target_16_Name:
NAD(P) transhydrogenase, mitochondrial

# Drug_Target_16_Number_of_Residues:
1086

# Drug_Target_16_PDB_ID:
1PT9

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF01262	AlaDh_PNT_C
PF02233	PNTB
PF05222	AlaDh_PNT_N

# Drug_Target_16_Protein_Sequence:
>NAD(P) transhydrogenase, mitochondrial precursor
MANLLKTVVTGCSCPLLSNLGSCKGLRVKKDFLRTFYTHQELWCKAPVKPGIPYKQLTVG
VPKEIFQNEKRVALSPAGVQNLVKQGFNVVVESGAGEASKFSDDHYRVAGAQIQGAKEVL
ASDLVVKVRAPMVNPTLGVHEADLLKTSGTLISFIYPAQNPELLNKLSQRKTTVLAMDQV
PRVTIAQGYDALSSMANIAGYKAVVLAANHFGRFFTGQITAAGKVPPAKILIVGGGVAGL
ASAGAAKSMGAIVRGFDTRAAALEQFKSLGAEPLEVDLKESGEGQGGYAKEMSKEFIEAE
MKLFAQQCKEVDILISTALIPGKKAPVLFNKEMIESMKEGSVVVDLAAEAGGNFETTKPG
ELYIHKGITHIGYTDLPSRMATQASTLYSNNITKLLKAISPDKDNFYFDVKDDFDFGTMG
HVIRGTVVMKDGKVIFPAPTPKNIPQGAPVKQKTVAELEAEKAATITPFRKTMSTASAYT
AGLTGILGLGIAAPNLAFSQMVTTFGLAGIVGYHTVWGVTPALHSPLMSVTNAISGLTAV
GGLALMGGHLYPSTTSQGLAALAAFISSVNIAGGFLVTQRMLDMFKRPTDPPEYNYLYLL
PAGTFVGGYLAALYSGYNIEQIMYLGSGLCCVGALAGLSTQGTARLGNALGMIGVAGGLA
ATLGVLKPGPELLAQMSGAMALGGTIGLTIAKRIQISDLPQLVAAFHSLVGLAAVLTCIA
EYIIEYPHFATDAAANLTKIVAYLGTYIGGVTFSGSLIAYGKLQGLLKSAPLLLPGRHLL
NAGLLAASVGGIIPFMVDPSFTTGITCLGSVSALSAVMGVTLTAAIGGADMPVVITVLNS
YSGWALCAEGFLLNNNLLTIVGALIGSSGAILSYIMCVAMNRSLANVILGGYGTTSTAGG
KPMEISGTHTEINLDNAIDMIREANSIIITPGYGLCAAKAQYPIADLVKMLTEQGKKVRF
GIHPVAGRMPGQLNVLLAEAGVPYDIVLEMDEINHDFPDTDLVLVIGANDTVNSAAQEDP
NSIIAGMPVLEVWKSKQVIVMKRSLGVGYAAVDNPIFYKPNTAMLLGDAKKTCDALQAKV
RESYQK

# Drug_Target_16_Reaction:
NADPH + NAD+ = NADP+ + NADH

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane

# Drug_Target_16_SwissProt_ID:
Q13423

# Drug_Target_16_SwissProt_Name:
NNTM_HUMAN

# Drug_Target_16_Synonyms:
EC 1.6.1.2
NAD(P) transhydrogenase, mitochondrial precursor
Nicotinamide nucleotide transhydrogenase
Pyridine nucleotide transhydrogenase

# Drug_Target_16_Theoretical_pI:
8.21

# Drug_Target_16_Transmembrane_Regions:
475-493
501-521
527-546
558-578
596-616
622-642
646-666
672-691
702-722
740-760
778-797
801-819
833-853
857-879

# Drug_Target_17_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass type II membrane protein

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
HSD11B1

# Drug_Target_17_GenBank_ID_Gene:
M76665

# Drug_Target_17_GenBank_ID_Protein:
179475

# Drug_Target_17_GeneCard_ID:
HSD11B1

# Drug_Target_17_Gene_Name:
HSD11B1

# Drug_Target_17_Gene_Sequence:
>879 bp
ATGGCTTTTATGAAAAAATATCTCCTCCCCATTCTGGGGCTCTTCATGGCCTACTACTAC
TATTCTGCAAACGAGGAATTCAGACCAGAGATGCTCCAAGGAAAGAAAGTGATTGTCACA
GGGGCCAGCAAAGGGATCGGAAGAGAGATGGCTTATCATCTGGCGAAGATGGGAGCCCAT
GTGGTGGTGACAGCGAGGTCAAAAGAAACTCTACAGAAGGTGGTATCCCACTGCCTGGAG
CTTGGAGCAGCCTCAGCACACTACATTGCTGGCACCATGGAAGACATGACCTTCGCAGAG
CAATTTGTTGCCCAAGCAGGAAAGCTCATGGGAGGACTAGACATGCTCATTCTCAACCAC
ATCACCAACACTTCTTTGAATCTTTTTCATGATGATATTCACCATGTGCGCAAAAGCATG
GAAGTCAACTTCCTCAGTTACGTGGTCCTGACTGTAGCTGCCTTGCCCATGCTGAAGCAG
AGCAATGGAAGCATTGTTGTCGTCTCCTCTCTGGCTGGGAAAGTGGCTTATCCAATGGTT
GCTGCCTATTCTGCAAGCAAGTTTGCTTTGGATGGGTTCTTCTCCTCCATCAGAAAGGAA
TATTCAGTGTCCAGGGTCAATGTATCAATCACTCTCTGTGTTCTTGGCCTCATAGACACA
GAAACAGCCATGAAGGCAGTTTCTGGGATAGTCCATATGCAAGCAGCTCCAAAGGAGGAA
TGTGCCCTGGAGATCATCAAAGGGGGAGCTCTGCGCCAAGAAGAAGTGTATTATGACAGC
TCACTCTGGACCACTCTTCTGATCAGAAATCCATGCAGGAAGATCCTGGAATTTCTCTAC
TCAACGAGCTATAATATGGACAGATTCATAAACAAGTAG

# Drug_Target_17_General_Function:
Lipid transport and metabolism

# Drug_Target_17_General_References:
1885595	Tannin GM, Agarwal AK, Monder C, New MI, White PC: The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem. 1991 Sep 5;266(25):16653-8.

# Drug_Target_17_HGNC_ID:
HGNC:5208

# Drug_Target_17_HPRD_ID:
07042

# Drug_Target_17_ID:
364

# Drug_Target_17_Locus:
1q32-q41

# Drug_Target_17_Molecular_Weight:
32270

# Drug_Target_17_Name:
Corticosteroid 11-beta-dehydrogenase isozyme 1

# Drug_Target_17_Number_of_Residues:
291

# Drug_Target_17_PDB_ID:
1XU9

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_17_Protein_Sequence:
>Corticosteroid 11-beta-dehydrogenase isozyme 1
AFMKKYLLPILGLFMAYYYYSANEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHV
VVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHI
TNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVA
AYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEEC
ALEIIKGGALRQEEVYYDSSLWTTLLIRNPCRKILEFLYSTSYNMDRFINK

# Drug_Target_17_Reaction:
an 11beta-hydroxysteroid + NADP+ = an 11-oxosteroid + NADPH + H+

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7- ketocholesterol to 7-beta-hydroxycholesterol

# Drug_Target_17_SwissProt_ID:
P28845

# Drug_Target_17_SwissProt_Name:
DHI1_HUMAN

# Drug_Target_17_Synonyms:
11-DH
11-beta-HSD1
11-beta-hydroxysteroid dehydrogenase 1
EC 1.1.1.146

# Drug_Target_17_Theoretical_pI:
8.77

# Drug_Target_17_Transmembrane_Regions:
7-23

# Drug_Target_18_Cellular_Location:
Cytoplasm

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
SPR

# Drug_Target_18_GenBank_ID_Gene:
M76231

# Drug_Target_18_GenBank_ID_Protein:
338021

# Drug_Target_18_GeneCard_ID:
SPR

# Drug_Target_18_Gene_Name:
SPR

# Drug_Target_18_Gene_Sequence:
>786 bp
ATGGAGGGCGGGCTGGGGCGTGCTGTGTGCTTGCTGACCGGGGCCTCCCGCGGCTTCGGC
CGGACGCTGGCCCCGCTCCTGGCCTCGCTGCTGTCGCCCGGCTCCGTGCTTGTCCTTAGC
GCCCGCAACGACGAGGCACTGCGCCAGCTGGAGGCCGAGCTGGGCGCCGAGCGGTCTGGC
CTGCGCGTGGTGCGGGTGCCCGCCGACCTGGGCGCCGAGGCCGGCTTGCAGCAGCTGCTC
GGCGCCCTGCGCGAGCTCCCCCGGCCCAAGGGGCTGCAGCGACTGCTGCTTATCAACAAC
GCGGGCTCTCTTGGGGATGTGTCCAAAGGCTTCGTGGACCTGAGTGACTCCACTCAAGTG
AACAACTACTGGGCACTGAACTTGACCTCCATGCTCTGCCTGACTTCCAGCGTCCTGAAG
GCCTTCCCGGACAGTCCTGGCCTCAACAGAACCGTGGTTAACATCTCGTCCCTCTGTGCC
CTGCAACCTTTCAAAGGCTGGGCGCTGTACTGTGCAGGAAAGGCTGCTCGTGATATGCTG
TTCCAGGTCCTGGCGCTGGAGGAACCTAATGTGAGGGTGCTGAACTATGCCCCAGGTCCT
CTGGACACAGACATGCAGCAGTTGGCCCGGGAGACCTCCGTGGACCCAGACATGCGAAAA
GGGCTGCAGGAGCTGAAGGCAAAGGGGAAGCTGGTGGATTGCAAGGTGTCAGCCCAGAAA
CTGCTGAGCTTACTGGAAAAGGACGAGTTCAAGTCTGGAGCCCACGTGGACTTCTATGAC
AAATAA

# Drug_Target_18_General_Function:
Lipid transport and metabolism

# Drug_Target_18_General_References:
11825621	Fujimoto K, Takahashi SY, Katoh S: Mutational analysis of sites in sepiapterin reductase phosphorylated by Ca2+/calmodulin-dependent protein kinase II. Biochim Biophys Acta. 2002 Jan 31;1594(1):191-8.
1883349	Ichinose H, Katoh S, Sueoka T, Titani K, Fujita K, Nagatsu T: Cloning and sequencing of cDNA encoding human sepiapterin reductase--an enzyme involved in tetrahydrobiopterin biosynthesis. Biochem Biophys Res Commun. 1991 Aug 30;179(1):183-9.
8440319	Maier J, Schott K, Werner T, Bacher A, Ziegler I: Detection of a novel sepiapterin reductase mRNA: assay of mRNA in various cells and tissues of various species. Exp Cell Res. 1993 Feb;204(2):217-22.

# Drug_Target_18_HGNC_ID:
HGNC:11257

# Drug_Target_18_HPRD_ID:
01632

# Drug_Target_18_ID:
1124

# Drug_Target_18_Locus:
2p14-p12

# Drug_Target_18_Molecular_Weight:
28049

# Drug_Target_18_Name:
Sepiapterin reductase

# Drug_Target_18_Number_of_Residues:
261

# Drug_Target_18_PDB_ID:
1Z6Z

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_18_Protein_Sequence:
>Sepiapterin reductase
MEGGLGRAVCLLTGASRGFGRTLAPLLASLLSPGSVLVLSARNDEALRQLEAELGAERSG
LRVVRVPADLGAEAGLQQLLGALRELPRPKGLQRLLLINNAGSLGDVSKGFVDLSDSTQV
NNYWALNLTSMLCLTSSVLKAFPDSPGLNRTVVNISSLCALQPFKGWALYCAGKAARDML
FQVLALEEPNVRVLNYAPGPLDTDMQQLARETSVDPDMRKGLQELKAKGKLVDCKVSAQK
LLSLLEKDEFKSGAHVDFYDK

# Drug_Target_18_Reaction:
7,8-dihydrobiopterin + NADP+ = sepiapterin + NADPH + H+

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Catalyzes the final one or two reductions in tetra- hydrobiopterin biosynthesis to form 5,6,7,8-tetrahydrobiopterin

# Drug_Target_18_SwissProt_ID:
P35270

# Drug_Target_18_SwissProt_Name:
SPRE_HUMAN

# Drug_Target_18_Synonyms:
EC 1.1.1.153
SPR

# Drug_Target_18_Theoretical_pI:
8.19

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Not Available

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
Not Available

# Drug_Target_19_GenBank_ID_Gene:
L01699

# Drug_Target_19_GenBank_ID_Protein:
13929426

# Drug_Target_19_GeneCard_ID:
Not Available

# Drug_Target_19_Gene_Name:
PTR1

# Drug_Target_19_Gene_Sequence:
>867 bp
ATGACTGCTCCGACCGTGCCGGTGGCGTTGGTAACAGGCGCCGCGAAGCGTCTTGGCCGC
AGTATCGCTGAGGGACTCCACGCGGAGGGGTACGCTGTCTGCTTGCACTATCATCGCTCT
GCTGCAGAAGCGAACGCACTATCCGCGACGCTCAACGCAAGGCGACCGAACAGCGCCATC
ACGGTGCAGGCGGATCTGAGCAACGTTGCCACAGCCCCGGTCAGCGGCGCTGATGGCTCT
GCACCTGTTACCCTCTTCACGCGCTGTGCTGAGTTGGTGGCTGCGTGCTACACCCACTGG
GGACGCTGCGACGTGCTAGTGAACAACGCCTCTTCTTTCTACCCCACGCCGCTGCTGAGG
AATGACGAGGATGGACACGAGCCCTGTGTCGGAGATAGAGAGGCAATGGAGACGGCCACC
GCTGACCTCTTCGGCTCCAACGCGATAGCGCCCTACTTCTTGATTAAGGCGTTCGCGCAT
CGCTTCGCGGGCACCCCAGCCAAGCATCGCGGCACCAACTACTCCATCATCAACATGGTC
GACGCCATGACGAACCAGCCTCTTCTCGGGTACACCATATATACCATGGCCAAAGGGGCG
TTGGAGGGGCTGACACGGTCTGCCGCGCTGGAGCTTGCGCCGCTGCAGATTCGAGTGAAC
GGCGTTGGTCCGGGTTTGTCGGTGCTCGTCGATGACATGCCCCCTGCTGTGTGGGAGGGC
CACCGCAGCAAGGTGCCTCTGTACCAGCGCGATTCCTCCGCCGCAGAGGTGAGCGACGTT
GTTATCTTTCTGTGCTCCTCCAAGGCCAAGTACATCACCGGCACCTGTGTCAAAGTGGAT
GGTGGCTACAGCCTTACCCGGGCCTGA

# Drug_Target_19_General_Function:
Lipid transport and metabolism

# Drug_Target_19_General_References:
1339441	Callahan HL, Beverley SM: A member of the aldoketo reductase family confers methotrexate resistance in Leishmania. J Biol Chem. 1992 Dec 5;267(34):24165-8.
7972081	Bello AR, Nare B, Freedman D, Hardy L, Beverley SM: PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11442-6.
9153248	Nare B, Hardy LW, Beverley SM: The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. J Biol Chem. 1997 May 23;272(21):13883-91.
9521731	Luba J, Nare B, Liang PH, Anderson KS, Beverley SM, Hardy LW: Leishmania major pteridine reductase 1 belongs to the short chain dehydrogenase family: stereochemical and kinetic evidence. Biochemistry. 1998 Mar 24;37(12):4093-104.

# Drug_Target_19_HGNC_ID:
Not Available

# Drug_Target_19_HPRD_ID:
Not Available

# Drug_Target_19_ID:
2675

# Drug_Target_19_Locus:
Not Available

# Drug_Target_19_Molecular_Weight:
30457

# Drug_Target_19_Name:
Pteridine reductase 1

# Drug_Target_19_Number_of_Residues:
288

# Drug_Target_19_PDB_ID:
1E92

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_19_Protein_Sequence:
>Pteridine reductase 1
MTAPTVPVALVTGAAKRLGRSIAEGLHAEGYAVCLHYHRSAAEANALSATLNARRPNSAI
TVQADLSNVATAPVSGADGSAPVTLFTRCAELVAACYTHWGRCDVLVNNASSFYPTPLLR
NDEDGHEPCVGDREAMETATADLFGSNAIAPYFLIKAFAHRFAGTPAKHRGTNYSIINMV
DAMTNQPLLGYTIYTMAKGALEGLTRSAALELAPLQIRVNGVGPGLSVLVDDMPPAVWEG
HRSKVPLYQRDSSAAEVSDVVIFLCSSKAKYITGTCVKVDGGYSLTRA

# Drug_Target_19_Reaction:
5,6,7,8-tetrahydrobiopterin + 2 NADP+ = biopterin + 2 NADPH + 2 H+

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Exhibits a NADPH-dependent biopterin reductase activity. Has good activity with folate and significant activity with dihydrofolate and dihydrobiopterin, but not with quinonoid dihydrobiopterin. Confers resistance to methotrexate (MTX)

# Drug_Target_19_SwissProt_ID:
Q01782

# Drug_Target_19_SwissProt_Name:
PTR1_LEIMA

# Drug_Target_19_Synonyms:
EC 1.5.1.33
H region methotrexate resistance protein

# Drug_Target_19_Theoretical_pI:
7.19

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ADH1B

# Drug_Target_1_GenBank_ID_Gene:
M24317

# Drug_Target_1_GenBank_ID_Protein:
178098

# Drug_Target_1_GeneCard_ID:
ADH1B

# Drug_Target_1_Gene_Name:
ADH1B

# Drug_Target_1_Gene_Sequence:
>1128 bp
ATGAGCACAGCAGGAAAAGTAATCAAATGCAAAGCAGCTGTGCTATGGGAGGTAAAGAAA
CCCTTTTCCATTGAGGATGTGGAGGTTGCACCTCCTAAGGCTTATGAAGTTCGCATTAAG
ATGGTGGCTGTAGGAATCTGTCGCACAGATGACCACGTGGTTAGTGGCAACCTGGTGACC
CCCCTTCCTGTGATTTTAGGCCATGAGGCAGCCGGCATCGTGGAGAGTGTTGGAGAAGGG
GTGACTACAGTCAAACCAGGTGATAAAGTCATCCCGCTCTTTACTCCTCAGTGTGGAAAA
TGCAGAGTTTGTAAAAACCCGGAGAGCAACTACTGCTTGAAAAATGATCTAGGCAATCCT
CGGGGGACCCTGCAGGATGGCACCAGGAGGTTCACCTGCAGGGGGAAGCCCATTCACCAC
TTCCTTGGCACCAGCACCTTCTCCCAGTACACGGTGGTGGATGAGAATGCAGTGGCCAAA
ATTGATGCAGCCTCGCCCCTGGAGAAAGTCTGCCTCATTGGCTGTGGATTCTCGACTGGT
TATGGGTCTGCAGTTAACGTTGCCAAGGTCACCCCAGGCTCTACCTGTGCTGTGTTTGGC
CTGGGAGGGGTCGGCCTATCTGCTGTTATGGGCTGTAAAGCAGCTGGAGCAGCCAGAATC
ATTGCGGTGGACATCAACAAGGACAAAAAAGCAAAGGCCAAAGAGTTGGGTGCCACTGAA
TGCATCAACCCTCAAGACTACAAGAAACCCATCCAGGAAGTGCTAAAGGAAATGACTGAT
GGAGGTGTGGATTTTTCGTTTGAAGTCATCGGTCGGCTTGACACCATGATGGCTTCCCTG
TTATGTTGTCATGAGGCATGTGGCACAAGCGTCATCGTAGGGGTACCTCCTGCTTCCCAG
AACCTCTCAATAAACCCTATGCTGCTACTGACTGGACGCACCTGGAAGGGGGCTGTTTAT
GGTGGCTTTAAGAGTAAAGAAGGTATCCCAAAACTTGTGGCTGATTTTATGGCTAAGAAG
TTTTCACTGGATGCGTTAATAACCCATGTTTTACCTTTTGAAAAAATAAATGAAGGATTT
GACCTGCTTCACTCTGGGAAAAGTATCCGTACCGTCCTGACGTTTTGA

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
10733556	Borras E, Coutelle C, Rosell A, Fernandez-Muixi F, Broch M, Crosas B, Hjelmqvist L, Lorenzo A, Gutierrez C, Santos M, Szczepanek M, Heilig M, Quattrocchi P, Farres J, Vidal F, Richart C, Mach T, Bogdal J, Jornvall H, Seitz HK, Couzigou P, Pares X: Genetic polymorphism of alcohol dehydrogenase in europeans: the ADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1. Hepatology. 2000 Apr;31(4):984-9.
11274460	Niederhut MS, Gibbons BJ, Perez-Miller S, Hurley TD: Three-dimensional structures of the three human class I alcohol dehydrogenases. Protein Sci. 2001 Apr;10(4):697-706.
1896463	Hurley TD, Bosron WF, Hamilton JA, Amzel LM: Structure of human beta 1 beta 1 alcohol dehydrogenase: catalytic effects of non-active-site substitutions. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8149-53.
2547609	Matsuo Y, Yokoyama R, Yokoyama S: The genes for human alcohol dehydrogenases beta 1 and beta 2 differ by only one nucleotide. Eur J Biochem. 1989 Aug 1;183(2):317-20.
2679216	Carr LG, Xu Y, Ho WH, Edenberg HJ: Nucleotide sequence of the ADH2(3) gene encoding the human alcohol dehydrogenase beta 3 subunit. Alcohol Clin Exp Res. 1989 Aug;13(4):594-6.
2935533	Duester G, Smith M, Bilanchone V, Hatfield GW: Molecular analysis of the human class I alcohol dehydrogenase gene family and nucleotide sequence of the gene encoding the beta subunit. J Biol Chem. 1986 Feb 15;261(5):2027-33.
2935875	Ikuta T, Szeto S, Yoshida A: Three human alcohol dehydrogenase subunits: cDNA structure and molecular and evolutionary divergence. Proc Natl Acad Sci U S A. 1986 Feb;83(3):634-8.
3000832	Heden LO, Hoog JO, Larsson K, Lake M, Lagerholm E, Holmgren A, Vallee BL, Jornvall H, von Bahr-Lindstrom H: cDNA clones coding for the beta-subunit of human liver alcohol dehydrogenase have differently sized 3'-non-coding regions. FEBS Lett. 1986 Jan 6;194(2):327-32.
3397059	Xu YL, Carr LG, Bosron WF, Li TK, Edenberg HJ: Genotyping of human alcohol dehydrogenases at the ADH2 and ADH3 loci following DNA sequence amplification. Genomics. 1988 Apr;2(3):209-14.
3619918	Burnell JC, Carr LG, Dwulet FE, Edenberg HJ, Li TK, Bosron WF: The human beta 3 alcohol dehydrogenase subunit differs from beta 1 by a Cys for Arg-369 substitution which decreases NAD(H) binding. Biochem Biophys Res Commun. 1987 Aug 14;146(3):1127-33.
6374651	Jornvall H, Hempel J, Vallee BL, Bosron WF, Li TK: Human liver alcohol dehydrogenase: amino acid substitution in the beta 2 beta 2 Oriental isozyme explains functional properties, establishes an active site structure, and parallels mutational exchanges in the yeast enzyme. Proc Natl Acad Sci U S A. 1984 May;81(10):3024-8.
6391920	Hempel J, Buhler R, Kaiser R, Holmquist B, de Zalenski C, von Wartburg JP, Vallee B, Jornvall H: Human liver alcohol dehydrogenase. 1. The primary structure of the beta 1 beta 1 isoenzyme. Eur J Biochem. 1984 Dec 17;145(3):437-45.
8201622	Hurley TD, Bosron WF, Stone CL, Amzel LM: Structures of three human beta alcohol dehydrogenase variants. Correlations with their functional differences. J Mol Biol. 1994 Jun 10;239(3):415-29.
8663387	Davis GJ, Bosron WF, Stone CL, Owusu-Dekyi K, Hurley TD: X-ray structure of human beta3beta3 alcohol dehydrogenase. The contribution of ionic interactions to coenzyme binding. J Biol Chem. 1996 Jul 19;271(29):17057-61.

# Drug_Target_1_HGNC_ID:
HGNC:250

# Drug_Target_1_HPRD_ID:
00065

# Drug_Target_1_ID:
444

# Drug_Target_1_Locus:
4q21-q23

# Drug_Target_1_Molecular_Weight:
39724

# Drug_Target_1_Name:
Alcohol dehydrogenase 1B

# Drug_Target_1_Number_of_Residues:
374

# Drug_Target_1_PDB_ID:
1HSZ

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_1_Protein_Sequence:
>Alcohol dehydrogenase 1B
STAGKVIKCKAAVLWEVKKPFSIEDVEVAPPKAYEVRIKMVAVGICRTDDHVVSGNLVTP
LPVILGHEAAGIVESVGEGVTTVKPGDKVIPLFTPQCGKCRVCKNPESNYCLKNDLGNPR
GTLQDGTRRFTCRGKPIHHFLGTSTFSQYTVVDENAVAKIDAASPLEKVCLIGCGFSTGY
GSAVNVAKVTPGSTCAVFGLGGVGLSAVMGCKAAGAARIIAVDINKDKFAKAKELGATEC
INPQDYKKPIQEVLKEMTDGGVDFSFEVIGRLDTMMASLLCCHEACGTSVIVGVPPASQN
LSINPMLLLTGRTWKGAVYGGFKSKEGIPKLVADFMAKKFSLDALITHVLPFEKINEGFD
LLHSGKSIRTVLTF

# Drug_Target_1_Reaction:
an alcohol + NAD+ = an aldehyde or ketone + NADH + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P00325

# Drug_Target_1_SwissProt_Name:
ADH1B_HUMAN

# Drug_Target_1_Synonyms:
Alcohol dehydrogenase beta subunit
EC 1.1.1.1

# Drug_Target_1_Theoretical_pI:
8.38

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Membrane
peripheral membrane protein. Note=Probably recruited to membranes via an interaction with

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
DCXR

# Drug_Target_20_GenBank_ID_Gene:
AB013846

# Drug_Target_20_GenBank_ID_Protein:
15425623

# Drug_Target_20_GeneCard_ID:
DCXR

# Drug_Target_20_Gene_Name:
DCXR

# Drug_Target_20_Gene_Sequence:
>735 bp
ATGGAGCTGTTCCTCGCGGGCCGCCGGGTGCTGGTCACCGGGGCAGGCAAAGGTATAGGG
CGCGGCACGGTCCAGGCGCTGCACGCGACGGGCGCGCGGGTGGTGGCTGTGAGCCGGACT
CAGGCGGATCTTGACAGCCTTGTCCGCGAGTGCCCGGGGATAGAACCCGTGTGCGTGGAC
CTGGGTGACTGGGAGGCCACCGAGCGGGCGCTGGGCAGCGTGGGCCCCGTGGACCTGCTG
GTGAACAACGCCGCTGTCGCCCTGCTGCAGCCCTTCCTGGAGGTCACCAAGGAGGCCTTT
GACAGATCCTTTGAGGTGAACCTGCGTGCGGTCATCCAGGTGTCGCAGATTGTGGCCAGG
GGCTTAATAGCCCGGGGAGTCCCAGGGGCCATCGTGAATGTCTCCAGCCAGTGCTCCCAG
CGGGCAGTAACTAACCATAGCGTCTACTGCTCCACCAAGGGTGCCCTGGACATGCTGACC
AAGGTGATGGCCCTAGAGCTCGGGCCCCACAAGATCCGAGTGAATGCAGTAAACCCCACA
GTGGTGATGACGTCCATGGGCCAGGCCACCTGGAGTGACCCCCACAAGGCCAAGACTATG
CTGAACCGAATCCCACTTGGCAAGTTTGCTGAGGTAGAGCACGTGGTGAACGCCATCCTC
TTTCTGCTGAGTGACCGAAGTGGCATGACCACGGGTTCCACTTTGCCGGTGGAAGGGGGC
TTCTGGGCCTGCTGA

# Drug_Target_20_General_Function:
Lipid transport and metabolism

# Drug_Target_20_General_References:
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.

# Drug_Target_20_HGNC_ID:
HGNC:18985

# Drug_Target_20_HPRD_ID:
16320

# Drug_Target_20_ID:
989

# Drug_Target_20_Locus:
17q25.3

# Drug_Target_20_Molecular_Weight:
25913

# Drug_Target_20_Name:
L-xylulose reductase

# Drug_Target_20_Number_of_Residues:
244

# Drug_Target_20_PDB_ID:
1PR9

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_20_Protein_Sequence:
>L-xylulose reductase
MELFLAGRRVLVTGAGKGIGRGTVQALHATGARVVAVSRTQADLDSLVRECPGIEPVCVD
LGDWEATERALGSVGPVDLLVNNAAVALLQPFLEVTKEAFDRSFEVNLRAVIQVSQIVAR
GLIARGVPGAIVNVSSQCSQRAVTNHSVYCSTKGALDMLTKVMALELGPHKIRVNAVNPT
VVMTSMGQATWSDPHKAKTMLNRIPLGKFAEVEHVVNAILFLLSDRSGMTTGSTLPVEGG
FWAC

# Drug_Target_20_Reaction:
xylitol + NADP+ = L-xylulose + NADPH + H+

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
Catalyzes the NADPH-dependent reduction of several pentoses, tetroses, trioses, alpha-dicarbonyl compounds and L- xylulose. Participates in the uronate cycle of glucose metabolism. May play a role in the water absorption and cellular osmoregulation in the proximal renal tubules by producing xylitol, an osmolyte, thereby preventing osmolytic stress from occurring in the renal tubules

# Drug_Target_20_SwissProt_ID:
Q7Z4W1

# Drug_Target_20_SwissProt_Name:
DCXR_HUMAN

# Drug_Target_20_Synonyms:
Carbonyl reductase II
Dicarbonyl/L-xylulose reductase
EC 1.1.1.10
Kidney dicarbonyl reductase
Sperm surface protein P34H
XR
kiDCR

# Drug_Target_20_Theoretical_pI:
8.23

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Cytoplasm. Peroxisome

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
IDH1

# Drug_Target_21_GenBank_ID_Gene:
AF020038

# Drug_Target_21_GenBank_ID_Protein:
3641398

# Drug_Target_21_GeneCard_ID:
IDH1

# Drug_Target_21_Gene_Name:
IDH1

# Drug_Target_21_Gene_Sequence:
>1245 bp
ATGTCCAAAAAAATCAGTGGCGGTTCTGTGGTAGAGATGCAAGGAGATGAAATGACACGA
ATCATTTGGGAATTGATTAAAGAGAAACTCATTTTTCCCTACGTGGAATTGGATCTACAT
AGCTATGATTTAGGCATAGAGAATCGTGATGCCACCAACGACCAAGTCACCAAGGATGCT
GCAGAAGCTATAAAGAAGCATAATGTTGGCGTCAAATGTGCCACTATCACTCCTGATGAG
AAGAGGGTTGAGGAGTTCAAGTTGAAACAAATGTGGAAATCACCAAATGGCACCATACGA
AATATTCTGGGTGGCACGGTCTTCAGAGAAGCCATTATCTGCAAAAATATCCCCCGGCTT
GTGAGTGGATGGGTAAAACCTATCATCATAGGTCGTCATGCTTATGGGGATCAATACAGA
GCAACTGATTTTGTTGTTCCTGGGCCTGGAAAAGTAGAGATAACCTACACACCAAGTGAC
GGAACCCAAAAGGTGACATACCTGGTACATAACTTTGAAGAAGGTGGTGGTGTTGCCATG
GGGATGTATAATCAAGATAAGTCAATTGAAGATTTTGCACACAGTTCCTTCCAGATGGCT
CTGTCTAAGGGTTGGCCTTTGTATCTGAGCACCAAAAACACTATTCTGAAGATATATGAT
GGGCGTTTTAAAGACATCTTTCAGGAGATATATGACAAGCAGTACAAGTCCCAGTTTGAA
GCTCAAAAGATCTGGTATGAGCATAGGCTCATCGACGACATGGTGGCCCAAGCTATGAAA
TCAGAGGGAGGCTTCATCTGGGCCTGTAAAAACTATGATGGTGACGTGCAGTCGGACTCT
GTGGCCCAAGGGTATGGCTCTCTCGGCATGATGACCAGCGTGCTGGTTTGTCCAGATGGC
AAGACAGTAGAAGCAGAGGCTGCCCACGGGACTGTAACCCGTCACTACCGCATGTACCAG
AAAGGACAGGAGACGTCCACCAACCTCATTGCTTCCATTTTTGCCTGGACCAGAGGGTTA
GCCCACAGAGCAAAGCTTGATAACAATAAAGAGCTTGCCTTCTTTGCAAATGCTTTGGAA
GAAGTCTCTATTGAGACAATTGAGGCTGGCTTCATGACCAAGGACTTGGCTGCTTGCATT
AGAGGTTTACCCAATGTGCAACGTTCTGACTACTTGAATACATTTGAGTTCATGGATAAA
CTTGGAGAAAACTTGAAGATCAAACTAGCTCAGGCCAAACTTTAA

# Drug_Target_21_General_Function:
Energy production and conversion

# Drug_Target_21_General_References:
10521434	Geisbrecht BV, Gould SJ: The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem. 1999 Oct 22;274(43):30527-33.
11230166	Wiemann S, Weil B, Wellenreuther R, Gassenhuber J, Glassl S, Ansorge W, Bocher M, Blocker H, Bauersachs S, Blum H, Lauber J, Dusterhoft A, Beyer A, Kohrer K, Strack N, Mewes HW, Ottenwalder B, Obermaier B, Tampe J, Heubner D, Wambutt R, Korn B, Klein M, Poustka A: Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs. Genome Res. 2001 Mar;11(3):422-35.
9866202	Nekrutenko A, Hillis DM, Patton JC, Bradley RD, Baker RJ: Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. Mol Biol Evol. 1998 Dec;15(12):1674-84.

# Drug_Target_21_HGNC_ID:
HGNC:5382

# Drug_Target_21_HPRD_ID:
00984

# Drug_Target_21_ID:
2305

# Drug_Target_21_Locus:
2q33.3

# Drug_Target_21_Molecular_Weight:
46660

# Drug_Target_21_Name:
Isocitrate dehydrogenase [NADP] cytoplasmic

# Drug_Target_21_Number_of_Residues:
414

# Drug_Target_21_PDB_ID:
1T0L

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00180	Iso_dh

# Drug_Target_21_Protein_Sequence:
>Isocitrate dehydrogenase [NADP] cytoplasmic
MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDA
AEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRL
VSGWVKPIIIGRHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAM
GMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFE
AQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDG
KTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALE
EVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL

# Drug_Target_21_Reaction:
(1) isocitrate + NADP+ = 2-oxoglutarate + CO2 + NADPH

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
Isocitrate + NADP(+) = 2-oxoglutarate + CO(2) + NADPH

# Drug_Target_21_SwissProt_ID:
O75874

# Drug_Target_21_SwissProt_Name:
IDHC_HUMAN

# Drug_Target_21_Synonyms:
Cytosolic NADP-isocitrate dehydrogenase
EC 1.1.1.42
IDH
IDP
NADP(+)-specific ICDH
Oxalosuccinate decarboxylase

# Drug_Target_21_Theoretical_pI:
7.00

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_22_Cellular_Location:
Not Available

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
Not Available

# Drug_Target_22_GenBank_ID_Gene:
J01609

# Drug_Target_22_GenBank_ID_Protein:
146006

# Drug_Target_22_GeneCard_ID:
Not Available

# Drug_Target_22_Gene_Name:
folA

# Drug_Target_22_Gene_Sequence:
>480 bp
ATGATCAGTCTGATTGCGGCGTTAGCGGTAGATCGCGTTATCGGCATGGAAAACGCCATG
CCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACACCTTAAATAAACCCGTG
ATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGACGCAAAAATATT
ATCCTCAGCAGTCAACCGGGTACGGACGATCGCGTAACGTGGGTGAAGTCGGTGGATGAA
GCCATCGCGGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGTCGCGTTTAT
GAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAGAAGTGGAA
GGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGCGAATTC
CACGATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGGTAA

# Drug_Target_22_General_Function:
Coenzyme transport and metabolism

# Drug_Target_22_General_References:
1630901	Yura T, Mori H, Nagai H, Nagata T, Ishihama A, Fujita N, Isono K, Mizobuchi K, Nakata A: Systematic sequencing of the Escherichia coli genome: analysis of the 0-2.4 min region. Nucleic Acids Res. 1992 Jul 11;20(13):3305-8.
1998681	Bystroff C, Kraut J: Crystal structure of unliganded Escherichia coli dihydrofolate reductase. Ligand-induced conformational changes and cooperativity in binding. Biochemistry. 1991 Feb 26;30(8):2227-39.
2185835	Bystroff C, Oatley SJ, Kraut J: Crystal structures of Escherichia coli dihydrofolate reductase: the NADP+ holoenzyme and the folate.NADP+ ternary complex. Substrate binding and a model for the transition state. Biochemistry. 1990 Apr 3;29(13):3263-77.
320005	Stone D, Phillips AW, Burchall JJ: The amino-acid sequence of the dihydrofolate reductase of a trimethoprim-resistant strain of Escherichia coli. Eur J Biochem. 1977 Feb;72(3):613-24.
350268	Bennett CD, Rodkey JA, Sondey JM, Hirschmann R: Dihydrofolate reductase: the amino acid sequence of the enzyme from a methotrexate-resistant mutant of Escherichia coli. Biochemistry. 1978 Apr 4;17(7):1328-37.
3549289	Flensburg J, Skold O: Massive overproduction of dihydrofolate reductase in bacteria as a response to the use of trimethoprim. Eur J Biochem. 1987 Feb 2;162(3):473-6.
6159575	Smith DR, Calvo JM: Nucleotide sequence of the E coli gene coding for dihydrofolate reductase. Nucleic Acids Res. 1980 May 24;8(10):2255-74.
6815179	Filman DJ, Bolin JT, Matthews DA, Kraut J: Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. II. Environment of bound NADPH and implications for catalysis. J Biol Chem. 1982 Nov 25;257(22):13663-72.
7007370	Baccanari DP, Stone D, Kuyper L: Effect of a single amino acid substitution on Escherichia coli dihydrofolate reductase catalysis and ligand binding. J Biol Chem. 1981 Feb 25;256(4):1738-47.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_22_HGNC_ID:
Not Available

# Drug_Target_22_HPRD_ID:
Not Available

# Drug_Target_22_ID:
3682

# Drug_Target_22_Locus:
Not Available

# Drug_Target_22_Molecular_Weight:
18000

# Drug_Target_22_Name:
Dihydrofolate reductase

# Drug_Target_22_Number_of_Residues:
159

# Drug_Target_22_PDB_ID:
1DDS

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00186	DHFR_1

# Drug_Target_22_Protein_Sequence:
>Dihydrofolate reductase
MISLIAALAVDRVIGMENAMPWNLPADLAWFKRNTLNKPVIMGRHTWESIGRPLPGRKNI
ILSSQPGTDDRVTWVKSVDEAIAACGDVPEIMVIGGGRVYEQFLPKAQKLYLTHIDAEVE
GDTHFPDYEPDDWESVFSEFHDADAQNSHSYCFEILERR

# Drug_Target_22_Reaction:
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+

# Drug_Target_22_Signals:
None

# Drug_Target_22_Specific_Function:
5,6,7,8-tetrahydrofolate + NADP(+) = 7,8- dihydrofolate + NADPH

# Drug_Target_22_SwissProt_ID:
P0ABQ4

# Drug_Target_22_SwissProt_Name:
DYR_ECOLI

# Drug_Target_22_Synonyms:
EC 1.5.1.3

# Drug_Target_22_Theoretical_pI:
4.61

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Cytoplasm

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
AKR1C1

# Drug_Target_23_GenBank_ID_Gene:
M86609

# Drug_Target_23_GenBank_ID_Protein:
181549

# Drug_Target_23_GeneCard_ID:
AKR1C1

# Drug_Target_23_Gene_Name:
AKR1C1

# Drug_Target_23_Gene_Sequence:
>972 bp
ATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGA
TTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTG
GCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTG
TCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGAC
ACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCC
AAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCA
GGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGA
AAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGA
TCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC
CTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC
GTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAAC
AGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCT
GATGAATATTAA

# Drug_Target_23_General_Function:
Involved in oxidoreductase activity

# Drug_Target_23_General_References:
10672042	Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S: Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000 Feb;5(2):111-25.
11013348	Zhang Y, Dufort I, Rheault P, Luu-The V: Characterization of a human 20alpha-hydroxysteroid dehydrogenase. J Mol Endocrinol. 2000 Oct;25(2):221-8.
12899831	Couture JF, Legrand P, Cantin L, Luu-The V, Labrie F, Breton R: Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J Mol Biol. 2003 Aug 15;331(3):593-604.
7626489	Khanna M, Qin KN, Cheng KC: Distribution of 3 alpha-hydroxysteroid dehydrogenase in rat brain and molecular cloning of multiple cDNAs encoding structurally related proteins in humans. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):41-6.
8132567	Lou H, Hammond L, Sharma V, Sparkes RS, Lusis AJ, Stolz A: Genomic organization and chromosomal localization of a novel human hepatic dihydrodiol dehydrogenase with high affinity bile acid binding. J Biol Chem. 1994 Mar 18;269(11):8416-22.
8172617	Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K, Hara A: Molecular cloning of two human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J. 1994 Apr 15;299 ( Pt 2):545-52.
8274401	Qin KN, New MI, Cheng KC: Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 1993 Dec;46(6):673-9.
8486699	Stolz A, Hammond L, Lou H, Takikawa H, Ronk M, Shively JE: cDNA cloning and expression of the human hepatic bile acid-binding protein. A member of the monomeric reductase gene family. J Biol Chem. 1993 May 15;268(14):10448-57.

# Drug_Target_23_HGNC_ID:
HGNC:384

# Drug_Target_23_HPRD_ID:
07194

# Drug_Target_23_ID:
139

# Drug_Target_23_Locus:
10p15-p14

# Drug_Target_23_Molecular_Weight:
36789

# Drug_Target_23_Name:
Aldo-keto reductase family 1 member C1

# Drug_Target_23_Number_of_Residues:
323

# Drug_Target_23_PDB_ID:
1MRQ

# Drug_Target_23_Pathway:
Not Available

# Drug_Target_23_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_23_Protein_Sequence:
>Aldo-keto reductase family 1 member C1
MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPV
SVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKP
GLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLN
RNVRYLTLDIFAGPPNYPFSDEY

# Drug_Target_23_Reaction:
17alpha,20alpha-dihydroxypregn-4-en-3-one + NAD(P)+ = 17alpha-hydroxyprogesterone + NAD(P)H + H+

# Drug_Target_23_Signals:
None

# Drug_Target_23_Specific_Function:
Converts progesterone to its inactive form, 20alpha- dihydroxyprogesterone (20alpha-OHP). In the liver and intestine, may have a role in the transport of bile. May have a role in monitoring the intrahepatic bile acid concentration. May play a role in myelin formation

# Drug_Target_23_SwissProt_ID:
Q04828

# Drug_Target_23_SwissProt_Name:
AK1C1_HUMAN

# Drug_Target_23_Synonyms:
20-alpha- hydroxysteroid dehydrogenase
20-alpha-HSD
Chlordecone reductase homolog HAKRC
DD1/DD2
Dihydrodiol dehydrogenase 1/2
EC 1.1.1.-
EC 1.1.1.149
EC 1.3.1.20
HBAB
High- affinity hepatic bile acid-binding protein
Trans- 1,2-dihydrobenzene-1,2-diol dehydrogenase

# Drug_Target_23_Theoretical_pI:
7.99

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_24_Cellular_Location:
Sarcolemma
peripheral membrane protein. In skeletal muscle, it is localized b
sarcolemmal membrane

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
NOS1

# Drug_Target_24_GenBank_ID_Gene:
U17327

# Drug_Target_24_GenBank_ID_Protein:
642526

# Drug_Target_24_GeneCard_ID:
NOS1

# Drug_Target_24_Gene_Name:
NOS1

# Drug_Target_24_Gene_Sequence:
>4305 bp
ATGGAGGATCACATGTTCGGTGTTCAGCAAATCCAGCCCAATGTCATTTCTGTTCGTCTC
TTCAAGCGCAAAGTTGGGGGCCTGGGATTTCTGGTGAAGGAGCGGGTCAGTAAGCCGCCC
GTGATCATCTCTGACCTGATTCGTGGGGGCGCCGCAGAGCAGAGTGGCCTCATCCAGGCC
GGAGACATCATTCTTGCGGTCAACGGCCGGCCCTTGGTGGACCTGAGCTATGACAGCGCC
CTGGAGGTACTCAGAGGCATTGCCTCTGAGACCCACGTGGTCCTCATTCTGAGGGGCCCT
GAAGGTTTCACCACGCACCTGGAGACCACCTTTACAGGTGATGGGACCCCCAAGACCATC
CGGGTGACACAGCCCCTGGGTCCCCCCACCAAAGCCGTGGATCTGTCCCACCAGCCACCG
GCCGGCAAAGAACAGCCCCTGGCAGTGGATGGGGCCTCGGGTCCCGGGAATGGGCCTCAG
CATGCCTACGATGATGGGCAGGAGGCTGGCTCACTCCCCCATGCCAACGGCCTGGCCCCC
AGGCCCCCAGGCCAGGACCCCGCGAAGAAAGCAACCAGAGTCAGCCTCCAAGGCAGAGGG
GAGAACAATGAACTGCTCAAGGAGATAGAGCCTGTGCTGAGCCTTCTCACCAGTGGGAGC
AGAGGGGTCAAGGGAGGGGCACCTGCCAAGGCAGAGATGAAAGATATGGGAATCCAGGTG
GACAGAGATTTGGACGGCAAGTCACACAAACCTCTGCCCCTCGGCGTGGAGAACGACCGA
GTCTTCAATGACCTATGGGGGAAGGGCAATGTGCCTGTCGTCCTCAACAACCCATATTCA
GAGAAGGAGCAGCCCCCCACCTCAGGAAAACAGTCCCCCACAAAGAATGGCAGCCCCTCC
AAGTGTCCACGCTTCCTCAAGGTCAAGAACTGGGAGACTGAGGTGGTTCTCACTGACACC
CTCCACCTTAAGAGCACATTGGAAACGGGATGCACTGAGTACATCTGCATGGGCTCCATC
ATGCATCCTTCTCAGCATGCAAGGAGGCCTGAAGACGTCCGCACAAAAGGACAGCTCTTC
CCTCTCGCCAAAGAGTTTATTGATCAATACTATTCATCAATTAAAAGATTTGGCTCCAAA
GCCCACATGGAAAGGCTGGAAGAGGTGAACAAAGAGATCGACACCACTAGCACTTACCAG
CTCAAGGACACAGAGCTCATCTATGGGGCCAAGCACGCCTGGCGGAATGCCTCGCGCTGT
GTGGGCAGGATCCAGTGGTCCAAGCTGCAGGTATTCGATGCCCGTGACTGCACCACGGCC
CACGGGATGTTCAACTACATCTGTAACCATGTCAAGTATGCCACCAACAAAGGGAACCTC
AGGTCTGCCATCACCATATTCCCCCAGAGGACAGACGGCAAGCACGACTTCCGAGTCTGG
AACTCCCAGCTCATCCGCTACGCTGGCTACAAGCAGCCTGACGGCTCCACCCTGGGGGAC
CCAGCCAATGTGCAGTTCACAGAGATATGCATACAGCAGGGCTGGAAACCGCCTAGAGGC
CGCTTCGATGTCCTGCCGCTCCTGCTTCAGGCCAACGGCAATGACCCTGAGCTCTTCCAG
ATTCCTCCAGAGCTGGTGTTGGAAGTTCCCATCAGGCACCCCAAGTTTGAGTGGTTCAAG
GACCTGGGGCTGAAGTGGTACGGCCTCCCCGCCGTGTCCAACATGCTCCTAGAGATTGGC
GGCCTGGAGTTCAGCGCCTGTCCCTTCAGTGGCTGGTACATGGGCACAGAGATTGGTGTC
CGCGACTACTGTGACAACTCCCGCTACAATATCCTGGAGGAAGTGGCCAAGAAGATGAAC
TTAGACATGAGGAAGACGTCCTCCCTGTGGAAGGACCAGGCGCTGGTGGAGATCAATATC
GCGGTTCTCTATAGCTTCCAGAGTGACAAAGTGACCATTGTTGACCATCACTCCGCCACC
GAGTCCTTCATTAAGCACATGGAGAATGAGTACCGCTGCCGGGGGGGCTGCCCTGCCGAC
TGGGTGTGGATCGTGCCCCCCATGTCCGGAAGCATCACCCCTGTGTTCCACCAGGAGATG
CTCAACTACCGGCTCACCCCCTCCTTCGAATACCAGCCTGATCCCTGGAACACGCATGTC
TGGAAAGGCACCAACGGGACCCCCACAAAGCGGCGAGCCATCGGCTTCAAGAAGCTAGCA
GAAGCTGTCAAGTTCTCGGCCAAGCTGATGGGGCAGGCTATGGCCAAGAGGGTGAAAGCG
ACCATCCTCTATGCCACAGAGACAGGCAAATCGCAAGCTTATGCCAAGACCTTGTGTGAG
ATCTTCAAACACGCCTTTGATGCCAAGGTGATGTCCATGGAAGAATATGACATTGTGCAC
CTGGAACATGAAACTCTGGTCCTTGTGGTCACCAGCACCTTTGGCAATGGAGATCCCCCT
GAGAATGGGGAGAAATTCGGCTGTGCTTTGATGGAAATGAGGCACCCCAACTCTGTGCAG
GAAGAAAGGAAGAGCTACAAGGTCCGATTCAACAGCGTCTCCTCCTACTCTGACTCCCAA
AAATCATCAGGCGATGGGCCCGACCTCAGAGACAACTTTGAGAGTGCTGGACCCCTGGCC
AATGTGAGGTTCTCAGTTTTTGGCCTCGGCTCACGAGCATACCCTCACTTTTGCGCCTTC
GGACACGCTGTGGACACCCTCCTGGAAGAACTGGGAGGGGAGAGGATCCTGAAGATGAGG
GAAGGGGATGAGCTCTGTGGGCAGGAAGAGGCTTTCAGGACCTGGGCCAAGAAGGTCTTC
AAGGCAGCCTGTGATGTCTTCTGTGTGGGAGATGATGTCAACATTGAAAAGGCCAACAAT
TCCCTCATCAGCAATGATCGCAGCTGGAAGAGAAACAAGTTCCGCCTCACCTTTGTGGCC
GAAGCTCCAGAACTCACACAAGGTCTATCCAATGTCCACAAAAAGCGAGTCTCAGCTGCC
CGGCTCCTTAGCCGTCAAAACCTCCAGAGCCCTAAATCCAGTCGGTCAACTATCTTCGTG
CGTCTCCACACCAACGGGAGCCAGGAGCTGCAGTACCAGCCTGGGGACCACCTGGGTGTC
TTCCCTGGCAACCACGAGGACCTCGTGAATGCCCTGATCGAGCGGCTGGAGGACGCGCCG
CCTGTCAACCAGATGGTGAAAGTGGAACTGCTGGAGGAGCGGAACACGGCTTTAGGTGTC
ATCAGTAACTGGACAGACGAGCTCCGCCTCCCGCCCTGCACCATCTTCCAGGCCTTCAAG
TACTACCTGGACATCACCACGCCACCAACGCCTCTGCAGCTGCAGCAGTTTGCCTCCCTA
GCTACCAGCGAGAAGGAGAAGCAGCGTCTGCTGGTCCTCAGCAAGGGTTTGCAGGAGTAC
GAGGAATGGAAATGGGGCAAGAACCCCACCATCGTGGAGGTGCTGGAGGAGTTCCCATCT
ATCCAGATGCCGGCCACCCTGCTCCTGACCCAGCTGTCCCTGCTGCAGCCCCGCTACTAT
TCCATCAGCTCCTCCCCAGACATGTACCCTGATGAAGTGCACCTCACTGTGGCCATCGTT
TCCTACCGCACTCGAGATGGAGAAGGACCAATTCACCACGGCGTATGCTCCTCCTGGCTC
AACCGGATACAGGCTGACGAACTGGTCCCCTGTTTCGTGAGAGGAGCACCCAGCTTCCAC
CTGCCCCGGAACCCCCAAGTCCCCTGCATCCTCGTTGGACCAGGCACCGGCATTGCCCCT
TTCCGAAGCTTCTGGCAACAGCGGCAATTTGATATCCAACACAAAGGAATGAACCCCTGC
CCCATGGTCCTGGTCTTCGGGTGCCGGCAATCCAAGATAGATCATATCTACAGGGAAGAG
ACCCTGCAGGCCAAGAACAAGGGGGTCTTCAGAGAGCTGTACACGGCTTACTCCCGGGAG
CCAGACAAACCAAAGAAGTACGTGCAGGACATCCTGCAGGAGCAGCTGGCGGAGTCTGTG
TACCGAGCCCTGAAGGAGCAAGGGGGCCACATATACGTCTGTGGGGACGTCACCATGGCT
GCTGATGTCCTCAAAGCCATCCAGCGCATCATGACCCAGCAGGGGAAGCTCTCGGCAGAG
GACGCCGGCGTATTCATCAGCCGGATGAGGGATGACAACCGATACCATGAGGATATTTTT
GGAGTCACCCTGCGAACGTACGAAGTGACCAACCGCCTTAGATCTGAGTCCATTGCCTTC
ATTGAAGAGAGCAAAAAAGACACCGATGAGGTTTTCAGCTCCTAA

# Drug_Target_24_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_24_General_References:
7515942	Fujisawa H, Ogura T, Kurashima Y, Yokoyama T, Yamashita J, Esumi H: Expression of two types of nitric oxide synthase mRNA in human neuroblastoma cell lines. J Neurochem. 1994 Jul;63(1):140-5.
7528745	Hall AV, Antoniou H, Wang Y, Cheung AH, Arbus AM, Olson SL, Lu WC, Kau CL, Marsden PA: Structural organization of the human neuronal nitric oxide synthase gene (NOS1). J Biol Chem. 1994 Dec 30;269(52):33082-90.
7678401	Nakane M, Schmidt HH, Pollock JS, Forstermann U, Murad F: Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett. 1993 Jan 25;316(2):175-80.
8879752	Park CS, Gianotti C, Park R, Krishna G: Neuronal isoform of nitric oxide synthase is expressed at low levels in human retina. Cell Mol Neurobiol. 1996 Aug;16(4):499-515.
9111048	Wang Y, Goligorsky MS, Lin M, Wilcox JN, Marsden PA: A novel, testis-specific mRNA transcript encoding an NH2-terminal truncated nitric-oxide synthase. J Biol Chem. 1997 Apr 25;272(17):11392-401.

# Drug_Target_24_HGNC_ID:
HGNC:7872

# Drug_Target_24_HPRD_ID:
01226

# Drug_Target_24_ID:
76

# Drug_Target_24_Locus:
12q24.2-q24.31

# Drug_Target_24_Molecular_Weight:
160972

# Drug_Target_24_Name:
Nitric-oxide synthase, brain

# Drug_Target_24_Number_of_Residues:
1434

# Drug_Target_24_PDB_ID:
1TLL

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00595	PDZ
PF00667	FAD_binding_1
PF02898	NO_synthase

# Drug_Target_24_Protein_Sequence:
>Nitric-oxide synthase, brain
MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA
GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI
RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP
RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV
DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS
KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF
PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC
VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW
NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ
IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV
RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT
ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV
WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE
IFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ
EERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAF
GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN
SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV
RLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGV
ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY
EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV
SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP
FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSRE
PDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAE
DAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS

# Drug_Target_24_Reaction:
L-arginine + n NADPH + n H+ + m O2 = citrulline + nitric oxide + n NADP+

# Drug_Target_24_Signals:
None

# Drug_Target_24_Specific_Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter

# Drug_Target_24_SwissProt_ID:
P29475

# Drug_Target_24_SwissProt_Name:
NOS1_HUMAN

# Drug_Target_24_Synonyms:
Constitutive NOS
EC 1.14.13.39
N-NOS
NC-NOS
NOS type I
Neuronal NOS
bNOS
nNOS

# Drug_Target_24_Theoretical_pI:
7.44

# Drug_Target_24_Transmembrane_Regions:
None

# Drug_Target_25_Cellular_Location:
Not Available

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
G6PD

# Drug_Target_25_GenBank_ID_Gene:
X03674

# Drug_Target_25_GenBank_ID_Protein:
31543

# Drug_Target_25_GeneCard_ID:
G6PD

# Drug_Target_25_Gene_Name:
G6PD

# Drug_Target_25_Gene_Sequence:
>1548 bp
ATGGCAGAGCAGGTGGCCCTGAGCCGGACCCACGTGTGCGGGATCCTGCGGGAAGAGCTT
TTCCAGGGCGATGCCTTCCATCAGTCGGATACACACATATTCATCATCATGGGTGCATCG
GGTGACCTGGCCAAGAAGAAGATCTACCCCACCATCTGGTGGCTGTTCCGGGATGGCCTT
CTGCCCGAAAACACCTTCATCGTGGGCTATGCCCGTTCCCGCCTCACAGTGGCTGACATC
CGCAAACAGAGTGAGCCCTTCTTCAAGGCCACCCCAGAGGAGAAGCTCAAGCTGGAGGAC
TTCTTTGCCCGCAACTCCTATGTGGCTGGCCAGTACGATGATGCAGCCTCCTACCAGCGC
CTCAACAGCCACATGAATGCCCTCCACCTGGGGTCACAGGCCAACCGCCTCTTCTACCTG
GCCTTGCCCCCGACCGTCTACGAGGCCGTCACCAAGAACATTCACGAGTCCTGCATGAGC
CAGATAGGCTGGAACCGCATCATCGTGGAGAAGCCCTTCGGGAGGGACCTGCAGAGCTCT
GACCGGCTGTCCAACCACATCTCCTCCCTGTTCCGTGAGGACCAGATCTACCGCATCGAC
CACTACCTGGGCAAGGAGATGGTGCAGAACCTCATGGTGCTGAGATTTGCCAACAGGATC
TTCGGCCCCATCTGGAACCGGGACAACATCGCCTGCGTTATCCTCACCTTCAAGGAGCCC
TTTGGCACTGAGGGTCGCGGGGGCTATTTCGATGAATTTGGGATCATCCGGGACGTGATG
CAGAACCACCTACTGCAGATGCTGTGTCTGGTGGCCATGGAGAAGCCCGCCTCCACCAAC
TCAGATGACGTCCGTGATGAGAAGGTCAAGGTGTTGAAATGCATCTCAGAGGTGCAGGCC
AACAATGTGGTCCTGGGCCAGTACGTGGGGAACCCCGATGGAGAGGGCGAGGCCACCAAA
GGGTACCTGGACGACCCCACGGTGCCCCGCGGGTCCACCACCGCCACTTTTGCAGCCGTC
GTCCTCTATGTGGAGAATGAGAGGTGGGATGGGGTGCCCTTCATCCTGCGCTGCGGCAAG
GCCCTGAACGAGCGCAAGGCCGAGGTGAGGCTGCAGTTCCATGATGTGGCCGGCGACATC
TTCCACCAGCAGTGCAAGCGCAACGAGCTGGTGATCCGCGTGCAGCCCAACGAGGCCGTG
TACACCAAGATGATGACCAAGAAGCCGGGCATGTTCTTCAACCCCGAGGAGTCGGAGCTG
GACCTGACCTACGGCAACAGATACAAGAACGTGAAGCTCCCTGACGCCTACGAGCGCCTC
ATCCTGGACGTCTTCTGCGGGAGCCAGATGCACTTCGTGCGCAGCGACGAGCTCCGTGAG
GCCTGGCGTATTTTCACCCCACTGCTGCACCAGATTGAGCTGGAGAAGCCCAAGCCCATC
CCCTATATTTATGGCAGCCGAGGCCCCACGGAGGCAGACGAGCTGATGAAGAGAGTGGGT
TTCCAGTATGAGGGCACCTACAAGTGGGTGAACCCCCACAAGCTCTGA

# Drug_Target_25_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_25_General_References:
10745013	Au SW, Gover S, Lam VM, Adams MJ: Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. Structure. 2000 Mar 15;8(3):293-303.
11857737	Kwok CJ, Martin AC, Au SW, Lam VM: G6PDdb, an integrated database of glucose-6-phosphate dehydrogenase (G6PD) mutations. Hum Mutat. 2002 Mar;19(3):217-24.
12524354	Saunders MA, Hammer MF, Nachman MW: Nucleotide variability at G6pd and the signature of malarial selection in humans. Genetics. 2002 Dec;162(4):1849-61.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
1303180	Perng LI, Chiou SS, Liu TC, Chang JG: A novel C to T substitution at nucleotide 1360 of cDNA which abolishes a natural Hha I site accounts for a new G6PD deficiency gene in Chinese. Hum Mol Genet. 1992 Jun;1(3):205.
1303182	Ahluwalia A, Corcoran CM, Vulliamy TJ, Ishwad CS, Naidu JM, Argusti A, Stevens DJ, Mason PJ, Luzzatto L: G6PD Kalyan and G6PD Kerala; two deficient variants in India caused by the same 317 Glu-->Lys mutation. Hum Mol Genet. 1992 Jun;1(3):209-10.
1611091	Beutler E, Westwood B, Prchal JT, Vaca G, Bartsocas CS, Baronciani L: New glucose-6-phosphate dehydrogenase mutations from various ethnic groups. Blood. 1992 Jul 1;80(1):255-6.
1874446	Toniolo D, Filippi M, Dono R, Lettieri T, Martini G: The CpG island in the 5' region of the G6PD gene of man and mouse. Gene. 1991 Jun 30;102(2):197-203.
1889820	Chen EY, Cheng A, Lee A, Kuang WJ, Hillier L, Green P, Schlessinger D, Ciccodicola A, D'Urso M: Sequence of human glucose-6-phosphate dehydrogenase cloned in plasmids and a yeast artificial chromosome. Genomics. 1991 Jul;10(3):792-800.
1945893	Chao LT, Du CS, Louie E, Zuo L, Chen E, Lubin B, Chiu DT: A to G substitution identified in exon 2 of the G6PD gene among G6PD deficient Chinese. Nucleic Acids Res. 1991 Nov 11;19(21):6056.
2428611	Martini G, Toniolo D, Vulliamy T, Luzzatto L, Dono R, Viglietto G, Paonessa G, D'Urso M, Persico MG: Structural analysis of the X-linked gene encoding human glucose 6-phosphate dehydrogenase. EMBO J. 1986 Aug;5(8):1849-55.
2758468	Kanno H, Huang IY, Kan YW, Yoshida A: Two structural genes on different chromosomes are required for encoding the major subunit of human red cell glucose-6-phosphate dehydrogenase. Cell. 1989 Aug 11;58(3):595-606.
2836867	Hirono A, Beutler E: Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). Proc Natl Acad Sci U S A. 1988 Jun;85(11):3951-4.
2910917	Hirono A, Beutler E: Alternative splicing of human glucose-6-phosphate dehydrogenase messenger RNA in different tissues. J Clin Invest. 1989 Jan;83(1):343-6.
2912069	De Vita G, Alcalay M, Sampietro M, Cappelini MD, Fiorelli G, Toniolo D: Two point mutations are responsible for G6PD polymorphism in Sardinia. Am J Hum Genet. 1989 Feb;44(2):233-40.
3012556	Takizawa T, Huang IY, Ikuta T, Yoshida A: Human glucose-6-phosphate dehydrogenase: primary structure and cDNA cloning. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4157-61.
3126064	Camardella L, Caruso C, Rutigliano B, Romano M, Di Prisco G, Descalzi-Cancedda F: Human erythrocyte glucose-6-phosphate dehydrogenase. Identification of a reactive lysyl residue labelled with pyridoxal 5'-phosphate. Eur J Biochem. 1988 Feb 1;171(3):485-9.
3393536	Vulliamy TJ, D'Urso M, Battistuzzi G, Estrada M, Foulkes NS, Martini G, Calabro V, Poggi V, Giordano R, Town M, et al.: Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5171-5.
3446582	Takizawa T, Yoneyama Y, Miwa S, Yoshida A: A single nucleotide base transition is the basis of the common human glucose-6-phosphate dehydrogenase variant A (+). Genomics. 1987 Nov;1(3):228-31.
3515319	Persico MG, Viglietto G, Martini G, Toniolo D, Paonessa G, Moscatelli C, Dono R, Vulliamy T, Luzzatto L, D'Urso M: Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5' non-coding region. Nucleic Acids Res. 1986 Mar 25;14(6):2511-22.
6696761	Descalzi-Cancedda F, Caruso C, Romano M, di Prisco G, Camardella L: Amino acid sequence of the carboxy-terminal end of human erythrocyte glucose-6-phosphate dehydrogenase. Biochem Biophys Res Commun. 1984 Jan 13;118(1):332-8.
7825590	Ganczakowski M, Town M, Bowden DK, Vulliamy TJ, Kaneko A, Clegg JB, Weatherall DJ, Luzzatto L: Multiple glucose 6-phosphate dehydrogenase-deficient variants correlate with malaria endemicity in the Vanuatu archipelago (southwestern Pacific). Am J Hum Genet. 1995 Jan;56(1):294-301.
7857286	Camardella L, Damonte G, Carratore V, Benatti U, Tonetti M, Moneti G: Glucose 6-phosphate dehydrogenase from human erythrocytes: identification of N-acetyl-alanine at the N-terminus of the mature protein. Biochem Biophys Res Commun. 1995 Feb 6;207(1):331-8.
7858267	Mason PJ, Sonati MF, MacDonald D, Lanza C, Busutil D, Town M, Corcoran CM, Kaeda JS, Stevens DJ, al-Ismail S, et al.: New glucose-6-phosphate dehydrogenase mutations associated with chronic anemia. Blood. 1995 Mar 1;85(5):1377-80.
7959695	Filosa S, Cai W, Galanello R, Cao A, de Mattia D, Schettini F, Martini G: A novel single-base mutation in the glucose 6-phosphate dehydrogenase gene is associated with chronic non-spherocytic haemolytic anaemia. Hum Genet. 1994 Nov;94(5):560-2.
8193373	Hirono A, Miwa S, Fujii H, Ishida F, Yamada K, Kubota K: Molecular study of eight Japanese cases of glucose-6-phosphate dehydrogenase deficiency by nonradioisotopic single-strand conformation polymorphism analysis. Blood. 1994 Jun 1;83(11):3363-8.
8364584	Vulliamy T, Beutler E, Luzzatto L: Variants of glucose-6-phosphate dehydrogenase are due to missense mutations spread throughout the coding region of the gene. Hum Mutat. 1993;2(3):159-67.
8466644	Kanno H, Kondoh T, Yoshida A: 5' structure and expression of human glucose-6-phosphate dehydrogenase mRNA. DNA Cell Biol. 1993 Apr;12(3):209-15.
8490627	Nafa K, Reghis A, Osmani N, Baghli L, Benabadji M, Kaplan JC, Vulliamy TJ, Luzzatto L: G6PD Aures: a new mutation (48 Ile-->Thr) causing mild G6PD deficiency is associated with favism. Hum Mol Genet. 1993 Jan;2(1):81-2.
8533762	Kaeda JS, Chhotray GP, Ranjit MR, Bautista JM, Reddy PH, Stevens D, Naidu JM, Britt RP, Vulliamy TJ, Luzzatto L, et al.: A new glucose-6-phosphate dehydrogenase variant, G6PD Orissa (44 Ala-->Gly), is the major polymorphic variant in tribal populations in India. Am J Hum Genet. 1995 Dec;57(6):1335-41.
8733135	Chen EY, Zollo M, Mazzarella R, Ciccodicola A, Chen CN, Zuo L, Heiner C, Burough F, Repetto M, Schlessinger D, D'Urso M: Long-range sequence analysis in Xq28: thirteen known and six candidate genes in 219.4 kb of high GC DNA between the RCP/GCP and G6PD loci. Hum Mol Genet. 1996 May;5(5):659-68.
9452072	Vlachos A, Westwood B, Lipton JM, Beutler E: G6PD Mount Sinai: a new severe hemolytic variant characterized by dual mutations at nucleotides 376G and 1159T (N126D). Hum Mutat. 1998;Suppl 1:S154-5.

# Drug_Target_25_HGNC_ID:
HGNC:4057

# Drug_Target_25_HPRD_ID:
02377

# Drug_Target_25_ID:
1799

# Drug_Target_25_Locus:
Xq28

# Drug_Target_25_Molecular_Weight:
59257

# Drug_Target_25_Name:
Glucose-6-phosphate 1-dehydrogenase

# Drug_Target_25_Number_of_Residues:
515

# Drug_Target_25_PDB_ID:
1QKI

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF00479	G6PD_N
PF02781	G6PD_C

# Drug_Target_25_Protein_Sequence:
>Glucose-6-phosphate 1-dehydrogenase
MAEQVALSRTQVCGILREELFQGDAFHQSDTHIFIIMGASGDLAKKKIYPTIWWLFRDGL
LPENTFIVGYARSRLTVADIRKQSEPFFKATPEEKLKLEDFFARNSYVAGQYDDAASYQR
LNSHMNALHLGSQANRLFYLALPPTVYEAVTKNIHESCMSQIGWNRIIVEKPFGRDLQSS
DRLSNHISSLFREDQIYRIDHYLGKEMVQNLMVLRFANRIFGPIWNRDNIACVILTFKEP
FGTEGRGGYFDEFGIIRDVMQNHLLQMLCLVAMEKPASTNSDDVRDEKVKVLKCISEVQA
NNVVLGQYVGNPDGEGEATKGYLDDPTVPRGSTTATFAAVVLYVENERWDGVPFILRCGK
ALNERKAEVRLQFHDVAGDIFHQQCKRNELVIRVQPNEAVYTKMMTKKPGMFFNPEESEL
DLTYGNRYKNVKLPDAYERLILDVFCGSQMHFVRSDELREAWRIFTPLLHQIELEKPKPI
PYIYGSRGPTEADELMKRVGFQYEGTYKWVNPHKL

# Drug_Target_25_Reaction:
D-glucose 6-phosphate + NADP+ = D-glucono-1,5-lactone 6-phosphate + NADPH + H+

# Drug_Target_25_Signals:
None

# Drug_Target_25_Specific_Function:
Produces pentose sugars for nucleic acid synthesis and main producer of NADPH reducing power

# Drug_Target_25_SwissProt_ID:
P11413

# Drug_Target_25_SwissProt_Name:
G6PD_HUMAN

# Drug_Target_25_Synonyms:
EC 1.1.1.49
G6PD

# Drug_Target_25_Theoretical_pI:
6.84

# Drug_Target_25_Transmembrane_Regions:
None

# Drug_Target_26_Cellular_Location:
Not Available

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
DHFR

# Drug_Target_26_GenBank_ID_Gene:
J00140

# Drug_Target_26_GenBank_ID_Protein:
182724

# Drug_Target_26_GeneCard_ID:
DHFR

# Drug_Target_26_Gene_Name:
DHFR

# Drug_Target_26_Gene_Sequence:
>564 bp
ATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAAC
GGGGACCTGCCCTGGCCACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACA
ACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCC
ATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTC
AAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTT
ACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCT
GTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATG
CAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTG
CCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTT
GAAGTATATGAGAAGAATGATTAA

# Drug_Target_26_General_Function:
Coenzyme transport and metabolism

# Drug_Target_26_General_References:
1731871	Stockman BJ, Nirmala NR, Wagner G, Delcamp TJ, DeYarman MT, Freisheim JH: Sequence-specific 1H and 15N resonance assignments for human dihydrofolate reductase in solution. Biochemistry. 1992 Jan 14;31(1):218-29.
2248959	Davies JF 2nd, Delcamp TJ, Prendergast NJ, Ashford VA, Freisheim JH, Kraut J: Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry. 1990 Oct 9;29(40):9467-79.
3383852	Oefner C, D'Arcy A, Winkler FK: Crystal structure of human dihydrofolate reductase complexed with folate. Eur J Biochem. 1988 Jun 1;174(2):377-85.
6235374	Yang JK, Masters JN, Attardi G: Human dihydrofolate reductase gene organization. Extensive conservation of the G + C-rich 5' non-coding sequence and strong intron size divergence from homologous mammalian genes. J Mol Biol. 1984 Jun 25;176(2):169-87.
6323448	Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J, Nienhuis AW: The functional human dihydrofolate reductase gene. J Biol Chem. 1984 Mar 25;259(6):3933-43.
6687716	Masters JN, Attardi G: The nucleotide sequence of the cDNA coding for the human dihydrofolic acid reductase. Gene. 1983 Jan-Feb;21(1-2):59-63.
9374868	Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Blakley RL: Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry. 1997 Nov 11;36(45):13897-903.

# Drug_Target_26_HGNC_ID:
HGNC:2861

# Drug_Target_26_HPRD_ID:
00519

# Drug_Target_26_ID:
365

# Drug_Target_26_Locus:
5q11.2-q13.2

# Drug_Target_26_Molecular_Weight:
21322

# Drug_Target_26_Name:
Dihydrofolate reductase

# Drug_Target_26_Number_of_Residues:
186

# Drug_Target_26_PDB_ID:
1MVT

# Drug_Target_26_Pathway:
Methotrexate Pathway	SMP00432

# Drug_Target_26_Pfam_Domain_Function:
PF00186	DHFR_1

# Drug_Target_26_Protein_Sequence:
>Dihydrofolate reductase
VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSI
PEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSV
YKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFE
VYEKND

# Drug_Target_26_Reaction:
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+

# Drug_Target_26_Signals:
None

# Drug_Target_26_Specific_Function:
Not Available

# Drug_Target_26_SwissProt_ID:
P00374

# Drug_Target_26_SwissProt_Name:
DYR_HUMAN

# Drug_Target_26_Synonyms:
EC 1.5.1.3

# Drug_Target_26_Theoretical_pI:
7.60

# Drug_Target_26_Transmembrane_Regions:
None

# Drug_Target_27_Cellular_Location:
Not Available

# Drug_Target_27_Chromosome_Location:
Not Available

# Drug_Target_27_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
Not Available

# Drug_Target_27_GenBank_ID_Gene:
M33577

# Drug_Target_27_GenBank_ID_Protein:
147576

# Drug_Target_27_GeneCard_ID:
Not Available

# Drug_Target_27_Gene_Name:
hldD

# Drug_Target_27_Gene_Sequence:
>933 bp
ATGATCATCGTTACCGGCGGCGCGGGCTTTATCGGCAGCAACATCGTTAAAGCCCTGAAT
GATAAAGGCATCACCGATATTCTGGTGGTGGACAACCTGAAAGACGGCACCAAGTTTGTG
AACCTGGTGGATCTGAATATCGCAGACTATATGGATAAGGAAGACTTCCTGATCCAGATT
ATGGCTGGCGAAGAGTTCGGCGATGTCGAAGCGATTTTCCACGAAGGCGCGTGCTCTTCC
ACCACCGAGTGGGACGGCAAGTATATGATGGATAACAACTATCAATACTCCAAGGAGCTG
CTGCACTACTGCCTGGAGCGTGAAATCCCGTTCCTGTACGCTTCTTCCGCAGCCACCTAC
GGCGGACGCACCTCCGACTTTATTGAATCCCGCGAGTACGAAAAACCGTTGAACGTCTAC
GGTTACTCAAAATTCCTGTTTGATGAATATGTTCGTCAAATCCTGCCTGAAGCGAACTCG
CAGATTGTTGGCTTCCGTTATTTCAACGTTTATGGACCGCGTGAAGGCCATAAAGGCAGC
ATGGCGAGCGTCGCTTTCCATCTCAACACCCAGCTTAACAACGGTGAATCACCGAAGCTG
TTTGAAGGTAGCGAGAACTTCAAACGCGACTTCGTCTATGTGGGCGACGTGGCTGATGTG
AATCTGTGGTTCCTGGAAAATGGCGTTTCCGGCATCTTCAATCTCGGTACTGGTCGTGCG
GAATCCTTCCAGGCGGTAGCTGATGCTACGCTGGCTTATCACAAGAAAGGCCAGATCGAA
TACATTCCGTTCCCGGATAAACTGAAAGGCCGCTATCAGGCGTTCACTCAGGCAGATCTG
ACAAATCTGCGCGCGGCGGGTTACGACAAACCGTTCAAAACCGTTGCTGAAGGTGTAACG
GAATACATGGCCTGGCTGAATCGCGACGCATAA

# Drug_Target_27_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_27_General_References:
1861974	Raina S, Georgopoulos C: The htrM gene, whose product is essential for Escherichia coli viability only at elevated temperatures, is identical to the rfaD gene. Nucleic Acids Res. 1991 Jul 25;19(14):3811-9.
2198271	Pegues JC, Chen LS, Gordon AW, Ding L, Coleman WG Jr: Cloning, expression, and characterization of the Escherichia coli K-12 rfaD gene. J Bacteriol. 1990 Aug;172(8):4652-60.
7929099	Ding L, Seto BL, Ahmed SA, Coleman WG Jr: Purification and properties of the Escherichia coli K-12 NAD-dependent nucleotide diphosphosugar epimerase, ADP-L-glycero-D-mannoheptose 6-epimerase. J Biol Chem. 1994 Sep 30;269(39):24384-90.
8041620	Sofia HJ, Burland V, Daniels DL, Plunkett G 3rd, Blattner FR: Analysis of the Escherichia coli genome. V. DNA sequence of the region from 76.0 to 81.5 minutes. Nucleic Acids Res. 1994 Jul 11;22(13):2576-86.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_27_HGNC_ID:
Not Available

# Drug_Target_27_HPRD_ID:
Not Available

# Drug_Target_27_ID:
2375

# Drug_Target_27_Locus:
Not Available

# Drug_Target_27_Molecular_Weight:
34893

# Drug_Target_27_Name:
ADP-L-glycero-D-manno-heptose-6-epimerase

# Drug_Target_27_Number_of_Residues:
310

# Drug_Target_27_PDB_ID:
1EQ2

# Drug_Target_27_Pathway:
Not Available

# Drug_Target_27_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_27_Protein_Sequence:
>ADP-L-glycero-D-manno-heptose-6-epimerase
MIIVTGGAGFIGSNIVKALNDKGITDILVVDNLKDGTKFVNLVDLNIADYMDKEDFLIQI
MAGEEFGDVEAIFHEGACSSTTEWDGKYMMDNNYQYSKELLHYCLEREIPFLYASSAATY
GGRTSDFIESREYEKPLNVYGYSKFLFDEYVRQILPEANSQIVGFRYFNVYGPREGHKGS
MASVAFHLNTQLNNGESPKLFEGSENFKRDFVYVGDVADVNLWFLENGVSGIFNLGTGRA
ESFQAVADATLAYHKKGQIEYIPFPDKLKGRYQAFTQADLTNLRAAGYDKPFKTVAEGVT
EYMAWLNRDA

# Drug_Target_27_Reaction:
ADP-D-glycero-D-manno-heptose = ADP-L-glycero-D-manno-heptose

# Drug_Target_27_Signals:
None

# Drug_Target_27_Specific_Function:
Catalyzes the interconversion between ADP-D-glycero- beta-D-manno-heptose and ADP-L-glycero-beta-D-manno-heptose via an epimerization at carbon 6 of the heptose

# Drug_Target_27_SwissProt_ID:
P67910

# Drug_Target_27_SwissProt_Name:
HLDD_ECOLI

# Drug_Target_27_Synonyms:
ADP-L- glycero-beta-D-manno-heptose-6-epimerase
ADP-glyceromanno-heptose 6- epimerase
ADP-hep 6-epimerase
AGME
EC 5.1.3.20

# Drug_Target_27_Theoretical_pI:
4.54

# Drug_Target_27_Transmembrane_Regions:
None

# Drug_Target_28_Cellular_Location:
Cytoplasm

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
MTHFD1

# Drug_Target_28_GenBank_ID_Gene:
J04031

# Drug_Target_28_GenBank_ID_Protein:
307178

# Drug_Target_28_GeneCard_ID:
MTHFD1

# Drug_Target_28_Gene_Name:
MTHFD1

# Drug_Target_28_Gene_Sequence:
>2808 bp
ATGGCGCCAGCAGAAATCCTGAACGGGAAGGAGATCTCCGCGCAAATAAGGGCGAGACTG
AAAAATCAAGTCACTCAGTTGAAGGAGCAAGTACCTGGTTTCACACCACGCCTGGCAATA
TTACAGGTTGGCAACAGAGATGATTCCAATCTTTATATAAATGTGAAGCTGAAGGCTGCT
GAAGAGATTGGGATCAAAGCCACTCACATTAAGTTACCAAGAACAACCACAGAATCTGAG
GTGATGAAGTACATTACATCTTTGAATGAAGACTCTACTGTACATGGGTTCTTAGTGCAG
CTACCTTTAGATTCAGAGAATTCCATTAACACTGAAGAAGTGATCAATGCTATTGCACCC
GAGAAGGATGTGGATGGATTGACTAGCATCAATGCTGGGAGACTTGCTAGAGGTGACCTC
AATGACTGTTTCATTCCTTGTACGCCTAAGGGATGCTTGGAACTCATCAAAGAGACAGGG
GTGCCGATTGCCGGAAGGCATGCTGTGGTGGTTGGGCGCAGTAAAATAGTTGGGGCCCCG
ATGCATGACTTGCTTCTGTGGAACAATGCCACAGTGACCACCTGCCACTCCAAGACTGCC
CATCTGGATGAGGAGGTAAATAAAGGTGACATCCTGGTGGTTGCAACTGGTCAGCCTGAA
ATGGTTAAAGGGGAGTGGATCAAACCTGGGGCAATAGTCATCGACTGTGGAATCAATTAT
GTCCCAGATGATAAAAAACCAAATGGGAGAAAAGTTGTGGGTGATGTGGCATACGACGAG
GCCAAAGAGAGGGCGAGCTTCATCACTCCTGTTCCTGGCGGCGTAGGGCCCATGACAGTT
GCAATGCTCATGCAGAGCACAGTAGAGAGTGCCAAGCGTTTCCTGGAGAAATTTAAGCCA
GGAAAGTGGATGATTCAGTATAACAACCTTAACCTCAAGACACCTGTTCCAAGTGACATT
GATATATCACGATCTTGTAAACCGAAGCCCATTGGTAAGCTGGCTCGAGAAATTGGTCTG
CTGTCTGAAGAGGTAGAATTATATGGTGAAACAAAGGCCAAAGTTCTGCTGTCAGCACTA
GAACGCCTGAAGCACCGGCCTGATGGGAAATACGTGGTGGTGACTGGAATAACTCCAACA
CCCCTGGGAGAAGGGAAAAGCACAACTACAATCGGGCTAGTGCAAGCCCTTGGTGCCCAT
CTCTACCAGAATGTCTTTGCGTGTGTGCGACAGCCTTCTCAGGGCCCCACCTTTGGAATA
AAAGGTGGCGCTGCAGGAGGCGGCTACTCCCAGGTCATTCCTATGGAAGAGTTTAATCTC
CACCTCACAGGTGACATCCATGCCATCACTGCAGCTAATAACCTCGTTGCTGCGGCCATT
GATGCTCGGATATTTCATGAACTGACCCAGACAGACAAGGCTCTCTTTAATCGTTTGGTG
CCATCAGTAAATGGAGTGAGAAGGTTCTCTGACATCCAAATCCGAAGGTTAAAGAGACTA
GGCATTGAAAAGACTGACCCTACCACACTGACAGATGAAGAGATAAACAGATTTGCAAGA
TTGGACATTGATCCAGAAACCATAACTTGGCAAAGAGTGTTGGATACCAATGATAGATTC
CTGAGGAAGATCACGATTGGACAGGCTCCAACGGAGAAGGGTCACACACGGACGGCCCAG
TTTGATATCTCTGTGGCCAGTGAAATTATGGCTGTCCTGGCTCTCACCACTTCTCTAGAA
GACATGAGAGAGAGACTGGGCAAAATGGTGGTGGCATCCAGTAAGAAAGGAGAGCCCGTC
AGTGCCGAAGATCTGGGGGTGAGTGGTGCACTGACAGTGCTTATGAAGGACGCAATCAAG
CCCAATCTCATGCAGACACTGGAGGGCACTCCAGTGTTTGTCCATGCTGGCCCGTTTGCC
AACATCGCACATGGCAATTCCTCCATCATTGCAGACCGGATCGCACTCAAGCTTGTTGGC
CCAGAAGGGTTTGTAGTGACGGAAGCAGGATTTGGAGCAGACATTGGAATGGAAAAGTTT
TTTAACATCAAATGCCGGTATTCCGGCCTCTGCCCCCACGTGGTGGTGCTTGTTGCCACT
GTCAGGGCTCTCAAGATGCACGGGGGCGGCCCCACGGTCACTGCTGGACTGCCTCTTCCC
AAGGCTTACATACAGGAGAACCTGGAGCTGGTTGAAAAAGGCTTCAGTAACTTGAAGAAA
CAAATTGAAAATGCCAGAATGTTTGGAATTCCAGTAGTAGTGGCCGTGAATGCATTCAAG
ACGGATACAGAGTCTGAGCTGGACCTCATCAGCCGCCTTTCCAGAGAACATGGGGCTTTT
GATGCCGTGAAGTGCACTCACTGGGCAGAAGGGGGCAAGGGTGCCTTAGCCCTGGCTCAG
GCCGTCCAGAGAGCAGCACAAGCACCCAGCAGCTTCCAGCTCCTTTATGACCTCAAGCTC
CCAGTTGAGGATAAAATCAGGATCATTGCACAGAAGATCTATGGAGCAGATGACATTGAA
TTACTTCCCGAAGCTCAACACAAAGCTGAAGTCTACACGAAGCAGGGCTTTGGGAATCTC
CCCATCTGCATGGCTAAAACACACTTGTCTTTGTCTCACAACCCAGAGCAAAAAGGTGTC
CCTACAGGCTTCATTCTGCCCATTCGCGACATCCGCGCCAGCGTTGGGGCTGGTTTTCTG
TACCCCTTAGTAGGAACGATGAGCACAATGCCTGGACTCCCCACCCGGCCCTGTTTTTAT
GATATTGATTTGGACCCTGAAACAGAACAGGTGAATGGATTATTCTAA

# Drug_Target_28_General_Function:
Nucleotide transport and metabolism

# Drug_Target_28_General_References:
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
3053686	Hum DW, Bell AW, Rozen R, MacKenzie RE: Primary structure of a human trifunctional enzyme. Isolation of a cDNA encoding methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase. J Biol Chem. 1988 Nov 5;263(31):15946-50.
9519408	Allaire M, Li Y, MacKenzie RE, Cygler M: The 3-D structure of a folate-dependent dehydrogenase/cyclohydrolase bifunctional enzyme at 1.5 A resolution. Structure. 1998 Feb 15;6(2):173-82.
9611072	Hol FA, van der Put NM, Geurds MP, Heil SG, Trijbels FJ, Hamel BC, Mariman EC, Blom HJ: Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin Genet. 1998 Feb;53(2):119-25.

# Drug_Target_28_HGNC_ID:
HGNC:7432

# Drug_Target_28_HPRD_ID:
01403

# Drug_Target_28_ID:
679

# Drug_Target_28_Locus:
14q24

# Drug_Target_28_Molecular_Weight:
101429

# Drug_Target_28_Name:
C-1-tetrahydrofolate synthase, cytoplasmic

# Drug_Target_28_Number_of_Residues:
934

# Drug_Target_28_PDB_ID:
1DIA

# Drug_Target_28_Pathway:
Not Available

# Drug_Target_28_Pfam_Domain_Function:
PF00763	THF_DHG_CYH
PF01268	FTHFS
PF02882	THF_DHG_CYH_C

# Drug_Target_28_Protein_Sequence:
>C-1-tetrahydrofolate synthase, cytoplasmic
APAEILNGKEISAQIRARLKNQVTQLKEQVPGFTPRLAILQVGNRDDSNLYINVKLKAAE
EIGIKATHIKLPRTTTESEVMKYITSLNEDSTVHGFLVQLPLDSENSINTEEVINAIAPE
KDVDGLTSINAGRLARGDLNDCFIPCTPKGCLELIKETGVPIAGRHAVVVGRSKIVGAPM
HDLLLWNNATVTTCHSKTAHLDEEVNKGDILVVATGQPEMVKGEWIKPGAIVIDCGINYV
PDDKKPNGRKVVGDVAYDEAKERASFITPVPGGVGPMTVAMLMQSTVESAKRFLEKFKPG
KWMIQYNNLNLKTPVPSDIDISRSCKPKPIGKLAREIGLLSEEVELYGETKAKVLLSALE
RLKHRPDGKYVVVTGITPTPLGEGKSTTTIGLVQALGAHLYQNVFACVRQPSQGPTFGIK
GGAAGGGYSQVIPMEEFNLHLTGDIHAITAANNLVAAAIDARIFHELTQTDKALFNRLVP
SVNGVRRFSDIQIRRLKRLGIEKTDPTTLTDEEINRFARLDIDPETITWQRVLDTNDRFL
RKITIGQAPTEKGHTRTAQFDISVASEIMAVLALTTSLEDMRERLGKMVVASSKKGEPVS
AEDLGVSGALTVLMKDAIKPNLMQTLEGTPVFVHAGPFANIAHGNSSIIADRIALKLVGP
EGFVVTEAGFGADIGMEKFFNIKCRYSGLCPHVVVLVATVRALKMHGGGPTVTAGLPLPK
AYIQENLELVEKGFSNLKKQIENARMFGIPVVVAVNAFKTDTESELDLISRLSREHGAFD
AVKCTHWAEGGKGALALAQAVQRAAQAPSSFQLLYDLKLPVEDKIRIIAQKIYGADDIEL
LPEAQHKAEVYTKQGFGNLPICMAKTHLSLSHNPEQKGVPTGFILPIRDIRASVGAGFLY
PLVGTMSTMPGLPTRPCFYDIDLDPETEQVNGLF

# Drug_Target_28_Reaction:
5,10-methylenetetrahydrofolate + NADP+ = 5,10-methenyltetrahydrofolate + NADPH + H+

# Drug_Target_28_Signals:
None

# Drug_Target_28_Specific_Function:
Not Available

# Drug_Target_28_SwissProt_ID:
P11586

# Drug_Target_28_SwissProt_Name:
C1TC_HUMAN

# Drug_Target_28_Synonyms:
C1-THF synthase

# Drug_Target_28_Theoretical_pI:
7.32

# Drug_Target_28_Transmembrane_Regions:
None

# Drug_Target_29_Cellular_Location:
Cytoplasm

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
AKR1C3

# Drug_Target_29_GenBank_ID_Gene:
S68288

# Drug_Target_29_GenBank_ID_Protein:
4261711

# Drug_Target_29_GeneCard_ID:
AKR1C3

# Drug_Target_29_Gene_Name:
AKR1C3

# Drug_Target_29_Gene_Sequence:
>972 bp
ATGGATTCCAAACAGCAGTGTGTAAAGCTAAATGATGGCCACTTCATGCCTGTATTGGGA
TTTGGCACCTATGCACCTCCAGAGGTTCCGAGAAGTAAAGCTTTGGAGGTCACAAAATTA
GCAATAGAAGCTGGGTTCCGCCATATAGATTCTGCTCATTTATACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTTGAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGTCCACTTTTCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AACTCACTGAAGAAAGCTCAATTGGACTATGTTGACCTCTATCTTATTCATTCTCCAATG
TCTCTAAAGCCAGGTGAGGAACTTTCACCAACAGATGAAAATGGAAAAGTAATATTTGAC
ATAGTGGATCTCTGTACCACCTGGGAGGCCATGGAGAAGTGTAAGGATGCAGGATTGGCC
AAGTCCATTGGGGTATCAAACTTCAACCGCAGGCAGCTGGAGATCATCCTCAACAAGCCA
GGACTCAAGTACAAGCCTGTCTGCAACCAGGTAGAATGTCATCCGTATTTCAACCGGAGT
AAATTGCTAGATTTCTGCAAGTCGAAAGATATTGTTCTGGTTGCCTATAGTGCTCTGGGA
TCTCAACGAGACAAACGATGGGTGGACCCGAACTCCCCGGTCCTCTTGGAGGACCCAGTC
CTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC
GTGCAGGTTTTTGAGTTCCAGTTGACTGCAGAGGACATGAAAGCCATAGATGGCCTAGAC
AGAAATCTCCACTATTTTAACAGTGATAGTTTTGCTAGCCACCCTAATTATCCATATTCA
GATGAATATTAA

# Drug_Target_29_General_Function:
Involved in oxidoreductase activity

# Drug_Target_29_General_References:
10557352	Griffin LD, Mellon SH: Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13512-7.
10622721	Suzuki-Yamamoto T, Nishizawa M, Fukui M, Okuda-Ashitaka E, Nakajima T, Ito S, Watanabe K: cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett. 1999 Dec 3;462(3):335-40.
10672042	Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S: Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000 Feb;5(2):111-25.
11165022	Penning TM, Burczynski ME, Jez JM, Lin HK, Ma H, Moore M, Ratnam K, Palackal N: Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Mol Cell Endocrinol. 2001 Jan 22;171(1-2):137-49.
7626489	Khanna M, Qin KN, Cheng KC: Distribution of 3 alpha-hydroxysteroid dehydrogenase in rat brain and molecular cloning of multiple cDNAs encoding structurally related proteins in humans. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):41-6.
7650035	Khanna M, Qin KN, Wang RW, Cheng KC: Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases. J Biol Chem. 1995 Aug 25;270(34):20162-8.
7788527	Nagase T, Miyajima N, Tanaka A, Sazuka T, Seki N, Sato S, Tabata S, Ishikawa K, Kawarabayasi Y, Kotani H, et al.: Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. 1995;2(1):37-43.
8274401	Qin KN, New MI, Cheng KC: Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 1993 Dec;46(6):673-9.
9415401	Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM: Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol. 1997 Dec;11(13):1971-84.
9927279	Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V: Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology. 1999 Feb;140(2):568-74.

# Drug_Target_29_HGNC_ID:
HGNC:386

# Drug_Target_29_HPRD_ID:
04911

# Drug_Target_29_ID:
650

# Drug_Target_29_Locus:
10p15-p14

# Drug_Target_29_Molecular_Weight:
36845

# Drug_Target_29_Name:
Aldo-keto reductase family 1 member C3

# Drug_Target_29_Number_of_Residues:
323

# Drug_Target_29_PDB_ID:
1XF0

# Drug_Target_29_Pathway:
Acetylsalicylic Acid Pathway	SMP00083
Bromfenac Pathway	SMP00102
Celecoxib Pathway	SMP00096
Diclofenac Pathway	SMP00093
Diflunisal Pathway	SMP00289
Etodolac Pathway	SMP00084
Ibuprofen Pathway	SMP00086
Indomethacin Pathway	SMP00104
Ketoprofen Pathway	SMP00085
Ketorolac Pathway	SMP00098
Mefanamic Acid Pathway	SMP00109
Meloxicam Pathway	SMP00106
Nabumetone Pathway	SMP00114
Naproxen Pathway	SMP00120
Oxaprozin Pathway	SMP00113
Piroxicam Pathway	SMP00077
Rofecoxib Pathway	SMP00087
Sulindac Pathway	SMP00094
Suprofen Pathway	SMP00101
Valdecoxib Pathway	SMP00116

# Drug_Target_29_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_29_Protein_Sequence:
>Aldo-keto reductase family 1 member C3
MDSKQQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPM
SLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKP
GLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLD
RNLHYFNSDSFASHPNYPYSDEY

# Drug_Target_29_Reaction:
estradiol-17beta + NAD(P)+ = estrone + NAD(P)H + H+

# Drug_Target_29_Signals:
None

# Drug_Target_29_Specific_Function:
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9alpha,11beta- PGF2 to PGD2. Functions as a bi-directional 3alpha-, 17beta- and 20alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone

# Drug_Target_29_SwissProt_ID:
P42330

# Drug_Target_29_SwissProt_Name:
AK1C3_HUMAN

# Drug_Target_29_Synonyms:
17-beta-HSD 5
17-beta-hydroxysteroid dehydrogenase type 5
3-alpha- hydroxysteroid dehydrogenase type 2
3-alpha-HSD type 2
3-alpha-HSD type II, brain
Chlordecone reductase homolog HAKRb
DD-3
DD3
Dihydrodiol dehydrogenase 3
Dihydrodiol dehydrogenase type I
EC 1.-.-.-
EC 1.1.1.188
EC 1.1.1.213
EC 1.1.1.62
EC 1.3.1.20
Estradiol 17-beta-dehydrogenase
HA1753
PGFS
Prostaglandin F synthase
Trans-1,2- dihydrobenzene-1,2-diol dehydrogenase

# Drug_Target_29_Theoretical_pI:
8.06

# Drug_Target_29_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
POR

# Drug_Target_2_GenBank_ID_Gene:
S90469

# Drug_Target_2_GenBank_ID_Protein:
247307

# Drug_Target_2_GeneCard_ID:
POR

# Drug_Target_2_Gene_Name:
POR

# Drug_Target_2_Gene_Sequence:
>2031 bp
GGAGACTCCCACGTGGACACCAGCTCCACCGTGTCCGAGGCGGTGGCCGAAGAAGTATCT
CTTTTCAGCATGACGGACATGATTCTGTTTTCGCTCATCGTGGGTCTCCTAACCTACTGG
TTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCGAGTTCACCAAAATTCAGACATTGACC
TCCTCTGTCAGAGAGAGCAGCTTTGTGGAAAAGATGAAGAAAACGGGGAGGAACATCATC
GTGTTCTACGGCTCCCAGACGGGGACTGCAGAGGAGTTTGCCAACCGCCTGTCCAAGGAC
GCCCACCGCTACGGGATGCGAGGCATGTCAGCGGACCCTGAGGAGTATGACCTGGCCGAC
CTGAGCAGCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATGGCCACCTACGGT
GAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTGGCTGCAGGAGACAGACGTG
GATCTCTCTGGGGTCAAGTTCGCGGTGTTTGGTCTTGGGAACAAGACCTACGAGCACTTC
AATGCCATGGGCAAGTACGTGGACAAGCGGCTGGAGCAGCTCGGCGCCCAGCGCATCTTT
GAGCTGGGGTTGGGCGACGACGATGGGAACTTGGAGGAGGACTTCATCACCTGGCGAGAG
CAGTTCTGGCCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGAGGAGTCCAGC
ATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGGCCAAGGTGTACATGGGG
GAGATGGGCCGGCTGAAGAGCTACGAGAACCAGAAGCCCCCCTTTGATGCCAAGAATCCG
TTCCTGGCTGCAGTCACCACCAACCGGAAGCTGAACCAGGGAACCGAGCGCCACCTCATG
CACCTGGAATTGGACATCTCGGACTCCAAAATCAGGTATGAATCTGGGGACCACGTGGCT
GTGTACCCAGCCAACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTGGGTGCCGAC
CTGGACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAAGAAGCACCCATTC
CCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTACCTGGACATCACCAACCCGCCG
CGTACCAACGTGCTGTACGAGCTGGCGCAGTACGCCTCGGAGCCCTCGGAGCAGGAGCTG
CTGCGCAAGATGGCCTCCTCCTCCGGCGAGGGCAAGGAGCTGTACCTGAGCTGGGTGGTG
GAGGCCCGGAGGCACATCCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGGCCCCCCATC
GACCACCTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTCCATCGCCTCATCC
TCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGTGGTTGTGGAGTACGAGACCAAG
GCCGGCCGCATCAACAAGGGCGTGGCCACCAACTGGCTGCGGGCCAAGGAGCCTGTCGGG
GAGAACGGCGGCCGTGCGCTGGTGCCCATGTTCGTGCGCAAGTCCCAGTTACGCCTGCCC
TTCAAGGCCACCACGCCTGTCATCATGGTGGGCCCCGGCACCGGGTGGCACCCTTTCATA
GGCTTCATCCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTGGGGGAGACGCTG
CTGTACTACGGCTGCCGCCGCTCGGATGAGGACTACCTGTACCGGGAGGAGCTGGCGCAG
TTCCACAGGGACGGTGCGCTCACCCAGCTCAACGTGGCCTTCTCCCGGGAGCAGTCCCAC
AAGGTCTACGTCCAGCACCTGCTAAAGCAAGACCGAGAGCACCTGTGGAAGTTGATCGAA
GGCGGTGCCCACATCTACGTCTGTGGGGATGCACGGAACATGGCCAGGGATGTGCAGAAC
ACCTTCTACGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGCAGGCGGTGGACTAC
ATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTGGACGTGTGGAGCTAG

# Drug_Target_2_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_2_General_References:
10048323	Zhao Q, Modi S, Smith G, Paine M, McDonagh PD, Wolf CR, Tew D, Lian LY, Roberts GC, Driessen HP: Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution. Protein Sci. 1999 Feb;8(2):298-306.
1550342	Shephard EA, Palmer CN, Segall HJ, Phillips IR: Quantification of cytochrome P450 reductase gene expression in human tissues. Arch Biochem Biophys. 1992 Apr;294(1):168-72.
2513880	Haniu M, McManus ME, Birkett DJ, Lee TD, Shively JE: Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites. Biochemistry. 1989 Oct 17;28(21):8639-45.

# Drug_Target_2_HGNC_ID:
HGNC:9208

# Drug_Target_2_HPRD_ID:
00485

# Drug_Target_2_ID:
4120

# Drug_Target_2_Locus:
7q11.2

# Drug_Target_2_Molecular_Weight:
76691

# Drug_Target_2_Name:
NADPH--cytochrome P450 reductase

# Drug_Target_2_Number_of_Residues:
677

# Drug_Target_2_PDB_ID:
1AMO

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00667	FAD_binding_1

# Drug_Target_2_Protein_Sequence:
>NADPH--cytochrome P450 reductase
MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTL
TSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLA
DLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEH
FNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEES
SIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHL
MHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHP
FPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWV
VEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYET
KAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPF
IGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQS
HKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVD
YIKKLMTKGRYSLDVWS

# Drug_Target_2_Reaction:
NADPH + H+ + n oxidized hemoprotein = NADP+ + n reduced hemoprotein ALL_REAC (other) R00106

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5

# Drug_Target_2_SwissProt_ID:
P16435

# Drug_Target_2_SwissProt_Name:
NCPR_HUMAN

# Drug_Target_2_Synonyms:
CPR
EC 1.6.2.4
P450R

# Drug_Target_2_Theoretical_pI:
5.28

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_30_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
BLVRB

# Drug_Target_30_GenBank_ID_Gene:
D26308

# Drug_Target_30_GenBank_ID_Protein:
1384068

# Drug_Target_30_GeneCard_ID:
BLVRB

# Drug_Target_30_Gene_Name:
BLVRB

# Drug_Target_30_Gene_Sequence:
>621 bp
ATGGCCGTCAAGAAGATCGCGATCTTCGGCGCCACTGGCCAGACCGGGCTCACCACCCTG
GCGCAGGCGGTGCAAGCAGGTTACGAAGTGACAGTGCTGGTGCGGGACTCCTCCAGGCTG
CCATCAGAGGGGCCCCGGCCGGCCCACGTGGTAGTGGGAGATGTTCTGCAGGCAGCCGAT
GTGGACAAGACCGTGGCTGGGCAGGACGCTGTCATCGTGCTGCTGGGCACCCGCAATGAC
CTCAGTCCCACGACAGTGATGTCCGAGGGCGCCCGGAACATTGTGGCAGCCATGAAGGCT
CATGGTGTGGACAAGGTCGTGGCCTGCACCTCGGCTTTCCTGCTCTGGGACCCTACCAAG
GTGCCCCCACGACTGCAGGCTGTGACTGATGACCACATCCGGATGCACAAGGTGCTGCGG
GAATCAGGCCTGAAGTACGTGGCTGTGATGCCGCCACACATAGGAGACCAGCCACTAACT
GGGGCGTACACAGTGACCCTGGATGGACGAGGGCCCTCAAGGGTCATCTCCAAACATGAC
CTGGGCCATTTCATGCTGCGCTGCCTCACCACCGATGAGTACGACGGACACAGCACCTAC
CCCTCCCACCAGTACCAGTAG

# Drug_Target_30_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_30_General_References:
11224564	Pereira PJ, Macedo-Ribeiro S, Parraga A, Perez-Luque R, Cunningham O, Darcy K, Mantle TJ, Coll M: Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme. Nat Struct Biol. 2001 Mar;8(3):215-20.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
7929092	Yamaguchi T, Komoda Y, Nakajima H: Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from human liver. Purification and characterization. J Biol Chem. 1994 Sep 30;269(39):24343-8.
8117274	Chikuba K, Yubisui T, Shirabe K, Takeshita M: Cloning and nucleotide sequence of a cDNA of the human erythrocyte NADPH-flavin reductase. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1170-6.
8280170	Yamaguchi T, Komuro A, Nakano Y, Tomita M, Nakajima H: Complete amino acid sequence of biliverdin-IX beta reductase from human liver. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1518-23.
8313871	Golaz O, Hughes GJ, Frutiger S, Paquet N, Bairoch A, Pasquali C, Sanchez JC, Tissot JD, Appel RD, Walzer C, et al.: Plasma and red blood cell protein maps: update 1993. Electrophoresis. 1993 Nov;14(11):1223-31.
8687377	Shalloe F, Elliott G, Ennis O, Mantle TJ: Evidence that biliverdin-IX beta reductase and flavin reductase are identical. Biochem J. 1996 Jun 1;316 ( Pt 2):385-7.
8799475	Komuro A, Tobe T, Hashimoto K, Nakano Y, Yamaguchi T, Nakajima H, Tomita M: Molecular cloning and expression of human liver biliverdin-IX beta reductase. Biol Pharm Bull. 1996 Jun;19(6):796-804.

# Drug_Target_30_HGNC_ID:
HGNC:1063

# Drug_Target_30_HPRD_ID:
02967

# Drug_Target_30_ID:
654

# Drug_Target_30_Locus:
19q13.1-q13.2

# Drug_Target_30_Molecular_Weight:
21988

# Drug_Target_30_Name:
Flavin reductase

# Drug_Target_30_Number_of_Residues:
205

# Drug_Target_30_PDB_ID:
1HE5

# Drug_Target_30_Pathway:
Not Available

# Drug_Target_30_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_30_Protein_Sequence:
>Flavin reductase
AVKKIAIFGATGQTGLTTLAQAVQAGYEVTVLVRDSSRLPSEGPRPAHVVVGDVLQAADV
DKTVAGQDAVIVLLGTRNDLSPTTVMSEGARNIVAAMKAHGVDKVVACTSAFLLWDPTKV
PPRLQAVTDDHIRMHKVLRESGLKYVAVMPPHIGDQPLTGAYTVTLDGRGPSRVISKHDL
GHFMLRCLTTDEYDGHSTYPSHQYQ

# Drug_Target_30_Reaction:
bilirubin + NAD(P)+ = biliverdin + NAD(P)H + H+

# Drug_Target_30_Signals:
None

# Drug_Target_30_Specific_Function:
Catalyzes electron transfer from reduced pyridine nucleotides to flavins as well as methylene blue, pyrroloquinoline quinone, riboflavin, or methemoglobin. Possible role in protecting cells from oxidative damage or in regulating iron metabolism. In the liver, converts biliverdin to bilirubin

# Drug_Target_30_SwissProt_ID:
P30043

# Drug_Target_30_SwissProt_Name:
BLVRB_HUMAN

# Drug_Target_30_Synonyms:
BVR-B
Biliverdin reductase B
Biliverdin-IX beta-reductase
EC 1.3.1.24
EC 1.5.1.30
FLR
FR
GHBP
Green heme-binding protein
NADPH-dependent diaphorase
NADPH-flavin reductase

# Drug_Target_30_Theoretical_pI:
7.76

# Drug_Target_30_Transmembrane_Regions:
None

# Drug_Target_31_Cellular_Location:
Cytoplasm

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
Not Available

# Drug_Target_31_GenBank_ID_Gene:
D73443

# Drug_Target_31_GenBank_ID_Protein:
1030696

# Drug_Target_31_GeneCard_ID:
Not Available

# Drug_Target_31_Gene_Name:
icd

# Drug_Target_31_Gene_Sequence:
>2226 bp
ATGTCCACACCGAAGATTATCTATACGCTCACTGATGAAGCACCCGCACTGGCGACTTAC
TCTCTGCTTCCCATCATCAAAGCGTTCACCGGATCTTCAGGTATCGCCGTTGAAACCCGC
GATATCTCCCTTGCAGGCCGCCTCATCGCAACCTTCCCCGAATACCTGACCGATACCCAG
AAAATCTCCGACGATTTGGCCGAACTGGGAAAACTGGCCACCACGCCGGACGCCAACATC
ATCAAGCTGCCGAACATCAGCGCCTCCGTCCCGCAACTCAAGGCCGCCATCAAGGAACTG
CAGCAGCAGGGCTACAAGCTCCCGGACTACCCTGAAGAGCCCAAGACCGACACCGAGAAG
GACGTCAAGGCCCGCTACGACAAGATCAAGGGCAGCGCCGTGAACCCCGTCCTGCGCGAA
GGCAACTCCGACCGCCGCGCGCCACTGTCCGTCAAGAACTACGCCAGAAAGCACCCTCAC
AAGATGGGCGCCTGGAGTGCGGACTCCAAGTCCCATGTCGCCCACATGGACAACGGTGAT
TTCTACGGCAGCGAGAAGGCCGCTCTGATTGGCGCCCCCGGCAGTGTGAAAATCGAGCTG
ATCGCCAAAGACGGCAGCAGCACTGTTCTGAAGGCAAAGACCTCTGTTCAGGCTGGCGAG
ATCATCGACTCTTCGGTAATGAGCAAGAACGCCTTGCGCAACTTCATCGCCGCTGAAATC
GAGGATGCGAAGAAGCAGGGAGTACTGCTGTCCGTGCACCTGAAGGCGACCATGATGAAG
GTGTCCGACCCCATCATGTTCGGCCAGATCGTCTCCGAGTTCTACAAGGACGCCCTCACC
AAGCACGCAGAGGTGCTGAAGCAGATCGGCTTCGACGTCAACAATGGCATCGGTGATCTC
TACGCCCGGATCAAGACTCTTCCCGAAGCAAAGCAGAAGGAAATCGAGGCCGACATCCAG
GCGGTTTACGCCCAGCGCCCGCAATTGGCGATGGTGAACTCCGACAAGGGCATCACCAAC
CTGCATGTGCCGAGCGACGTCATCGTCGACGCCTCGATGCCGGCGATGATCCGCGACTCC
GGCAAGATGTGGGGCCCCGACGGCAAGCTGCATGACACCAAGGCGGTCATCCCCGACCGT
TGCTATGCCGGCGTGTACCAGGTGGTCATCGAGGACTGCAAGCAGCACGGCGCCTTCGAC
CCCACCACCATGGGCAGCGTGCCCAACGTCGGTTTGATGGCTCAGAAAGCCGAGGAATAC
GGCTCCCACGACAAGACCTTCCAGATTCCTGCAGACGGCGTGGTCCGTGTGACCGATGAA
AGCGGCAAGCTCTTGCTGGAGCAAAGCGTGGAGGCCGGCGACATTTGGCGCATGTGCCAG
GCGAAAGACGCCCCGATCCAGGACTGGGTCAAGCTGGCCGTCAACCGCGCCCGCGCCACC
AATACCCCGGCGGTGTTCTGGCTGGACCCGGCGCGTGCCCATGATGCCCAGGTTATTGCC
AAGGTCGAGCGTTACCTGAAGGACTACGATACCAGCGGTCTCGACATCCGCATCTTGTCG
CCGGTCGAGGCAACCCGCTTCTCGCTGGCCCGCATCCGCGAAGGCAAGGACACCATTTCC
GTCACCGGCAACGTCCTGCGCGACTACCTGACCGACCTGTTCCCGATCATGGAACTGGGT
ACCAGCGCCAAAATGTTGTCGATCGTCCCGCTGATGAGCGGCGGCGGTCTGTTCGAAACC
GGCGCGGGCGGCTCGGCTCCCAAGCATGTCCAGCAGTTCCTCGAGGAAGGTTACCTGCGT
TGGGATTCGCTCGGCGAGTTCCTCGCTCTTGCCGCATCCCTGGAGCACTTGGGCAACGCC
TACAAGAACCCGAAAGCGCTTGTCCTGGCCAGCACCCTGGACCAGGCTACCGGCAAGATT
CTCGATAACAACAAATCGCCGGCACGTAAGGTTGGCGAGATCGATAACCGCGGTAGCCAC
TTCTACTTGGCACTCTACTGGGCCCAGGCATTGGCAGCGCAAACCGAGGACAAGGAACTG
CAAGCCCAGTTCACCGGCATTGCCAAGGCTCTGACCGACAACGAGACCAAGATCGTCGGC
GAGTTGGCTGCAGCCCAAGGCAAGCCTGTGGATATCGCTGGCTACTACCATCCGAATACC
GACCTGACCAGCAAGGCCATCCGCCCGAGCGCTACTTTCAACGCGGCTCTGGCACCTCTT
GCATAA

# Drug_Target_31_General_Function:
Energy production and conversion

# Drug_Target_31_General_References:
12005040	Sahara T, Takada Y, Takeuchi Y, Yamaoka N, Fukunaga N: Cloning, sequencing, and expression of a gene encoding the monomeric isocitrate dehydrogenase of the nitrogen-fixing bacterium, Azotobacter vinelandii. Biosci Biotechnol Biochem. 2002 Mar;66(3):489-500.
12467571	Yasutake Y, Watanabe S, Yao M, Takada Y, Fukunaga N, Tanaka I: Structure of the monomeric isocitrate dehydrogenase: evidence of a protein monomerization by a domain duplication. Structure. 2002 Dec;10(12):1637-48.
4149369	Edwards DJ, Heinrikson RL, Chung AE: Triphosphopyridine nucleotide specific isocitrate dehydrogenase from Azotobacter vinelandii. Alkylation of a specific methionine residue and amino acid sequence of the peptide containing this residue. Biochemistry. 1974 Feb 12;13(4):677-83.

# Drug_Target_31_HGNC_ID:
Not Available

# Drug_Target_31_HPRD_ID:
Not Available

# Drug_Target_31_ID:
2286

# Drug_Target_31_Locus:
Not Available

# Drug_Target_31_Molecular_Weight:
80390

# Drug_Target_31_Name:
Isocitrate dehydrogenase [NADP]

# Drug_Target_31_Number_of_Residues:
741

# Drug_Target_31_PDB_ID:
1J1W

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF03971	IDH

# Drug_Target_31_Protein_Sequence:
>Isocitrate dehydrogenase [NADP]
MSTPKIIYTLTDEAPALATYSLLPIIKAFTGSSGIAVETRDISLAGRLIATFPEYLTDTQ
KISDDLAELGKLATTPDANIIKLPNISASVPQLKAAIKELQQQGYKLPDYPEEPKTDTEK
DVKARYDKIKGSAVNPVLREGNSDRRAPLSVKNYARKHPHKMGAWSADSKSHVAHMDNGD
FYGSEKAALIGAPGSVKIELIAKDGSSTVLKAKTSVQAGEIIDSSVMSKNALRNFIAAEI
EDAKKQGVLLSVHLKATMMKVSDPIMFGQIVSEFYKDALTKHAEVLKQIGFDVNNGIGDL
YARIKTLPEAKQKEIEADIQAVYAQRPQLAMVNSDKGITNLHVPSDVIVDASMPAMIRDS
GKMWGPDGKLHDTKAVIPDRCYAGVYQVVIEDCKQHGAFDPTTMGSVPNVGLMAQKAEEY
GSHDKTFQIPADGVVRVTDESGKLLLEQSVEAGDIWRMCQAKDAPIQDWVKLAVNRARAT
NTPAVFWLDPARAHDAQVIAKVERYLKDYDTSGLDIRILSPVEATRFSLARIREGKDTIS
VTGNVLRDYLTDLFPIMELGTSAKMLSIVPLMSGGGLFETGAGGSAPKHVQQFLEEGYLR
WDSLGEFLALAASLEHLGNAYKNPKALVLASTLDQATGKILDNNKSPARKVGEIDNRGSH
FYLALYWAQALAAQTEDKELQAQFTGIAKALTDNETKIVGELAAAQGKPVDIAGYYHPNT
DLTSKAIRPSATFNAALAPLA

# Drug_Target_31_Reaction:
(1) isocitrate + NADP+ = 2-oxoglutarate + CO2 + NADPH

# Drug_Target_31_Signals:
None

# Drug_Target_31_Specific_Function:
Isocitrate + NADP(+) = 2-oxoglutarate + CO(2) + NADPH

# Drug_Target_31_SwissProt_ID:
P16100

# Drug_Target_31_SwissProt_Name:
IDH_AZOVI

# Drug_Target_31_Synonyms:
EC 1.1.1.42
IDH
Oxalosuccinate decarboxylase

# Drug_Target_31_Theoretical_pI:
6.58

# Drug_Target_31_Transmembrane_Regions:
None

# Drug_Target_32_Cellular_Location:
Not Available

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
Not Available

# Drug_Target_32_GenBank_ID_Gene:
M26495

# Drug_Target_32_GenBank_ID_Protein:
169408

# Drug_Target_32_GeneCard_ID:
Not Available

# Drug_Target_32_Gene_Name:
Not Available

# Drug_Target_32_Gene_Sequence:
>621 bp
ATGAATCAGCAAAAGTCTTTAACATTGATTGTTGCACTTACAACTTCTTATGGAATTGGC
CGATCAAACTCTCTTCCATGGAAATTAAAGAAAGAAATAAGTTATTTTAAACGAGTAACC
TCTTTTGTACCAACTTTTGATTCATTTGAATCGATGAATGTTGTATTGATGGGTCGAAAA
ACATGGGAAAGTATTCCTTTGCAATTTCGGCCCCTTAAAGGTCGTATTAATGTTGTTATC
ACTCGAAATGAATCTCTGGATCTAGGAAATGGAATTCATTCTGCAAAATCCTTGGATCAT
GCTTTGGAATTGTTATATCGTACATATGGTTCTGAAAGTTCGGTTCAAATTAATCGAATT
TTCGTTATAGGTGGTGCACAGCTATATAAAGCAGCTATGGATCATCCTAAATTAGATAGA
ATTATGGCTACAATAATATACAAGGATATTCATTGTGATGTATTTTTTCCACTTAAATTT
AGGGATAAAGAATGGTCTTCTGTATGGAAAAAAGAAAAACATTCAGATTTAGAATCTTGG
GTTGGTACTAAAGTTCCTCATGGTAAAATAAATGAAGACGGTTTTGATTATGAATTCGAA
ATGTGGACAAGAGATTTATAA

# Drug_Target_32_General_Function:
Coenzyme transport and metabolism

# Drug_Target_32_General_References:
10194348	Cody V, Galitsky N, Rak D, Luft JR, Pangborn W, Queener SF: Ligand-induced conformational changes in the crystal structures of Pneumocystis carinii dihydrofolate reductase complexes with folate and NADP+. Biochemistry. 1999 Apr 6;38(14):4303-12.
2682653	Edman JC, Edman U, Cao M, Lundgren B, Kovacs JA, Santi DV: Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8625-9.
7866743	Champness JN, Achari A, Ballantine SP, Bryant PK, Delves CJ, Stammers DK: The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 A resolution. Structure. 1994 Oct 15;2(10):915-24.

# Drug_Target_32_HGNC_ID:
Not Available

# Drug_Target_32_HPRD_ID:
Not Available

# Drug_Target_32_ID:
2833

# Drug_Target_32_Locus:
Not Available

# Drug_Target_32_Molecular_Weight:
23884

# Drug_Target_32_Name:
Dihydrofolate reductase

# Drug_Target_32_Number_of_Residues:
206

# Drug_Target_32_PDB_ID:
1LY4

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF00186	DHFR_1

# Drug_Target_32_Protein_Sequence:
>Dihydrofolate reductase
MNQQKSLTLIVALTTSYGIGRSNSLPWKLKKEISYFKRVTSFVPTFDSFESMNVVLMGRK
TWESIPLQFRPLKGRINVVITRNESLDLGNGIHSAKSLDHALELLYRTYGSESSVQINRI
FVIGGAQLYKAAMDHPKLDRIMATIIYKDIHCDVFFPLKFRDKEWSSVWKKEKHSDLESW
VGTKVPHGKINEDGFDYEFEMWTRDL

# Drug_Target_32_Reaction:
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+

# Drug_Target_32_Signals:
None

# Drug_Target_32_Specific_Function:
5,6,7,8-tetrahydrofolate + NADP(+) = 7,8- dihydrofolate + NADPH

# Drug_Target_32_SwissProt_ID:
P16184

# Drug_Target_32_SwissProt_Name:
DYR_PNECA

# Drug_Target_32_Synonyms:
EC 1.5.1.3

# Drug_Target_32_Theoretical_pI:
9.67

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Cytoplasm

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
CRYZ

# Drug_Target_33_GenBank_ID_Gene:
L13278

# Drug_Target_33_GenBank_ID_Protein:
292415

# Drug_Target_33_GeneCard_ID:
CRYZ

# Drug_Target_33_Gene_Name:
CRYZ

# Drug_Target_33_Gene_Sequence:
>990 bp
ATGGCGACTGGACAGAAGTTGATGAGAGCTGTTAGAGTTTTTGAATTTGGTGGGCCAGAA
GTCCTGAAATTGCGATCAGATATTGCAGTACCGATTCCAAAAGACCATCAGGTTCTAATC
AAGGTCCATGCATGTGGTGTCAACCCCGTGGAGACATACATTCGCTCTGGTACTTATAGT
AGAAAACCACTCTTACCCTATACTCCTGGCTCAGATGTGGCTGGGGTGATAGAAGCTGTT
GGAGATAATGCATCTGCTTTCAAGAAAGGTGACAGAGTTTTCACTAGCAGCACGATCTCT
GGGGGTTATGCAGAGTATGCTCTTGCAGCAGACCACACTGTTTACAAACTACCTGAAAAA
CTGGACTTTAAACAAGGAGCTGCCATCGGCATTCCATATTTTACTGCTTATCGAGCTCTG
ATCCACAGTGCCTGTGTGAAAGCTGGAGAGAGTGTTCTGGTTCATGGGGCAAGTGGAGGA
GTTGGATTAGCAGCATGCCAAATTGCTAGAGCTTATGGCTTAAAGATTTTGGGCACTGCT
GGTACTGAGGAAGGACAAAAGATTGTTTTGCAAAATGGAGCCCATGAAGTGTTCAATCAC
AGAGAAGTGAATTACATTGATAAAATTAAGAAGTATGTTGGTGAGAAAGGAATTGATATA
ATTATTGAAATGTTAGCTAATGTAAATCTTAGTAAAGACTTGAGTCTTCTGTCACATGGA
GGACGAGTGATAGTTGTTGGCAGCAGAGGTACTATTGAAATAAACCCACGAGACACCATG
GCAAAGGAGTCGAGTATAATTGGAGTTACTCTCTTTTCCTCAACCAAGGAGGAATTTCAG
CAATATGCAGCAGCCCTTCAAGCTGGAATGGAAATTGGCTGGTTGAAACCTGTGATAGGT
TCTCAATATCCATTGGAGAAGGTGGCCGAGGCTCATGAAAATATCATTCATGGTAGTGGG
GCTACTGGAAAAATGATTCTTCTCTTATGA

# Drug_Target_33_General_Function:
Energy production and conversion

# Drug_Target_33_General_References:
8088825	Gonzalez P, Rao PV, Zigler JS Jr: Organization of the human zeta-crystallin/quinone reductase gene (CRYZ). Genomics. 1994 May 15;21(2):317-24.
8466529	Gonzalez P, Rao PV, Zigler JS Jr: Molecular cloning and sequencing of zeta-crystallin/quinone reductase cDNA from human liver. Biochem Biophys Res Commun. 1993 Mar 31;191(3):902-7.

# Drug_Target_33_HGNC_ID:
HGNC:2419

# Drug_Target_33_HPRD_ID:
00437

# Drug_Target_33_ID:
2159

# Drug_Target_33_Locus:
1p31-p22

# Drug_Target_33_Molecular_Weight:
35207

# Drug_Target_33_Name:
Quinone oxidoreductase

# Drug_Target_33_Number_of_Residues:
329

# Drug_Target_33_PDB_ID:
1YB5

# Drug_Target_33_Pathway:
Not Available

# Drug_Target_33_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_33_Protein_Sequence:
>Quinone oxidoreductase
MATGQKLMRAVRVFEFGGPEVLKLRSDIAVPIPKDHQVLIKVHACGVNPVETYIRSGTYS
RKPLLPYTPGSDVAGVIEAVGDNASAFKKGDRVFTSSTISGGYAEYALAADHTVYKLPEK
LDFKQGAAIGIPYFTAYRALIHSACVKAGESVLVHGASGGVGLAACQIARAYGLKILGTA
GTEEGQKIVLQNGAHEVFNHREVNYIDKIKKYVGEKGIDIIIEMLANVNLSKDLSLLSHG
GRVIVVGSRGTIEINPRDTMAKESSIIGVTLFSSTKEEFQQYAAALQAGMEIGWLKPVIG
SQYPLEKVAEAHENIIHGSGATGKMILLL

# Drug_Target_33_Reaction:
NADPH + H+ + quinone = NADP+ + semiquinone

# Drug_Target_33_Signals:
None

# Drug_Target_33_Specific_Function:
Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones are the best substrates. May act in the detoxification of xenobiotics

# Drug_Target_33_SwissProt_ID:
Q08257

# Drug_Target_33_SwissProt_Name:
QOR_HUMAN

# Drug_Target_33_Synonyms:
EC 1.6.5.5
NADPH:quinone reductase
Zeta- crystallin

# Drug_Target_33_Theoretical_pI:
8.70

# Drug_Target_33_Transmembrane_Regions:
None

# Drug_Target_34_Cellular_Location:
Secreted protein (Potential)

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
Not Available

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
Not Available

# Drug_Target_34_GenBank_ID_Gene:
AY358712

# Drug_Target_34_GenBank_ID_Protein:
Not Available

# Drug_Target_34_GeneCard_ID:
Not Available

# Drug_Target_34_Gene_Name:
DHRS11

# Drug_Target_34_Gene_Sequence:
>783 bp
ATGGCCAGGCCCGGCATGGAGCGGTGGCGCGACCGGCTGGCGCTGGTGACGGGGGCCTCG
GGGGGCATCGGCGCGGCCGTGGCCCGGGCCCTGGTCCAGCAGGGACTGAAGGTGGTGGGC
TGCGCCCGCACTGTGGGCAACATCGAGGAGCTGGCTGCTGAATGTAAGAGTGCAGGCTAC
CCCGGGACTTTGATCCCCTACAGATGTGACCTATCAAATGAAGAGGACATCCTCTCCATG
TTCTCAGCTATCCGTTCTCAGCACAGCGGTGTAGACATCTGCATCAACAATGCTGGCTTG
GCCCGGCCTGACACCCTGCTCTCAGGCAGCACCAGTGGTTGGAAGGACATGTTCAATGTG
AACGTGCTGGCCCTCAGCATCTGCACACGGGAAGCCTACCAGTCCATGAAGGAGCGGAAT
GTGGACGATGGGCACATCATTAACATCAATAGCATGTCTGGCCACCGAGTGTTACCCCTG
TCTGTGACCCACTTCTATAGTGCCACCAAGTATGCCGTCACTGCGCTGACAGAGGGACTG
AGGCAAGAGCTTCGGGAGGCCCAGACCCACATCCGAGCCACGTGCATCTCTCCAGGTGTG
GTGGAGACACAATTCGCCTTCAAACTCCACGACAAGGACCCTGAGAAGGCAGCTGCCACC
TATGAGCAAATGAAGTGTCTCAAACCCGAGGATGTGGCCGAGGCTGTTATCTACGTCCTC
AGCACCCCCGCACACATCCAGATTGGAGACATCCAGATGAGGCCCACGGAGCAGGTGACC
TAG

# Drug_Target_34_General_Function:
Involved in oxidoreductase activity

# Drug_Target_34_General_References:
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_34_HGNC_ID:
Not Available

# Drug_Target_34_HPRD_ID:
Not Available

# Drug_Target_34_ID:
5157

# Drug_Target_34_Locus:
Not Available

# Drug_Target_34_Molecular_Weight:
28309

# Drug_Target_34_Name:
Dehydrogenase/reductase SDR family member 11

# Drug_Target_34_Number_of_Residues:
260

# Drug_Target_34_PDB_ID:
1XG5

# Drug_Target_34_Pathway:
Not Available

# Drug_Target_34_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_34_Protein_Sequence:
>Dehydrogenase/reductase SDR family member 11
MARPGMERWRDRLALVTGASGGIGAAVARALVQQGLKVVGCARTVGNIEELAAECKSAGY
PGTLIPYRCDLSNEEDILSMFSAIRSQHSGVDICINNAGLARPDTLLSGSTSGWKDMFNV
NVLALSICTREAYQSMKERNVDDGHIININSMSGHRVLPLSVTHFYSATKYAVTALTEGL
RQELREAQTHIRATCISPGVVETQFAFKLHDKDPEKAAATYEQMKCLKPEDVAEAVIYVL
STPAHIQIGDIQMRPTEQVT

# Drug_Target_34_Reaction:
Not Available

# Drug_Target_34_Signals:
1-30

# Drug_Target_34_Specific_Function:
Not Available

# Drug_Target_34_SwissProt_ID:
Q6UWP2

# Drug_Target_34_SwissProt_Name:
DHR11_HUMAN

# Drug_Target_34_Synonyms:
Dehydrogenase/reductase SDR family member 11 precursor
EC 1.-.-.-

# Drug_Target_34_Theoretical_pI:
6.62

# Drug_Target_34_Transmembrane_Regions:
None

# Drug_Target_35_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
multi-pass membrane protein. Peroxisome
pero

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
HMGCR

# Drug_Target_35_GenBank_ID_Gene:
M11058

# Drug_Target_35_GenBank_ID_Protein:
306865

# Drug_Target_35_GeneCard_ID:
HMGCR

# Drug_Target_35_Gene_Name:
HMGCR

# Drug_Target_35_Gene_Sequence:
>2667 bp
ATGTTGTCAAGACTTTTTCGAATGCATGGCCTCTTTGTGGCCTCCCATCCCTGGGAAGTC
ATAGTGGGGACAGTGACACTGACCATCTGCATGATGTCCATGAACATGTTTACTGGTAAC
AATAAGATCTGTGGTTGGAATTATGAATGTCCAAAGTTTGAAGAGGATGTTTTGAGCAGT
GACATTATAATTCTGACAATAACACGATGCATAGCCATCCTGTATATTTACTTCCAGTTC
CAGAATTTACGTCAACTTGGATCAAAATATATTTTGGGTATTGCTGGCCTTTTCACAATT
TTCTCAAGTTTTGTATTCAGTACAGTTGTCATTCACTTCTTAGACAAAGAATTGACAGGC
TTGAATGAAGCTTTGCCCTTTTTCCTACTTTTGATTGACCTTTCCAGAGCAAGCACATTA
GCAAAGTTTGCCCTCAGTTCCAACTCACAGGATGAAGTAAGGGAAAATATTGCTCGTGGA
ATGGCAATTTTAGGTCCTACGTTTACCCTCGATGCTCTTGTTGAATGTCTTGTGATTGGA
GTTGGTACCATGTCAGGGGTACGTCAGCTTGAAATTATGTGCTGCTTTGGCTGCATGTCA
GTTCTTGCCAACTACTTCGTGTTCATGACTTTCTTCCCAGCTTGTGTGTCCTTGGTATTA
GAGCTTTCTCGGGAAAGCCGCGAGGGTCGTCCAATTTGGCAGCTCAGCCATTTTGCCCGA
GTTTTAGAAGAAGAAGAAAATAAGCCGAATCCTGTAACTCAGAGGGTCAAGATGATTATG
TCTCTAGGCTTGGTTCTTGTTCATGCTCACAGTCGCTGGATAGCTGATCCTTCTCCTCAA
AACAGTACAGCAGATACTTCTAAGGTTTCATTAGGACTGGATGAAAATGTGTCCAAGAGA
ATTGAACCAAGTGTTTCCCTCTGGCAGTTTTATCTCTCTAAAATGATCAGCATGGATATT
GAACAAGTTATTACCCTAAGTTTAGCTCTCCTTCTGGCTGTCAAGTACATCTTCTTTGAA
CAAACAGAGACAGAATCTACACTCTCATTAAAAAACCCTATCACATCTCCTGTAGTGACA
CAAAAGAAAGTCCCAGACAATTGTTGTAGACGTGAACCTATGCTGGTCAGAAATAACCAG
AAATGTGATTCAGTAGAGGAAGAGACAGGGATAAACCGAGAAAGAAAAGTTGAGGTTATA
AAACCCTTAGTGGCTGAAACAGATACCCCAAACAGAGCTACATTTGTGGTTGGTAACTCC
TCCTTACTCGATACTTCATCAGTACTGGTGACACAGGAACCTGAAATTGAACTTCCCAGG
GAACCTCGGCCTAATGAAGAATGTCTACAGATACTTGGGAATGCAGAGAAAGGTGCAAAA
TTCCTTAGTGATGCTGAGATCATCCAGTTAGTCAATGCTAAGCATATCCCAGCCTACAAG
TTGGAAACTCTGATGGAAACTCATGAGCGTGGTGTATCTATTCGCCGACAGTTACTTTCC
AAGAAGCTTTCAGAACCTTCTTCTCTCCAGTACCTACCTTACAGGGATTATAATTACTCC
TTGGTGATGGGAGCTTGTTGTGAGAATGTTATTGGATATATGCCCATCCCTGTTGGAGTG
GCAGGACCCCTTTGCTTAGATGAAAAAGAATTTCAGGTTCCAATGGCAACAACAGAAGGT
TGTCTTGTGGCCAGCACCAATAGAGGCTGCAGAGCAATAGGTCTTGGTGGAGGTGCCAGC
AGCCGAGTCCTTGCAGATGGGATGACTCGTGGCCCAGTTGTGCGTCTTCCACGTGCTTGT
GACTCTGCAGAAGTGAAAGCCTGGCTCGAAACATCTGAAGGGTTCGCAGTGATAAAGGAG
GCATTTGACAGCACTAGCAGATTTGCACGTCTACAGAAACTTCATACAAGTATAGCTGGA
CGCAACCTTTATATCCGTTTCCAGTCCAGGTCAGGGGATGCCATGGGGATGAACATGATT
TCAAAGGGTACAGAGAAAGCACTTTCAAAACTTCACGAGTATTTCCCTGAAATGCAGATT
CTAGCCGTTAGTGGTAACTATTGTACTGACAAGAAACCTGCTGCTATAAATTGGATAGAG
GGAAGAGGAAAATCTGTTGTTTGTGAAGCTGTCATTCCAGCCAAGGTTGTCAGAGAAGTA
TTAAAGACTACCACAGAGGCTATGATTGAGGTCAACATTAACAAGAATTTAGTGGGCTCT
GCCATGGCTGGGAGCATAGGAGGCTACAACGCCCATGCAGCAAACATTGTCACCGCCATC
TACATTGCCTGTGGACAGGATGCAGCACAGAATGTTGGTAGTTCAAACTGTATTACTTTA
ATGGAAGCAAGTGGTCCCACAAATGAAGATTTATATATCAGCTGCACCATGCCATCTATA
GAGATAGGAACGGTGGGTGGTGGGACCAACCTACTACCTCAGCAAGCCTGTTTGCAGATG
CTAGGTGTTCAAGGAGCATGCAAAGATAATCCTGGGGAAAATGCCCGGCAGCTTGCCCGA
ATTGTGTGTGGGACCGTAATGGCTGGGGAATTGTCACTTATGGCAGCATTGGCAGCAGGA
CATCTTGTCAAAAGTCACATGATTCACAACAGGTCGAAGATCAATTTACAAGACCTCCAA
GGAGCTTGCACCAAGAAGACAGCCTGA

# Drug_Target_35_General_Function:
Lipid transport and metabolism

# Drug_Target_35_General_References:
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
10698924	Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J: Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J. 2000 Mar 1;19(5):819-30.
2991281	Luskey KL, Stevens B: Human 3-hydroxy-3-methylglutaryl coenzyme A reductase. Conserved domains responsible for catalytic activity and sterol-regulated degradation. J Biol Chem. 1985 Aug 25;260(18):10271-7.

# Drug_Target_35_HGNC_ID:
HGNC:5006

# Drug_Target_35_HPRD_ID:
00836

# Drug_Target_35_ID:
631

# Drug_Target_35_Locus:
5q13.3-q14

# Drug_Target_35_Molecular_Weight:
97477

# Drug_Target_35_Name:
3-hydroxy-3-methylglutaryl-coenzyme A reductase

# Drug_Target_35_Number_of_Residues:
888

# Drug_Target_35_PDB_ID:
1HWL

# Drug_Target_35_Pathway:
Alendronate pathway	SMP00095
Atorvastatin Pathway	SMP00131
Cerivastatin Pathway	SMP00111
Fluvastatin Pathway	SMP00119
Ibandronate Pathway	SMP00079
Lovastatin Pathway	SMP00099
Pamidronate Pathway	SMP00117
Pravastatin Pathway	SMP00089
Risedronate Pathway	SMP00112
Rosuvastatin Pathway	SMP00092
Zoledronate Pathway	SMP00107

# Drug_Target_35_Pfam_Domain_Function:
PF00368	HMG-CoA_red

# Drug_Target_35_Protein_Sequence:
>3-hydroxy-3-methylglutaryl-coenzyme A reductase
MLSRLFRMHGLFVASHPWEVIVGTVTLTICMMSMNMFTGNNKICGWNYECPKFEEDVLSS
DIIILTITRCIAILYIYFQFQNLRQLGSKYILGIAGLFTIFSSFVFSTVVIHFLDKELTG
LNEALPFFLLLIDLSRASTLAKFALSSNSQDEVRENIARGMAILGPTFTLDALVECLVIG
VGTMSGVRQLEIMCCFGCMSVLANYFVFMTFFPACVSLVLELSRESREGRPIWQLSHFAR
VLEEEENKPNPVTQRVKMIMSLGLVLVHAHSRWIADPSPQNSTADTSKVSLGLDENVSKR
IEPSVSLWQFYLSKMISMDIEQVITLSLALLLAVKYIFFEQTETESTLSLKNPITSPVVT
QKKVPDNCCRREPMLVRNNQKCDSVEEETGINRERKVEVIKPLVAETDTPNRATFVVGNS
SLLDTSSVLVTQEPEIELPREPRPNEECLQILGNAEKGAKFLSDAEIIQLVNAKHIPAYK
LETLMETHERGVSIRRQLLSKKLSEPSSLQYLPYRDYNYSLVMGACCENVIGYMPIPVGV
AGPLCLDEKEFQVPMATTEGCLVASTNRGCRAIGLGGGASSRVLADGMTRGPVVRLPRAC
DSAEVKAWLETSEGFAVIKEAFDSTSRFARLQKLHTSIAGRNLYIRFQSRSGDAMGMNMI
SKGTEKALSKLHEYFPEMQILAVSGNYCTDKKPAAINWIEGRGKSVVCEAVIPAKVVREV
LKTTTEAMIEVNINKNLVGSAMAGSIGGYNAHAANIVTAIYIACGQDAAQNVGSSNCITL
MEASGPTNEDLYISCTMPSIEIGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLAR
IVCGTVMAGELSLMAALAAGHLVKSHMIHNRSKINLQDLQGACTKKTA

# Drug_Target_35_Reaction:
(R)-mevalonate + CoA + 2 NADP+ = (S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+

# Drug_Target_35_Signals:
None

# Drug_Target_35_Specific_Function:
This transmembrane glycoprotein is involved in the control of cholesterol biosynthesis. It is the rate-limiting enzyme of sterol biosynthesis

# Drug_Target_35_SwissProt_ID:
P04035

# Drug_Target_35_SwissProt_Name:
HMDH_HUMAN

# Drug_Target_35_Synonyms:
EC 1.1.1.34
HMG-CoA reductase

# Drug_Target_35_Theoretical_pI:
6.72

# Drug_Target_35_Transmembrane_Regions:
10-39
57-78
90-114
124-149
160-187
192-220
315-339

# Drug_Target_36_Cellular_Location:
Cytoplasm

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
MDH1

# Drug_Target_36_GenBank_ID_Gene:
D55654

# Drug_Target_36_GenBank_ID_Protein:
1255604

# Drug_Target_36_GeneCard_ID:
MDH1

# Drug_Target_36_Gene_Name:
MDH1

# Drug_Target_36_Gene_Sequence:
>1005 bp
ATGTCTGAACCAATCAGAGTCCTTGTGACTGGAGCAGCTGGTCAAATTGCATATTCACTG
CTGTACAGTATTGGAAATGGATCTGTCTTTGGTAAAGATCAGCCTATAATTCTTGTGCTG
TTGGATATCACCCCCATGATGGGTGTCCTGGACGGTGTCCTAATGGAACTGCAAGACTGT
GCCCTTCCCCTCCTGAAAGATGTCATCGCAACAGATAAAGAAGACGTTGCCTTCAAAGAC
CTGGATGTGGCCATTCTTGTGGGCTCCATGCCAAGAAGGGAAGGCATGGAGAGAAAAGAT
TTACTGAAAGCAAATGTGAAAATCTTCAAATCCCAGGGTGCAGCCTTAGATAAATACGCC
AAGAAGTCAGTTAAGGTTATTGTTGTGGGTAATCCAGCCAATACCAACTGCCTGACTGCT
TCCAAGTCAGCTCCATCCATCCCCAAGGAGAACTTCAGTTGCTTGACTCGTTTGGATCAC
AACCGAGCTAAAGCTCAAATTGCTCTTAAACTTGGTGTGACTGCTAATGATGTAAAGAAT
GTCATTATCTGGGGAAACCATTCCTCGACTCAGTATCCAGATGTCAACCATGCCAAGGTG
AAATTGCAAGGAAAGGAAGTTGGTGTTTATGAAGCTCTGAAAGATGACAGCTGGCTCAAG
GGAGAATTTGTCACGACTGTGCAGCAGCGTGGCGCTGCTGTCATCAAGGCTCGAAAACTA
TCCAGTGCCATGTCTGCTGCAAAAGCCATCTGTGACCACGTCAGGGACATCTGGTTTGGA
ACCCCAGAGGGAGAGTTTGTGTCCATGGGTGTTATCTCTGATGGCAACTCCTATGGTGTT
CCTGATGATCTGCTCTACTCATTCCCTGTTGTAATCAAGAATAAGACCTGGAAGTTTGTT
GAAGGTCTCCCTATTAATGATTTCTCACGTGAGAAGATGGATCTTACTGCAAAGGAACTG
ACAGAAGAAAAAGAAAGTGCTTTTGAATTTCTTTCCTCTGCCTGA

# Drug_Target_36_General_Function:
Energy production and conversion

# Drug_Target_36_General_References:
7895732	Corbett JM, Wheeler CH, Baker CS, Yacoub MH, Dunn MJ: The human myocardial two-dimensional gel protein database: update 1994. Electrophoresis. 1994 Nov;15(11):1459-65.
8786100	Tanaka T, Inazawa J, Nakamura Y: Molecular cloning and mapping of a human cDNA for cytosolic malate dehydrogenase (MDH1). Genomics. 1996 Feb 15;32(1):128-30.

# Drug_Target_36_HGNC_ID:
HGNC:6970

# Drug_Target_36_HPRD_ID:
01100

# Drug_Target_36_ID:
646

# Drug_Target_36_Locus:
2p13.3

# Drug_Target_36_Molecular_Weight:
36295

# Drug_Target_36_Name:
Malate dehydrogenase, cytoplasmic

# Drug_Target_36_Number_of_Residues:
333

# Drug_Target_36_PDB_ID:
5MDH

# Drug_Target_36_Pathway:
Not Available

# Drug_Target_36_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_36_Protein_Sequence:
>Malate dehydrogenase, cytoplasmic
SEPIRVLVTGAAGQIAYSLLYSIGNGSVFGKDQPIILVLLDITPMMGVLDGVLMELQDCA
LPLLKDVIATDKEDVAFKDLDVAILVGSMPRREGMERKDLLKANVKIFKSQGAALDKYAK
KSVKVIVVGNPANTNCLTASKSAPSIPKENFSCLTRLDHNRAKAQIALKLGVTANDVKNV
IIWGNHSSTQYPDVNHAKVKLQGKEVGVYEALKDDSWLKGEFVTTVQQRGAAVIKARKLS
SAMSAAKAICDHVRDIWFGTPEGEFVSMGVISDGNSYGVPDDLLYSFPVVIKNKTWKFVE
GLPINDFSREKMDLTAKELTEEKESAFEFLSSA

# Drug_Target_36_Reaction:
(S)-malate + NAD+ = oxaloacetate + NADH + H+

# Drug_Target_36_Signals:
None

# Drug_Target_36_Specific_Function:
Not Available

# Drug_Target_36_SwissProt_ID:
P40925

# Drug_Target_36_SwissProt_Name:
MDHC_HUMAN

# Drug_Target_36_Synonyms:
Cytosolic malate dehydrogenase
EC 1.1.1.37

# Drug_Target_36_Theoretical_pI:
7.45

# Drug_Target_36_Transmembrane_Regions:
None

# Drug_Target_37_Cellular_Location:
Not Available

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
Not Available

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
Not Available

# Drug_Target_37_GenBank_ID_Gene:
U00096

# Drug_Target_37_GenBank_ID_Protein:
Not Available

# Drug_Target_37_GeneCard_ID:
Not Available

# Drug_Target_37_Gene_Name:
ydhF

# Drug_Target_37_Gene_Sequence:
>897 bp
TTACGGTACGTCGTACCCCAGTGCCGCTTTACGGATACGAAACCATTGTTGACGGGTCAT
TTTCAGTGTTTCTGCTTCGACAGCTGCCCGTACGCGCTCAATTTTACCTGAACCGATAAT
TGGCAGCGGCTGCGATGGTAAACGTAATACCCAGGCGTAAACCACCTGTTCAATCGAGCC
CGCGTTTAACTCCTCTGCCACCACAGCCAGTTCATCACGCAGCGGCTGGAAATAATCATC
ATTAAACAGACGACCACCACCAAGGCAGGACCACGCCATCGGACGAACACGCAGTTGTTG
TAGTTGGTCGAGCGTGCCATCCAGCAGTAACGGCTGATGCACCGGGGATATTTCCACCTG
ATTAGTGGCAAGGGTAAACGGCAGACGTGATTGCAACAGGGCAAATTGCGCAGGCGTAAA
GTTCGATACGCCAAAATGACGCACTTTGCCGCTCTGATGCAGATGTTTGAACGCGTCCGC
CACTTCATCGGCATCCATTAACGGGTCTGGTCGGTGGATTAACAGCAAATCCAGATGATC
GGTCGCGAGATTAATTAGCGACTGTTCGGCGCTCTTAATGATGTGATCGCGGTCAGTGAT
GTAATGACCAATGACGTTTTCTTCACGCGCGGTCGTCGCGATACCGCATTTACTGACGAT
TTCCATCCGTTCACGCAGGTGAGGTGCCAGTTTCAGTGCCTCGCCAAACGCCGCTTCGCA
CTGATAGCCACCATAAATATCAGCATGGTCCACGGTGGTCACGCCGAGATCCAGATGCTC
TTCAATAAAACTGACCAGCTGGCGGGCGGACATATTCCAGTCCATCAATCGCCAGTAGCC
CATCACAAAACGGGAAAACTCCGGGCCTTGCGGCGCAATAGTAATACGCTGAACCAT

# Drug_Target_37_General_Function:
Involved in oxidoreductase activity

# Drug_Target_37_General_References:
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_37_HGNC_ID:
Not Available

# Drug_Target_37_HPRD_ID:
Not Available

# Drug_Target_37_ID:
5322

# Drug_Target_37_Locus:
Not Available

# Drug_Target_37_Molecular_Weight:
33676

# Drug_Target_37_Name:
Oxidoreductase ydhF

# Drug_Target_37_Number_of_Residues:
298

# Drug_Target_37_PDB_ID:
1OG6

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_37_Protein_Sequence:
>Oxidoreductase ydhF
MVQRITIAPQGPEFSRFVMGYWRLMDWNMSARQLVSFIEEHLDLGVTTVDHADIYGGYQC
EAAFGEALKLAPHLRERMEIVSKCGIATTAREENVIGHYITDRDHIIKSAEQSLINLATD
HLDLLLIHRPDPLMDADEVADAFKHLHQSGKVRHFGVSNFTPAQFALLQSRLPFTLATNQ
VEISPVHQPLLLDGTLDQLQQLRVRPMAWSCLGGGRLFNDDYFQPLRDELAVVAEELNAG
SIEQVVYAWVLRLPSQPLPIIGSGKIERVRAAVEAETLKMTRQQWFRIRKAALGYDVP

# Drug_Target_37_Reaction:
Not Available

# Drug_Target_37_Signals:
None

# Drug_Target_37_Specific_Function:
May function as oxidoreductase (Potential)

# Drug_Target_37_SwissProt_ID:
P76187

# Drug_Target_37_SwissProt_Name:
YDHF_ECOLI

# Drug_Target_37_Synonyms:
EC 1.-.-.-

# Drug_Target_37_Theoretical_pI:
6.13

# Drug_Target_37_Transmembrane_Regions:
None

# Drug_Target_38_Cellular_Location:
Not Available

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
Not Available

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
Not Available

# Drug_Target_38_GenBank_ID_Gene:
AY162404

# Drug_Target_38_GenBank_ID_Protein:
Not Available

# Drug_Target_38_GeneCard_ID:
Not Available

# Drug_Target_38_Gene_Name:
ptr2

# Drug_Target_38_Gene_Sequence:
>828 bp
ATGAACGAAACGTCGCATGAAGCCTCGGAGTGCCCCGCTGCCATCATCACCGGAGGGGCG
CGACGCATCGGCCACAGTATCGCTGTGCGTCTGCACCAGCAGGGATTTCGAGTCGTCGTG
CACTACCGTCACTCCGAAGGGGCGGCGCAGCGGCTCGTTGCGGAGCTCAATGCTGCTCGC
GCTGGATCCGCTGTGTTGTGCAAGGGGGACCTCAGTCTCAGCAGCTCTCTTCTCGATTGC
TGCGAGGACATCATCGACTGCTCTTTTCGTGCCTTTGGTCGGTGCGATGTGTTGGTGAAC
AACGCCTCTGCGTATTACCCGACTCCGCTGCTGCCGGGAGATGACACGAACGGCGCCGCG
GAAGCGAAGCCGATTGATGCGCAGGTCGCCGAGTTATTTGGTTCAAACGCCGTTGCGCCG
CTTTTTTTGATCCGGGCGTTTGCCCGCAGGCAGGGCGAGGGGGGTGCGTGGAGGAGCCGC
AACCTGTCGGTGGTTAACCTTTGCGACGCCATGACTGATCTTCCGCTGCCGGGCTTTTGT
GTCTACACGATGGCGAAACATGCGCTTGGCGGACTCACGAGGGCGGCTGCTTTGGAGTTG
GCGCCGCGCCACATCCGCGTCAATGCGGTTGCGCCGGGGCTGAGTCTTCTCCCCCCCGCA
ATGCCGCAGGAGACGCAGGAGGAGTATCGGCGTAAAGTACCGCTTGGCCAAAGCGAGGCC
TCTGCTGCTCAAATTGCGGATGTCATTGCATTTCTTGTGTCGAAGGACGCAGGTTACATC
ACCGGCACTACATTAAAGGTGGACGGTGGGCTGATTCTCGCCCGTGCC

# Drug_Target_38_General_Function:
Involved in oxidoreductase activity

# Drug_Target_38_General_References:
12615341	Senkovich O, Pal B, Schormann N, Chattopadhyay D: Trypanosoma cruzi genome encodes a pteridine reductase 2 protein. Mol Biochem Parasitol. 2003 Mar;127(1):89-92.
8114910	Lima CD, Wang JC, Mondragon A: Three-dimensional structure of the 67K N-terminal fragment of E. coli DNA topoisomerase I. Nature. 1994 Jan 13;367(6459):138-46.

# Drug_Target_38_HGNC_ID:
Not Available

# Drug_Target_38_HPRD_ID:
Not Available

# Drug_Target_38_ID:
4582

# Drug_Target_38_Locus:
Not Available

# Drug_Target_38_Molecular_Weight:
29205

# Drug_Target_38_Name:
Putative pteridine reductase 2

# Drug_Target_38_Number_of_Residues:
276

# Drug_Target_38_PDB_ID:
1MXH

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_38_Protein_Sequence:
>Putative pteridine reductase 2
MNETSHEASECPAAIITGGARRIGHSIAVRLHQQGFRVVVHYRHSEGAAQRLVAELNAAR
AGSAVLCKGDLSLSSSLLDCCEDIIDCSFRAFGRCDVLVNNASAYYPTPLLPGDDTNGAA
EAKPIDAQVAELFGSNAVAPLFLIRAFARRQGEGGAWRSRNLSVVNLCDAMTDLPLPGFC
VYTMAKHALGGLTRAAALELAPRHIRVNAVAPGLSLLPPAMPQETQEEYRRKVPLGQSEA
SAAQIADVIAFLVSKDAGYITGTTLKVDGGLILARA

# Drug_Target_38_Reaction:
Not Available

# Drug_Target_38_Signals:
None

# Drug_Target_38_Specific_Function:
Not Available

# Drug_Target_38_SwissProt_ID:
Q8I814

# Drug_Target_38_SwissProt_Name:
Q8I814_TRYCR

# Drug_Target_38_Synonyms:
Not Available

# Drug_Target_38_Theoretical_pI:
7.13

# Drug_Target_38_Transmembrane_Regions:
None

# Drug_Target_39_Cellular_Location:
Not Available

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
HSD17B8

# Drug_Target_39_GenBank_ID_Gene:
BT007239

# Drug_Target_39_GenBank_ID_Protein:
30583317

# Drug_Target_39_GeneCard_ID:
HSD17B8

# Drug_Target_39_Gene_Name:
HSD17B8

# Drug_Target_39_Gene_Sequence:
>786 bp
ATGGCGTCTCAGCTCCAGAACCGACTCCGCTCCGCACTGGCCTTGGTCACAGGTGCGGGG
AGCGGCATCGGCCGAGCGGTCAGTGTACGCCTGGCCGGAGAGGGGGCCACCGTAGCTGCC
TGCGACCTGGACCGGGCAGCGGCACAGGAGACGGTGCGGCTGCTGGGCGGGCCAGGGAGC
AAGGAGGGGCCGCCCCGAGGGAACCATGCTGCCTTCCAGGCTGACGTGTCTGAGGCCAGG
GCCGCCAGGTGCCTGCTGGAACAAGTGCAGGCCTGCTTTTCTCGCCCACCATCTGTCGTT
GTGTCCTGTGCGGGCATCACCCAGGATGAGTTTCTGCTGCACATGTCTGAGGATGACTGG
GACAAAGTCATAGCTGTCAACCTCAAGGGCACCTTCCTAGTCACTCAGGCTGCAGCACAA
GCCCTGGTGTCCAATGGTTGTCGTGGTTCCATCATCAACATCAGTAGCATCGTAGGAAAG
GTGGGGAACGTGGGGCAGACAAACTATGCAGCATCCAAGGCTGGAGTGATTGGGCTGACC
CAGACCGCAGCCCGGGAGCTTGGACGACATGGGATCCGCTGTAACTCTGTCCTCCCAGGG
TTCATTGCAACACCCATGACACAGAAAGTGCCACAGAAAGTGGTGGACAAGATTACTGAA
ATGATCCCGATGGGACACTTGGGGGACCCTGAGGATGTGGCAGATGTGGTCGCATTCTTG
GCATCTGAAGATAGTGGATACATCACAGGGACCTCAGTGGAAGTCACTGGAGGTCTTTTC
ATGTAG

# Drug_Target_39_General_Function:
Lipid transport and metabolism

# Drug_Target_39_General_References:
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
8812499	Ando A, Kikuti YY, Shigenari A, Kawata H, Okamoto N, Shiina T, Chen L, Ikemura T, Abe K, Kimura M, Inoko H: cDNA cloning of the human homologues of the mouse Ke4 and Ke6 genes at the centromeric end of the human MHC region. Genomics. 1996 Aug 1;35(3):600-2.

# Drug_Target_39_HGNC_ID:
HGNC:3554

# Drug_Target_39_HPRD_ID:
03248

# Drug_Target_39_ID:
635

# Drug_Target_39_Locus:
6p21.3

# Drug_Target_39_Molecular_Weight:
26974

# Drug_Target_39_Name:
Estradiol 17-beta-dehydrogenase 8

# Drug_Target_39_Number_of_Residues:
261

# Drug_Target_39_PDB_ID:
Not Available

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_39_Protein_Sequence:
>Estradiol 17-beta-dehydrogenase 8
MASQLQNRLRSALALVTGAGSGIGRAVSVRLAGEGATVAACDLDRAAAQETVRLLGGPGS
KEGPPRGNHAAFQADVSEARAARCLLEQVQACFSRPPSVVVSCAGITQDEFLLHMSEDDW
DKVIAVNLKGTFLVTQAAAQALVSNGCRGSIINISSIVGKVGNVGQTNYAASKAGVIGLT
QTAARELGRHGIRCNSVLPGFIATPMTQKVPQKVVDKITEMIPMGHLGDPEDVADVVAFL
ASEDSGYITGTSVEVTGGLFM

# Drug_Target_39_Reaction:
estradiol-17beta + NAD(P)+ = estrone + NAD(P)H + H+

# Drug_Target_39_Signals:
None

# Drug_Target_39_Specific_Function:
Uses estradiol as its preferred substrate

# Drug_Target_39_SwissProt_ID:
Q92506

# Drug_Target_39_SwissProt_Name:
DHB8_HUMAN

# Drug_Target_39_Synonyms:
17- beta-hydroxysteroid dehydrogenase 8
17-beta-HSD 8
EC 1.1.1.62
Ke-6
Protein Ke6

# Drug_Target_39_Theoretical_pI:
6.50

# Drug_Target_39_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Y00710

# Drug_Target_3_GenBank_ID_Protein:
40978

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
aroE

# Drug_Target_3_Gene_Sequence:
>819 bp
ATGGAAACCTATGCTGTTTTTGGTAATCCGATAGCCCACAGCAAATCGCCATTCATTCAT
CAGCAATTTGCTCAGCAACTGAATATTGAACATCCCTATGGGCGCGTGTTGGCACCCATC
AATGATTTCATCAACACACTGAACGCTTTCTTTAGTGCTGGTGGTAAAGGTGCGAATGTG
ACGGTGCCTTTTAAAGAAGAGGCTTTTGCCAGAGCGGATGAGCTTACTGAACGGGCAGCG
TTGGCTGGTGCTGTTAATACCCTCATGCGGTTAGAAGATGGACGCCTGCTGGGTGACAAT
ACCGATGGTGTAGGCTTGTTAAGCGATCTGGAACGTCTGTCTTTTATCCGCCCTGGTTTA
CGTATTCTGCTTATCGGCGCTGGTGGAGCATCTCGCGGCGTACTACTGCCACTCCTTTCC
CTGGACTGTGCGGTGACAATAACTAATCGGACGGTATCCCGCGCGGAAGAGTTGGCTAAA
TTGTTTGCGCACACTGGCAGTATTCAGGCGTTGAGTATGGACGAACTGGAAGGTCATGAG
TTTGATCTCATTATTAATGCAACATCCAGTGGCATCAGTGGTGATATTCCGGCGATCCCG
TCATCGCTCATTCATCCAGGCATTTATTGCTATGACATGTTCTATCAGAAAGGAAAAACT
CCTTTTCTGGCATGGTGTGAGCAGCGAGGCTCAAAGCGTAATGCTGATGGTTTAGGAATG
CTGGTGGCACAGGCGGCTCATGCCTTTCTTCTCTGGCACGGTGTTCTGCCTGACGTAGAA
CCAGTTATAAAGCAATTGCAGGAGGAATTGTCCGCGTGA

# Drug_Target_3_General_Function:
Amino acid transport and metabolism

# Drug_Target_3_General_References:
10739937	Maclean J, Campbell SA, Pollock K, Chackrewarthy S, Coggins JR, Lapthorn AJ: Crystallization and preliminary X-ray analysis of shikimate dehydrogenase from Escherichia coli. Acta Crystallogr D Biol Crystallogr. 2000 Apr;56(Pt 4):512-5.
3277621	Anton IA, Coggins JR: Sequencing and overexpression of the Escherichia coli aroE gene encoding shikimate dehydrogenase. Biochem J. 1988 Jan 15;249(2):319-26.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3515

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
29414

# Drug_Target_3_Name:
Shikimate dehydrogenase

# Drug_Target_3_Number_of_Residues:
272

# Drug_Target_3_PDB_ID:
1NYT

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01488	Shikimate_DH
PF08501	Shikimate_dh_N

# Drug_Target_3_Protein_Sequence:
>Shikimate dehydrogenase
METYAVFGNPIAHSKSPFIHQQFAQQLNIEHPYGRVLAPINDFINTLNAFFSAGGKGANV
TVPFKEEAFARADELTERAALAGAVNTLMRLEDGRLLGDNTDGVGLLSDLERLSFIRPGL
RILLIGAGGASRGVLLPLLSLDCAVTITNRTVSRAEELAKLFAHTGSIQALSMDELEGHE
FDLIINATSSGISGDIPAIPSSLIHPGIYCYDMFYQKGKTPFLAWCEQRGSKRNADGLGM
LVAQAAHAFLLWHGVLPDVEPVIKQLQEELSA

# Drug_Target_3_Reaction:
shikimate + NADP+ = 3-dehydroshikimate + NADPH + H+

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Shikimate + NADP(+) = 3-dehydroshikimate + NADPH

# Drug_Target_3_SwissProt_ID:
P15770

# Drug_Target_3_SwissProt_Name:
AROE_ECOLI

# Drug_Target_3_Synonyms:
EC 1.1.1.25

# Drug_Target_3_Theoretical_pI:
5.31

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_40_Cellular_Location:
Not Available

# Drug_Target_40_Chromosome_Location:
1

# Drug_Target_40_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
Not Available

# Drug_Target_40_GenBank_ID_Gene:
J04794

# Drug_Target_40_GenBank_ID_Protein:
178481

# Drug_Target_40_GeneCard_ID:
AKR1A1

# Drug_Target_40_Gene_Name:
AKR1A1

# Drug_Target_40_Gene_Sequence:
>978 bp
ATGGCGGCTTCCTGTGTTCTACTGCACACTGGGCAGAAGATGCCTCTGATTGGTCTGGGT
ACCTGGAAGAGTGAGCCTGGTCAGGTAAAAGCAGCTGTTAAGTATGCCCTTAGCGTAGGC
TACCGCCACATTGATTGTGCTGCTATCTACGGCAATGAGCCTGAGATTGGGGAGGCCCTG
AAGGAGGACGTGGGACCAGGCAAGGCGGTGCCTCGGGAGGAGCTGTTTGTGACATCCAAG
CTGTGGAACACCAAGCACCACCCCGAGGATGTGGAGCCTGCCCTCCGGAAGACTCTGGCT
GACCTCCAGCTGGAGTATCTGGACCTGTACCTGATGCACTGGCCTTATGCCTTTGAGCGG
GGAGACAACCCCTTCCCCAAGAATGCTGATGGGACTATATGCTACGACTCCACCCACTAC
AAGGAGACTTGGAAGGCTCTGGAGGCACTGGTGGCTAAGGGGCTGGTGCAGGCGCTGGGC
CTGTCCAACTTCAACAGTCGGCAGATTGATGACATACTCAGTGTGGCCTCCGTGCGTCCA
GCTGTCTTGCAGGTGGAATGCCACCCATACTTGGCTCAAAATGAGCTAATTGCCCACTGC
CAAGCACGTGGCTTGGAGGTAACTGCTTATAGCCCTTTGGGCTCCTCTGATCGTGCATGG
CGTGATCCTGATGAGCCTGTCCTGCTGGAGGAACCAGTAGTCCTGGCATTGGCTGAAAAG
TATGGCCGATCTCCAGCTCAGATCTTGCTCAGGTGGCAGGTCCAGCGGAAAGTGATCTGC
ATCCCCAAAAGTATCACTCCTTCTCGAATCCTTCAGAACATCAAGGTGTTTGACTTCACC
TTTAGCCCAGAAGAGATGAAGCAGCTAAATGCCCTGAACAAAAATTGGAGATATATTGTG
CCTATGCTTACGGTGGATGGGAAGAGAGTCCCAAGGGATGCAGGGCATCCTCTGTACCCC
TTTAATGACCCGTACTGA

# Drug_Target_40_General_Function:
Involved in alcohol dehydrogenase (NADP+) activity

# Drug_Target_40_General_References:
10393438	Fujii J, Hamaoka R, Matsumoto A, Fujii T, Yamaguchi Y, Egashira M, Miyoshi O, Niikawa N, Taniguchi N: The structural organization of the human aldehyde reductase gene, AKR1A1, and mapping to chromosome 1p33-->p32. Cytogenet Cell Genet. 1999;84(3-4):230-2.
10486210	Barski OA, Gabbay KH, Bohren KM: Characterization of the human aldehyde reductase gene and promoter. Genomics. 1999 Sep 1;60(2):188-98.
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16710414	Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1. Nature. 2006 May 18;441(7091):315-21.
2498333	Bohren KM, Bullock B, Wermuth B, Gabbay KH: The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem. 1989 Jun 5;264(16):9547-51.
3615425	Wermuth B, Omar A, Forster A, di Francesco C, Wolf M, von Wartburg JP, Bullock B, Gabbay KH: Primary structure of aldehyde reductase from human liver. Prog Clin Biol Res. 1987;232:297-307.

# Drug_Target_40_HGNC_ID:
GNC:380

# Drug_Target_40_HPRD_ID:
Not Available

# Drug_Target_40_ID:
6861

# Drug_Target_40_Locus:
1p33-p32

# Drug_Target_40_Molecular_Weight:
36572.7

# Drug_Target_40_Name:
Alcohol dehydrogenase [NADP+]

# Drug_Target_40_Number_of_Residues:
325

# Drug_Target_40_PDB_ID:
2ALR

# Drug_Target_40_Pathway:
Cyclophosphamide Pathway	SMP00447

# Drug_Target_40_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_40_Protein_Sequence:
>Alcohol dehydrogenase [NADP+]
MAASCVLLHTGQKMPLIGLGTWKSEPGQVKAAVKYALSVGYRHIDCAAIYGNEPEIGEAL
KEDVGPGKAVPREELFVTSKLWNTKHHPEDVEPALRKTLADLQLEYLDLYLMHWPYAFER
GDNPFPKNADGTICYDSTHYKETWKALEALVAKGLVQALGLSNFNSRQIDDILSVASVRP
AVLQVECHPYLAQNELIAHCQARGLEVTAYSPLGSSDRAWRDPDEPVLLEEPVVLALAEK
YGRSPAQILLRWQVQRKVICIPKSITPSRILQNIKVFDFTFSPEEMKQLNALNKNWRYIV
PMLTVDGKRVPRDAGHPLYPFNDPY

# Drug_Target_40_Reaction:
Not Available

# Drug_Target_40_Signals:
None

# Drug_Target_40_Specific_Function:
Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4- nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D- glucuronic acid. Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotics and drugs, including the anthracyclines doxorubicin (DOX) and daunorubicin (DAUN)

# Drug_Target_40_SwissProt_ID:
P14550

# Drug_Target_40_SwissProt_Name:
AK1A1_HUMAN

# Drug_Target_40_Synonyms:
Aldehyde reductase
Aldo-keto reductase family 1 member A1

# Drug_Target_40_Theoretical_pI:
6.79

# Drug_Target_40_Transmembrane_Regions:
None

# Drug_Target_41_Cellular_Location:
Not Available

# Drug_Target_41_Chromosome_Location:
Not Available

# Drug_Target_41_Drug_References:
Not Available

# Drug_Target_41_Essentiality:
Non-Essential

# Drug_Target_41_GenAtlas_ID:
Not Available

# Drug_Target_41_GenBank_ID_Gene:
M19536

# Drug_Target_41_GenBank_ID_Protein:
Not Available

# Drug_Target_41_GeneCard_ID:
Not Available

# Drug_Target_41_Gene_Name:
actIII

# Drug_Target_41_Gene_Sequence:
>786 bp
ATGGCCACGCAGGACTCCGAAGTCGCACTGGTGACGGGTGCGACCAGCGGAATCGGGCTG
GAGATCGCCCGCAGGCTCGGTAAGGAGGGGTTGCGCGTGTTCGTCTGCGCGCGCGGCGAA
GAAGGACTGCGGACGACGCTGAAGGAGTTGCGGGAGGCGGGCGTGGAGGCGGACGGGCGG
ACCTGCGACGTCCGCTCGGTCCCGGAGATCGAGGCTCTCGTGGCGGCGGTGGTCGAGCGT
TACGGTCCGGTCGACGTGCTGGTGAACAACGCGGGCCGGCCCGGCGGCGGCGCCACGGCC
GAACTCGCCGACGAACTCTGGCTCGATGTCGTGGAGACCAACCTCACCGGCGTGTTCCGG
GTGACCAAACAGGTCCTCAAGGCGGGCGGCATGCTCGAACGGGGCACGGGCCGAATCGTC
AACATCGCCTCGACCGGCGGAAAGCAGGGTGTGGTGCACGCCGCGCCCTACTCCGCCTCG
AAGCACGGCGTGGTCGGCTTCACCAAGGCGCTCGGTCTCGAACTGGCGAGGACCGGCATC
ACGGTGAACGCCGTCTGCCCCGGATTCGTCGAGACGCCGATGGCCGCGTCCGTGCGCGAG
CACTACTCGGACATCTGGGAGGTGTCGACCGAGGAGGCCTTCGACCGGATCACCGCGCGC
GTGCCGATCGGCCGGTACGTGCAGCCGTCCGAGGTGGCGGAGATGGTGGCGTACCTGATC
GGGCCCGGTGCGGCCGCGGTCACCGCGCAGGCGCTGAACGTCTGCGGCGGGCTGGGGAAC
TACTGA

# Drug_Target_41_General_Function:
Involved in oxidoreductase activity

# Drug_Target_41_General_References:
12000953	Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S, Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, Woodward J, Barrell BG, Parkhill J, Hopwood DA: Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature. 2002 May 9;417(6885):141-7.
2469622	Hallam SE, Malpartida F, Hopwood DA: Nucleotide sequence, transcription and deduced function of a gene involved in polyketide antibiotic synthesis in Streptomyces coelicolor. Gene. 1988 Dec 30;74(2):305-20.

# Drug_Target_41_HGNC_ID:
Not Available

# Drug_Target_41_HPRD_ID:
Not Available

# Drug_Target_41_ID:
4531

# Drug_Target_41_Locus:
Not Available

# Drug_Target_41_Molecular_Weight:
27265

# Drug_Target_41_Name:
Putative ketoacyl reductase

# Drug_Target_41_Number_of_Residues:
261

# Drug_Target_41_PDB_ID:
1X7H

# Drug_Target_41_Pathway:
Not Available

# Drug_Target_41_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_41_Protein_Sequence:
>Putative ketoacyl reductase
MATQDSEVALVTGATSGIGLEIARRLGKEGLRVFVCARGEEGLRTTLKELREAGVEADGR
TCDVRSVPEIEALVAAVVERYGPVDVLVNNAGRPGGGATAELADELWLDVVETNLTGVFR
VTKQVLKAGGMLERGTGRIVNIASTGGKQGVVHAAPYSASKHGVVGFTKALGLELARTGI
TVNAVCPGFVETPMAASVREHYSDIWEVSTEEAFDRITARVPIGRYVQPSEVAEMVAYLI
GPGAAAVTAQALNVCGGLGNY

# Drug_Target_41_Reaction:
Not Available

# Drug_Target_41_Signals:
None

# Drug_Target_41_Specific_Function:
Not Available

# Drug_Target_41_SwissProt_ID:
P16544

# Drug_Target_41_SwissProt_Name:
ACT3_STRCO

# Drug_Target_41_Synonyms:
EC 1.3.1.-

# Drug_Target_41_Theoretical_pI:
5.02

# Drug_Target_41_Transmembrane_Regions:
None

# Drug_Target_42_Cellular_Location:
Mitochondrion

# Drug_Target_42_Chromosome_Location:
Not Available

# Drug_Target_42_Drug_References:
Not Available

# Drug_Target_42_Essentiality:
Non-Essential

# Drug_Target_42_GenAtlas_ID:
DECR1

# Drug_Target_42_GenBank_ID_Gene:
L26050

# Drug_Target_42_GenBank_ID_Protein:
Not Available

# Drug_Target_42_GeneCard_ID:
Not Available

# Drug_Target_42_Gene_Name:
DECR1

# Drug_Target_42_Gene_Sequence:
>1008 bp
ATGAAGCTACCGGCCAGGGTTTTCTTTACTCTGGGGTCCCGGCTGCCCTGTGGCCTCGCT
CCTCGGAGGTTTTTCAGTTATGGGACAAAAATATTATATCAAAACACTGAAGCTTTGCAA
TCTAAATTCTTTTCACCTCTTCAAAAAGCGATGCTACCACCTAATAGTTTTCAAGGAAAA
GTGGCATTCATTACTGGGGGAGGTACTGGCCTTGGTAAAGGAATGACAACTCTTCTGTCC
AGCCTAGGTGCTCAGTGCGTGATAGCCAGCCGGAAGATGGATGTTTTGAAAGCTACCGCA
GAACAAATTTCTTCTCAAACTGGAAATAAGGTTCATGCAATTCAGTGTGATGTGAGGGAT
CCTGATATGGTTCAAAACACTGTGTCAGAACTGATCAAAGTTGCAGGACATCCTAATATT
GTGATAAACAATGCAGCAGGGAATTTTATTTCTCCTACTGAAAGACTTTCTCCTAATGCT
TGGAAAACCATAACTGACATAGTTCTAAATGGCACAGCCTTCGTGACACTAGAAATTGGA
AAACAACTAATTAAAGCACAGAAAGGAGCAGCATTTCTTTCTATTACTACTATCTATGCT
GAGACTGGTTCAGGTTTTGTAGTACCAAGTGCTTCTGCCAAAGCAGGTGTGGAAGCCATG
AGCAAGTCTCTTGCAGCTGAATGGGGTAAATATGGAATGCGATTCAATGTGATTCAACCA
GGGCCTATAAAAACCAAAGGTGCCTTTAGCCGTCTGGACCCAACTGGAACATTTGAGAAA
GAAATGATTGGCAGAATTCCCTGTGGTCGCCTGGGGACTGTAGAAGAACTCGCAAATCTT
GCTGCTTTCCTTTGTAGTGATTATGCTTCTTGGATTAATGGAGCAGTCATTAAATTTGAC
GGTGGAGAGGAAGTACTTATTTCAGGGGAATTCAACGACCTGAGAAAGGTCACCAAGGAG
CAGTGGGACACCATAGAAGAACTCATCAGGAAGACAAAAGGTTCCTAA

# Drug_Target_42_General_Function:
Involved in oxidoreductase activity

# Drug_Target_42_General_References:
7818482	Koivuranta KT, Hakkola EH, Hiltunen JK: Isolation and characterization of cDNA for human 120 kDa mitochondrial 2,4-dienoyl-coenzyme A reductase. Biochem J. 1994 Dec 15;304 ( Pt 3):787-92.
9403065	Helander HM, Koivuranta KT, Horelli-Kuitunen N, Palvimo JJ, Palotie A, Hiltunen JK: Molecular cloning and characterization of the human mitochondrial 2,4-dienoyl-CoA reductase gene (DECR). Genomics. 1997 Nov 15;46(1):112-9.

# Drug_Target_42_HGNC_ID:
HGNC:2753

# Drug_Target_42_HPRD_ID:
Not Available

# Drug_Target_42_ID:
5325

# Drug_Target_42_Locus:
8q21.3

# Drug_Target_42_Molecular_Weight:
36068

# Drug_Target_42_Name:
2,4-dienoyl-CoA reductase, mitochondrial

# Drug_Target_42_Number_of_Residues:
335

# Drug_Target_42_PDB_ID:
1W6U

# Drug_Target_42_Pathway:
Not Available

# Drug_Target_42_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_42_Protein_Sequence:
>2,4-dienoyl-CoA reductase, mitochondrial
MKLPARVFFTLGSRLPCGLAPRRFFSYGTKILYQNTEALQSKFFSPLQKAMLPPNSFQGK
VAFITGGGTGLGKGMTTLLSSLGAQCVIASRKMDVLKATAEQISSQTGNKVHAIQCDVRD
PDMVQNTVSELIKVAGHPNIVINNAAGNFISPTERLSPNAWKTITDIVLNGTAFVTLEIG
KQLIKAQKGAAFLSITTIYAETGSGFVVPSASAKAGVEAMSKSLAAEWGKYGMRFNVIQP
GPIKTKGAFSRLDPTGTFEKEMIGRIPCGRLGTVEELANLAAFLCSDYASWINGAVIKFD
GGEEVLISGEFNDLRKVTKEQWDTIEELIRKTKGS

# Drug_Target_42_Reaction:
Not Available

# Drug_Target_42_Signals:
None

# Drug_Target_42_Specific_Function:
Auxiliary enzyme of beta-oxidation. It participates in the metabolism of unsaturated fatty enoyl-CoA esters having double bonds in both even- and odd-numbered positions. Catalyzes the NADP-dependent reduction of 2,4-dienoyl-CoA to yield trans-3- enoyl-CoA

# Drug_Target_42_SwissProt_ID:
Q16698

# Drug_Target_42_SwissProt_Name:
DECR_HUMAN

# Drug_Target_42_Synonyms:
2,4- dienoyl-CoA reductase [NADPH]
2,4-dienoyl-CoA reductase, mitochondrial precursor
4-enoyl-CoA reductase [NADPH]
EC 1.3.1.34

# Drug_Target_42_Theoretical_pI:
9.84

# Drug_Target_42_Transmembrane_Regions:
None

# Drug_Target_43_Cellular_Location:
Not Available

# Drug_Target_43_Chromosome_Location:
Not Available

# Drug_Target_43_Drug_References:
Not Available

# Drug_Target_43_Essentiality:
Non-Essential

# Drug_Target_43_GenAtlas_ID:
Not Available

# Drug_Target_43_GenBank_ID_Gene:
AE000512

# Drug_Target_43_GenBank_ID_Protein:
Not Available

# Drug_Target_43_GeneCard_ID:
Not Available

# Drug_Target_43_Gene_Name:
TM_0441

# Drug_Target_43_Gene_Sequence:
>768 bp
GTGAAAGAGGTGTTCGATCTCAGGGGGAGGGTTGCCCTCGTAACCGGTGGCTCTCGTGGG
CTGGGTTTTGGAATCGCTCAGGGGCTGGCAGAGGCCGGATGTTCAGTGGTCGTTGCAAGC
AGAAATCTGGAGGAAGCATCAGAAGCGGCTCAAAAGTTGACAGAAAAATACGGTGTTGAA
ACGATGGCTTTCCGATGCGATGTTTCAAACTATGAGGAAGTGAAAAAACTTTTGGAAGCA
GTGAAAGAGAAATTTGGAAAGCTCGATACGGTGGTCAACGCTGCGGGGATAAACAGAAGA
CATCCAGCGGAAGAATTTCCTCTCGATGAGTTCAGACAGGTGATAGAGGTGAACCTTTTT
GGAACTTACTACGTGTGTAGGGAGGCCTTTTCACTCCTGAGAGAATCCGATAACCCCTCT
ATCATAAACATAGGATCTCTCACCGTTGAAGAAGTCACCATGCCCAACATATCCGCGTAC
GCTGCTTCGAAAGGGGGCGTAGCTTCTCTCACAAAAGCTCTGGCGAAGGAATGGGGAAGG
TACGGCATAAGGGTGAATGTGATAGCGCCGGGCTGGTACAGAACCAAGATGACAGAGGCT
GTGTTCAGCGATCCAGAAAAACTGGACTACATGCTCAAGAGGATACCCCTTGGCAGAACG
GGTGTACCAGAGGATTTGAAGGGTGTGGCAGTCTTCCTTGCTTCCGAAGAGGCGAAGTAC
GTGACTGGACAGATCATATTTGTAGACGGTGGTTGGACTGCGAATTGA

# Drug_Target_43_General_Function:
Involved in oxidoreductase activity

# Drug_Target_43_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_43_HGNC_ID:
Not Available

# Drug_Target_43_HPRD_ID:
Not Available

# Drug_Target_43_ID:
5326

# Drug_Target_43_Locus:
Not Available

# Drug_Target_43_Molecular_Weight:
27917

# Drug_Target_43_Name:
Oxidoreductase, short chain dehydrogenase/reductase family

# Drug_Target_43_Number_of_Residues:
255

# Drug_Target_43_PDB_ID:
1VL8

# Drug_Target_43_Pathway:
Not Available

# Drug_Target_43_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_43_Protein_Sequence:
>Oxidoreductase, short chain dehydrogenase/reductase family
MKEVFDLRGRVALVTGGSRGLGFGIAQGLAEAGCSVVVASRNLEEASEAAQKLTEKYGVE
TMAFRCDVSNYEEVKKLLEAVKEKFGKLDTVVNAAGINRRHPAEEFPLDEFRQVIEVNLF
GTYYVCREAFSLLRESDNPSIINIGSLTVEEVTMPNISAYAASKGGVASLTKALAKEWGR
YGIRVNVIAPGWYRTKMTEAVFSDPEKLDYMLKRIPLGRTGVPEDLKGVAVFLASEEAKY
VTGQIIFVDGGWTAN

# Drug_Target_43_Reaction:
Not Available

# Drug_Target_43_Signals:
None

# Drug_Target_43_Specific_Function:
Not Available

# Drug_Target_43_SwissProt_ID:
Q9WYS2

# Drug_Target_43_SwissProt_Name:
Q9WYS2_THEMA

# Drug_Target_43_Synonyms:
Not Available

# Drug_Target_43_Theoretical_pI:
5.25

# Drug_Target_43_Transmembrane_Regions:
None

# Drug_Target_44_Cellular_Location:
Not Available

# Drug_Target_44_Chromosome_Location:
Not Available

# Drug_Target_44_Drug_References:
Not Available

# Drug_Target_44_Essentiality:
Non-Essential

# Drug_Target_44_GenAtlas_ID:
Not Available

# Drug_Target_44_GenBank_ID_Gene:
AB034727

# Drug_Target_44_GenBank_ID_Protein:
Not Available

# Drug_Target_44_GeneCard_ID:
Not Available

# Drug_Target_44_Gene_Name:
Tb11.02.2310

# Drug_Target_44_Gene_Sequence:
>831 bp
ATGGCTCTCACTCAATCCCTAAAACTCTCGAATGGAGTGATGATGCCAGTTCTTGGTTTC
GGTATGTGGAAGTTACAGGATGGCAATGAAGCCGAGACGGCGACGATGTGGGCCATAAAA
AGCGGCTATCGTCACATCGATACTGCAGCCATCTATAAAAATGAAGAAAGCGCTGGCAGA
GCCATTGCCTCATGTGGTGTACCGCGGGAAGAGCTATTCGTCACGACGAAGCTTTGGAAC
TCCGACCAGGGATATGAGAGCACGCTGAGCGCATTTGAGAAGAGCATTAAGAAGCTCGGC
CTGGAATATGTTGACCTATACCTCATCCACTGGCCGGGGAAGGACAAGTTTATCGACACA
TGGAAGGCGTTTGAGAAACTGTACGCCGATAAGAAGGTGCGCGCCATTGGCGTTTCCAAC
TTTCACGAGCACCACATCGAGGAACTGCTAAAGCACTGTAAGGTTGCACCGATGGTTAAC
CAGATCGAGCTCCATCCGCTGCTCAATCAGAAGGCACTCTGCGAGTACTGCAAGTCGAAG
AACATCGCCGTCACTGCCTGGTCGCCGCTTGGTCAAGGACATCTCGTCGAAGACGCCCGT
CTGAAAGCTATCGGAGGAAAGTATGGTAAGACAGCTGCGCAGGTGATGCTCCGCTGGGAA
ATACAAGCAGGGGTCATCACGATTCCCAAATCGGGCAACGAGGCCCGCATCAAGGAAAAT
GGCAATATATTTGACTTCGAACTAACTGCGGAGGACATTCAAGTCATCGATGGTATGAAT
GCCGGCCACCGCTACGGCCCCGATCCGGAGGTCTTCATGAACGACTTTTGA

# Drug_Target_44_General_Function:
Involved in oxidoreductase activity

# Drug_Target_44_General_References:
11067881	Kubata BK, Duszenko M, Kabututu Z, Rawer M, Szallies A, Fujimori K, Inui T, Nozaki T, Yamashita K, Horii T, Urade Y, Hayaishi O: Identification of a novel prostaglandin f(2alpha) synthase in Trypanosoma brucei. J Exp Med. 2000 Nov 6;192(9):1327-38.

# Drug_Target_44_HGNC_ID:
Not Available

# Drug_Target_44_HPRD_ID:
Not Available

# Drug_Target_44_ID:
5328

# Drug_Target_44_Locus:
Not Available

# Drug_Target_44_Molecular_Weight:
30993

# Drug_Target_44_Name:
Prostaglandin F synthase

# Drug_Target_44_Number_of_Residues:
276

# Drug_Target_44_PDB_ID:
1VBJ

# Drug_Target_44_Pathway:
Not Available

# Drug_Target_44_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_44_Protein_Sequence:
>Prostaglandin F synthase
MALTQSLKLSNGVMMPVLGFGMWKLQDGNEAETATMWAIKSGYRHIDTAAIYKNEESAGR
AIASCGVPREELFVTTKLWNSDQGYESTLSAFEKSIKKLGLEYVDLYLIHWPGKDKFIDT
WKAFEKLYADKKVRAIGVSNFHEHHIEELLKHCKVAPMVNQIELHPLLNQKALCEYCKSK
NIAVTAWSPLGQGHLVEDARLKAIGGKYGKTAAQVMLRWEIQAGVITIPKSGNEARIKEN
GNIFDFELTAEDIQVIDGMNAGHRYGPDPEVFMNDF

# Drug_Target_44_Reaction:
Not Available

# Drug_Target_44_Signals:
None

# Drug_Target_44_Specific_Function:
Not Available

# Drug_Target_44_SwissProt_ID:
Q9GV41

# Drug_Target_44_SwissProt_Name:
Q9GV41_9TRYP

# Drug_Target_44_Synonyms:
EC 1.1.-.-

# Drug_Target_44_Theoretical_pI:
6.79

# Drug_Target_44_Transmembrane_Regions:
None

# Drug_Target_45_Cellular_Location:
Not Available

# Drug_Target_45_Chromosome_Location:
Not Available

# Drug_Target_45_Drug_References:
Not Available

# Drug_Target_45_Essentiality:
Non-Essential

# Drug_Target_45_GenAtlas_ID:
Not Available

# Drug_Target_45_GenBank_ID_Gene:
Y14082

# Drug_Target_45_GenBank_ID_Protein:
Not Available

# Drug_Target_45_GeneCard_ID:
Not Available

# Drug_Target_45_Gene_Name:
yhdN

# Drug_Target_45_Gene_Sequence:
>996 bp
ATGGAATATACCAGTATAGCAGATACAGGAATAGAAGCCTCCAGAATCGGCCTCGGCACA
TGGGCCATTGGCGGAACGATGTGGGGAGGCACTGACGAAAAAACATCGATTGAAACAATC
CGCGCCGCTCTTGATCAGGGGATTACACTGATTGACACCGCACCGGCTTACGGCTTCGGG
CAGTCCGAGGAAATTGTCGGAAAGGCAATCAAAGAGTACGGCAAAAGAGACCAGGTGATT
CTCGCAACGAAAACGGCTCTGGACTGGAAGAACAACCAGCTGTTCCGCCATGCGAACAGA
GCGAGAATTGTAGAGGAAGTTGAGAATTCTTTGAAGCGGCTTCAAACAGACTATATTGAT
CTTTATCAGGTGCATTGGCCCGATCCGCTTGTGCCAATTGAAGAAACGGCTGAAGTCATG
AAGGAATTATATGATGCGGGAAAAATCCGGGCGATTGGCGTCAGCAATTTTTCAATTGAG
CAAATGGATACATTTCGCGCCGTCGCACCTCTCCATACGATTCAGCCTCCATATAATCTG
TTTGAAAGAGAGATGGAAGAGAGTGTCCTTCCTTATGCGAAAGATAACAAGATAACAACA
TTATTATACGGCAGTTTATGCAGAGGGCTGTTAACAGGCAAAATGACTGAAGAATATACA
TTTGAGGGCGATGATCTGCGTAATCACGATCCAAAATTCCAGAAGCCCCGCTTTAAAGAG
TATCTTTCTGCTGTGAATCAATTGGATAAGCTGGCGAAGACACGTTATGGAAAATCAGTG
ATTCACTTGGCTGTCAGATGGATCTTAGATCAGCCGGGAGCGGATATCGCTCTTTGGGGA
GCAAGAAAGCCTGGGCAGCTTGAGGCCCTATCTGAGATTACAGGCTGGACGCTGAACAGT
GAAGATCAGAAAGATATCAATACTATATTGGAAAATACGATATCAGACCCTGTCGGACCG
GAGTTTATGGCCCCGCCGACCAGAGAGGAAATATAA

# Drug_Target_45_General_Function:
Energy production and conversion

# Drug_Target_45_General_References:
9298659	Antelmann H, Bernhardt J, Schmid R, Mach H, Volker U, Hecker M: First steps from a two-dimensional protein index towards a response-regulation map for Bacillus subtilis. Electrophoresis. 1997 Aug;18(8):1451-63.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.
9579061	Noback MA, Holsappel S, Kiewiet R, Terpstra P, Wambutt R, Wedler H, Venema G, Bron S: The 172 kb prkA-addAB region from 83 degrees to 97 degrees of the Bacillus subtilis chromosome contains several dysfunctional genes, the glyB marker, many genes encoding transporter proteins, and the ubiquitous hit gene. Microbiology. 1998 Apr;144 ( Pt 4):859-75.

# Drug_Target_45_HGNC_ID:
Not Available

# Drug_Target_45_HPRD_ID:
Not Available

# Drug_Target_45_ID:
5330

# Drug_Target_45_Locus:
Not Available

# Drug_Target_45_Molecular_Weight:
37313

# Drug_Target_45_Name:
General stress protein 69

# Drug_Target_45_Number_of_Residues:
331

# Drug_Target_45_PDB_ID:
1PZ1

# Drug_Target_45_Pathway:
Not Available

# Drug_Target_45_Pfam_Domain_Function:
Not Available

# Drug_Target_45_Protein_Sequence:
>General stress protein 69
MEYTSIADTGIEASRIGLGTWAIGGTMWGGTDEKTSIETIRAALDQGITLIDTAPAYGFG
QSEEIVGKAIKEYGKRDQVILATKTALDWKNNQLFRHANRARIVEEVENSLKRLQTDYID
LYQVHWPDPLVPIEETAEVMKELYDAGKIRAIGVSNFSIEQMDTFRAVAPLHTIQPPYNL
FEREMEESVLPYAKDNKITTLLYGSLCRGLLTGKMTEEYTFEGDDLRNHDPKFQKPRFKE
YLSAVNQLDKLAKTRYGKSVIHLAVRWILDQPGADIALWGARKPGQLEALSEITGWTLNS
EDQKDINTILENTISDPVGPEFMAPPTREEI

# Drug_Target_45_Reaction:
Not Available

# Drug_Target_45_Signals:
None

# Drug_Target_45_Specific_Function:
Not Available

# Drug_Target_45_SwissProt_ID:
P80874

# Drug_Target_45_SwissProt_Name:
GS69_BACSU

# Drug_Target_45_Synonyms:
AKR11B
EC 1.1.1.-
GSP69

# Drug_Target_45_Theoretical_pI:
4.69

# Drug_Target_45_Transmembrane_Regions:
None

# Drug_Target_46_Cellular_Location:
Cellular thylakoid membrane

# Drug_Target_46_Chromosome_Location:
Not Available

# Drug_Target_46_Drug_References:
Not Available

# Drug_Target_46_Essentiality:
Non-Essential

# Drug_Target_46_GenAtlas_ID:
Not Available

# Drug_Target_46_GenBank_ID_Gene:
X72394

# Drug_Target_46_GenBank_ID_Protein:
Not Available

# Drug_Target_46_GeneCard_ID:
Not Available

# Drug_Target_46_Gene_Name:
petH

# Drug_Target_46_Gene_Sequence:
>1323 bp
ATGTCTAATCAAGGTGCTTTTGATGGTGCTGCCAACGTAGAATCAGGTAGCCGCGTCTTC
GTTTACGAAGTGGTGGGTATGCGTCAGAACGAAGAAACTGATCAAACGAACTACCCAATT
CGTAAAAGTGGCAGTGTGTTCATTAGAGTGCCTTACAACCGCATGAATCAAGAAATGCAG
CGTATCACTCGACTAGGCGGCAAGATTGTTACGATTCAAACAGTAAGCGCACTACAACAA
CTCAATGGTAGAACTACCATTGCAACAGTAACAGATGCGTCTAGTGAGATTGCTAAGTCT
GAGGGGAATGGTAAAGCCACACCTGTAAAAACTGATAGTGGAGCTAAAGCGTTCGCTAAA
CCACCAGCTGAAGAACAGCTTAAGAAAAAAGACAACAAAGGCAACACCATGACTCAAGCG
AAAGCCAAACACGCTGATGTTCCTGTTAATCTTTACCGTCCCAATGCTCCATTTATTGGT
AAGGTAATCTCTAATGAACCACTGGTAAAAGAAGGCGGGATAGGTATTGTTCAGCACATT
AAATTTGATCTAACTGGTGGTAACTTAAAGTACATCGAAGGTCAAAGTATTGGTATCATT
CCACCAGGAGTGGACAAGAACGGCAAGCCGGAAAAATTGAGACTCTACTCCATTGCCTCG
ACCCGTCACGGCGATGATGTGGATGATAAAACCATCTCACTGTGCGTCCGTCAATTAGAG
TACAAACATCCAGAAAGCGGCGAAACAGTTTACGGTGTTTGTTCTACTTACTTGACTCAC
ATTGAACCAGGTTCAGAAGTGAAAATCACTGGGCCTGTGGGTAAAGAAATGCTGTTACCC
GATGATCCTGAAGCTAATGTCATCATGTTGGCAACAGGTACTGGTATTGCGCCTATGCGG
ACTTACCTGTGGCGGATGTTCAAGGATGCAGAAAGAGCTGCTAACCCAGAATATCAATTC
AAAGGATTCTCTTGGTTAGTCTTTGGTGTTCCTACAACTCCTAACATTCTTTATAAAGAA
GAACTGGAAGAAATCCAACAAAAATATCCCGATAACTTCCGCCTAACTTACGCTATCAGC
CGGGAGCAAAAGAATCCCCAAGGTGGCAGAATGTACATCCAAGACCGTGTGGCAGAACAC
GCTGATGAACTGTGGCAATTAATCAAGAATCAAAAAACCCACACCTACATCTGTGGTTTG
CGCGGTATGGAAGAGGGCATTGATGCTGCTTTAAGTGCTGCGGCTGCGAAAGAAGGTGTT
ACCTGGAGTGATTACCAAAAAGACCTCAAGAAAGCTGGTCGCTGGCACGTAGAAACATAC
TAA

# Drug_Target_46_General_Function:
Involved in oxidoreductase activity

# Drug_Target_46_General_References:
10651039	Mayoral T, Medina M, Sanz-Aparicio J, Gomez-Moreno C, Hermoso JA: Structural basis of the catalytic role of Glu301 in Anabaena PCC 7119 ferredoxin-NADP+ reductase revealed by x-ray crystallography. Proteins. 2000 Jan 1;38(1):60-9.
11053838	Morales R, Kachalova G, Vellieux F, Charon MH, Frey M: Crystallographic studies of the interaction between the ferredoxin-NADP+ reductase and ferredoxin from the cyanobacterium Anabaena: looking for the elusive ferredoxin molecule. Acta Crystallogr D Biol Crystallogr. 2000 Nov;56(Pt 11):1408-12.
2124680	Fillat MF, Bakker HA, Weisbeek PJ: Sequence of the ferredoxin-NADP(+)-reductase gene from Anabaena PCC 7119. Nucleic Acids Res. 1990 Dec 11;18(23):7161.
3124746	Sancho J, Peleato ML, Gomez-Moreno C, Edmondson DE: Purification and properties of ferredoxin-NADP+ oxidoreductase from the nitrogen-fixing cyanobacteria Anabaena variabilis. Arch Biochem Biophys. 1988 Jan;260(1):200-7.
8343609	Fillat MF, Flores E, Gomez-Moreno C: Homology of the N-terminal domain of the petH gene product from Anabaena sp. PCC 7119 to the CpcD phycobilisome linker polypeptide. Plant Mol Biol. 1993 Jul;22(4):725-9.
8890910	Serre L, Vellieux FM, Medina M, Gomez-Moreno C, Fontecilla-Camps JC, Frey M: X-ray structure of the ferredoxin:NADP+ reductase from the cyanobacterium Anabaena PCC 7119 at 1.8 A resolution, and crystallographic studies of NADP+ binding at 2.25 A resolution. J Mol Biol. 1996 Oct 18;263(1):20-39.
9922134	Martinez-Julvez M, Hermoso J, Hurley JK, Mayoral T, Sanz-Aparicio J, Tollin G, Gomez-Moreno C, Medina M: Role of Arg100 and Arg264 from Anabaena PCC 7119 ferredoxin-NADP+ reductase for optimal NADP+ binding and electron transfer. Biochemistry. 1998 Dec 22;37(51):17680-91.

# Drug_Target_46_HGNC_ID:
Not Available

# Drug_Target_46_HPRD_ID:
Not Available

# Drug_Target_46_ID:
5073

# Drug_Target_46_Locus:
Not Available

# Drug_Target_46_Molecular_Weight:
48866

# Drug_Target_46_Name:
Ferredoxin--NADP reductase

# Drug_Target_46_Number_of_Residues:
440

# Drug_Target_46_PDB_ID:
1GJR

# Drug_Target_46_Pathway:
Not Available

# Drug_Target_46_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00667	FAD_binding_1
PF01383	CpcD

# Drug_Target_46_Protein_Sequence:
>Ferredoxin--NADP reductase
MSNQGAFDGAANVESGSRVFVYEVVGMRQNEETDQTNYPIRKSGSVFIRVPYNRMNQEMQ
RITRLGGKIVTIQTVSALQQLNGRTTIATVTDASSEIAKSEGNGKATPVKTDSGAKAFAK
PPAEEQLKKKDNKGNTMTQAKAKHADVPVNLYRPNAPFIGKVISNEPLVKEGGIGIVQHI
KFDLTGGNLKYIEGQSIGIIPPGVDKNGKPEKLRLYSIASTRHGDDVDDKTISLCVRQLE
YKHPESGETVYGVCSTYLTHIEPGSEVKITGPVGKEMLLPDDPEANVIMLATGTGIAPMR
TYLWRMFKDAERAANPEYQFKGFSWLVFGVPTTPNILYKEELEEIQQKYPDNFRLTYAIS
REQKNPQGGRMYIQDRVAEHADELWQLIKNQKTHTYICGLRGMEEGIDAALSAAAAKEGV
TWSDYQKDLKKAGRWHVETY

# Drug_Target_46_Reaction:
Not Available

# Drug_Target_46_Signals:
None

# Drug_Target_46_Specific_Function:
Reduced ferredoxin + NADP(+) = oxidized ferredoxin + NADPH

# Drug_Target_46_SwissProt_ID:
P21890

# Drug_Target_46_SwissProt_Name:
FENR_ANASO

# Drug_Target_46_Synonyms:
EC 1.18.1.2
FNR

# Drug_Target_46_Theoretical_pI:
8.37

# Drug_Target_46_Transmembrane_Regions:
None

# Drug_Target_47_Cellular_Location:
Cytoplasm

# Drug_Target_47_Chromosome_Location:
Not Available

# Drug_Target_47_Drug_References:
Not Available

# Drug_Target_47_Essentiality:
Non-Essential

# Drug_Target_47_GenAtlas_ID:
Not Available

# Drug_Target_47_GenBank_ID_Gene:
Not Available

# Drug_Target_47_GenBank_ID_Protein:
Not Available

# Drug_Target_47_GeneCard_ID:
Not Available

# Drug_Target_47_Gene_Name:
mtdA

# Drug_Target_47_Gene_Sequence:
Not Available

# Drug_Target_47_General_Function:
Not Available

# Drug_Target_47_General_References:
11297742	Hagemeier CH, Bartoschek S, Griesinger C, Thauer RK, Vorholt JA: Re-face stereospecificity of NADP dependent methylenetetrahydromethanopterin dehydrogenase from Methylobacterium extorquens AM1 as determined by NMR spectroscopy. FEBS Lett. 2001 Apr 6;494(1-2):95-8.
8144463	Chistoserdova LV, Lidstrom ME: Genetics of the serine cycle in Methylobacterium extorquens AM1: identification of sgaA and mtdA and sequences of sgaA, hprA, and mtdA. J Bacteriol. 1994 Apr;176(7):1957-68.
9765566	Vorholt JA, Chistoserdova L, Lidstrom ME, Thauer RK: The NADP-dependent methylene tetrahydromethanopterin dehydrogenase in Methylobacterium extorquens AM1. J Bacteriol. 1998 Oct;180(20):5351-6.

# Drug_Target_47_HGNC_ID:
Not Available

# Drug_Target_47_HPRD_ID:
Not Available

# Drug_Target_47_ID:
5332

# Drug_Target_47_Locus:
Not Available

# Drug_Target_47_Molecular_Weight:
29736

# Drug_Target_47_Name:
MtdA bifunctional protein

# Drug_Target_47_Number_of_Residues:
288

# Drug_Target_47_PDB_ID:
1LUA

# Drug_Target_47_Pathway:
Not Available

# Drug_Target_47_Pfam_Domain_Function:
Not Available

# Drug_Target_47_Protein_Sequence:
>MtdA bifunctional protein
MSKKLLFQFDTDATPSVFDVVVGYDGGADHITGYGNVTPDNVGAYVDGTIYTRGGKEKQS
TAIFVGGGDMAAGERVFEAVKKRFFGPFRVSCMLDSNGSNTTAAAGVALVVKAAGGSVKG
KKAVVLAGTGPVGMRSAALLAGEGAEVVLCGRKLDKAQAAADSVNKRFKVNVTAAETADD
ASRAEAVKGAHFVFTAGAIGLELLPQAAWQNESSIEIVADYNAQPPLGIGGIDATDKGKE
YGGKRAFGALGIGGLKLKLHRACIAKLFESSEGVFDAEEIYKLAKEMA

# Drug_Target_47_Reaction:
Not Available

# Drug_Target_47_Signals:
None

# Drug_Target_47_Specific_Function:
Catalyzes the dehydrogenation of methylene-H(4)MPT. Can also catalyze the reversible dehydrogenation of methylene-H(4)F with 20-fold lower catalytic efficiency

# Drug_Target_47_SwissProt_ID:
P55818

# Drug_Target_47_SwissProt_Name:
MTDA_METEA

# Drug_Target_47_Synonyms:
Not Available

# Drug_Target_47_Theoretical_pI:
7.43

# Drug_Target_47_Transmembrane_Regions:
None

# Drug_Target_48_Cellular_Location:
Not Available

# Drug_Target_48_Chromosome_Location:
Not Available

# Drug_Target_48_Drug_References:
Not Available

# Drug_Target_48_Essentiality:
Non-Essential

# Drug_Target_48_GenAtlas_ID:
Not Available

# Drug_Target_48_GenBank_ID_Gene:
AE000512

# Drug_Target_48_GenBank_ID_Protein:
Not Available

# Drug_Target_48_GeneCard_ID:
Not Available

# Drug_Target_48_Gene_Name:
TM_0920

# Drug_Target_48_Gene_Sequence:
>1080 bp
GTGTGGGAATTCTACATGCCCACGGATGTCTTTTTTGGAGAAAAAATCCTCGAGAAGAGA
GGAAACATAATAGATCTTCTTGGAAAAAGAGCTTTGGTAGTAACCGGCAAATCTTCTTCG
AAAAAGAACGGATCTCTCGATGATCTGAAAAAGCTTCTCGACGAAACAGAAATATCCTAC
GAGATCTTCGATGAAGTCGAGGAGAATCCGTCTTTCGACAACGTTATGAAGGCTGTTGAG
AGATACAGAAACGATTCTTTCGATTTCGTCGTGGGACTCGGTGGAGGAAGCCCTATGGAT
TTCGCCAAGGCGGTGGCCGTACTTTTGAAAGAGAAAGATCTTTCCGTCGAAGATCTTTAC
GATAGAGAAAAAGTGAAGCACTGGCTTCCAGTCGTGGAGATACCAACCACCGCTGGAACG
GGTAGTGAAGTCACTCCGTATTCCATACTCACCGATCCAGAGGGAAACAAAAGAGGTTGT
ACACTCATGTTTCCGGTGTACGCGTTTCTCGATCCCAGATACACCTACTCCATGTCAGAT
GAACTGACCTTATCGACTGGAGTCGATGCGCTTTCTCATGCGGTCGAAGGATACCTTTCT
AGAAAGAGTACGCCGCCTTCCGATGCCCTCGCGATCGAAGCCATGAAGATAATTCACAGG
AATTTACCGAAGGCCATTGAAGGAAACAGAGAAGCCAGAAAGAAGATGTTCGTGGCCTCC
TGCCTTGCCGGGATGGTGATTGCGCAAACTGGGACCACACTGGCGCACGCTCTGGGTTAT
CCTCTAACAACGGAGAAGGGAATAAAACACGGGAAAGCGACAGGTATGGTACTACCATTT
GTAATGGAGGTAATGAAAGAAGAAATTCCAGAAAAGGTGGATACTGTGAATCACATATTC
GGCGGCAGTCTTTTGAAATTTCTGAAAGAACTCGGACTTTACGAAAAAGTGGCAGTTTCC
TCTGAAGAACTGGAGAAGTGGGTCGAAAAGGGTTCCAGAGCGAAACATCTCAAAAACACG
CCGGGTACCTTCACTCCCGAAAAGATCAGAAACATATACAGGGAGGCACTCGGGGTGTGA

# Drug_Target_48_General_Function:
Involved in oxidoreductase activity

# Drug_Target_48_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_48_HGNC_ID:
Not Available

# Drug_Target_48_HPRD_ID:
Not Available

# Drug_Target_48_ID:
5333

# Drug_Target_48_Locus:
Not Available

# Drug_Target_48_Molecular_Weight:
39943

# Drug_Target_48_Name:
Alcohol dehydrogenase, iron-containing

# Drug_Target_48_Number_of_Residues:
359

# Drug_Target_48_PDB_ID:
1VHD

# Drug_Target_48_Pathway:
Not Available

# Drug_Target_48_Pfam_Domain_Function:
PF00465	Fe-ADH

# Drug_Target_48_Protein_Sequence:
>Alcohol dehydrogenase, iron-containing
MWEFYMPTDVFFGEKILEKRGNIIDLLGKRALVVTGKSSSKKNGSLDDLKKLLDETEISY
EIFDEVEENPSFDNVMKAVERYRNDSFDFVVGLGGGSPMDFAKAVAVLLKEKDLSVEDLY
DREKVKHWLPVVEIPTTAGTGSEVTPYSILTDPEGNKRGCTLMFPVYAFLDPRYTYSMSD
ELTLSTGVDALSHAVEGYLSRKSTPPSDALAIEAMKIIHRNLPKAIEGNREARKKMFVAS
CLAGMVIAQTGTTLAHALGYPLTTEKGIKHGKATGMVLPFVMEVMKEEIPEKVDTVNHIF
GGSLLKFLKELGLYEKVAVSSEELEKWVEKGSRAKHLKNTPGTFTPEKIRNIYREALGV

# Drug_Target_48_Reaction:
Not Available

# Drug_Target_48_Signals:
None

# Drug_Target_48_Specific_Function:
Not Available

# Drug_Target_48_SwissProt_ID:
Q9X022

# Drug_Target_48_SwissProt_Name:
Q9X022_THEMA

# Drug_Target_48_Synonyms:
Not Available

# Drug_Target_48_Theoretical_pI:
5.97

# Drug_Target_48_Transmembrane_Regions:
None

# Drug_Target_49_Cellular_Location:
Not Available

# Drug_Target_49_Chromosome_Location:
Not Available

# Drug_Target_49_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_49_Essentiality:
Non-Essential

# Drug_Target_49_GenAtlas_ID:
Not Available

# Drug_Target_49_GenBank_ID_Gene:
Not Available

# Drug_Target_49_GenBank_ID_Protein:
Not Available

# Drug_Target_49_GeneCard_ID:
Not Available

# Drug_Target_49_Gene_Name:
FDXR

# Drug_Target_49_Gene_Sequence:
Not Available

# Drug_Target_49_General_Function:
Not Available

# Drug_Target_49_General_References:
Not Available

# Drug_Target_49_HGNC_ID:
Not Available

# Drug_Target_49_HPRD_ID:
Not Available

# Drug_Target_49_ID:
6990

# Drug_Target_49_Locus:
Not Available

# Drug_Target_49_Molecular_Weight:
Not Available

# Drug_Target_49_Name:
NADPH:adrenodoxin oxidoreductase, mitochondrial

# Drug_Target_49_Number_of_Residues:
0

# Drug_Target_49_PDB_ID:
Not Available

# Drug_Target_49_Pathway:
Not Available

# Drug_Target_49_Pfam_Domain_Function:
Not Available

# Drug_Target_49_Protein_Sequence:
Not Available

# Drug_Target_49_Reaction:
Not Available

# Drug_Target_49_Signals:
Not Available

# Drug_Target_49_Specific_Function:
Not Available

# Drug_Target_49_SwissProt_ID:
P22570

# Drug_Target_49_SwissProt_Name:
ADRO_HUMAN

# Drug_Target_49_Synonyms:
Not Available

# Drug_Target_49_Theoretical_pI:
Not Available

# Drug_Target_49_Transmembrane_Regions:
Not Available

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
X64841

# Drug_Target_4_GenBank_ID_Protein:
1771791

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
adh

# Drug_Target_4_Gene_Sequence:
>1059 bp
ATGAAAGGTTTTGCAATGCTCAGTATCGGTAAAGTTGGCTGGATTGAGAAGGAAAAGCCT
GCTCCTGGCCCATTTGATGCTATTGTAAGACCTCTAGCTGTGGCCCCTTGCACTTCGGAC
ATTCATACCGTTTTTGAAGGCGCCATTGGCGAAAGACATAACATGATACTCGGTCACGAA
GCTGTAGGTGAAGTAGTTGAAGTAGGTAGTGAGGTAAAAGATTTTAAACCTGGTGATCGC
GTTGTTGTGCCAGCTATTACCCCTGATTGGCGGACCTCTGAAGTACAAAGAGGATATCAC
CAGCACTCCGGTGGAATGCTGGCAGGCTGGAAATTTTCGAATGTAAAAGATGGTGTTTTT
GGTGAATTTTTTCATGTGAATGATGCTGATATGAATTTAGCACATCTGCCTAAAGAAATT
CCATTGGAAGCTGCAGTTATGATTCCCGATATGATGACCACTGGTTTTCACGGAGCTGAA
CTGGCAGATATAGAATTAGGTGCGACGGTAGCAGTTTTGGGTATTGGCCCAGTAGGTCTT
ATGGCAGTCGCTGGTGCCAAATTGCGTGGAGCCGGAAGAATTATTGCCGTAGGCAGTAGA
CCAGTTTGTGTAGATGCTGCAAAATACTATGGAGCTACTGATATTGTAAACTATAAAGAT
GGTCCTATCGAAAGTCAGATTATGAATCTAACTGAAGGCAAAGGTGTCGATGCTGCCATC
ATCGCTGGAGGAAATGCTGACATTATGGCTACAGCAGTTAAGATTGTTAAACCTGGTGGC
ACCATCGCTAATGTAAATTATTTTGGCGAAGGAGAGGTTTTGCCTGTTCCTCGTCTTGAA
TGGGGTTGCGGCATGGCTCATAAAACTATAAAAGGCGGGCTATGCCCCGGTGGACGTCTA
AGAATGGAAAGACTGATTGACCTTGTTTTTTATAAGCGTGTCGATCCTTCTAAGCTCGTC
ACTCACGTTTTCCGGGGATTTGACAATATTGAAAAAGCCTTTATGTTGATGAAAGACAAA
CCAAAAGACCTAATCAAACCTGTTGTAATATTAGCATAA

# Drug_Target_4_General_Function:
Amino acid transport and metabolism

# Drug_Target_4_General_References:
2790012	Peretz M, Burstein Y: Amino acid sequence of alcohol dehydrogenase from the thermophilic bacterium Thermoanaerobium brockii. Biochemistry. 1989 Aug 8;28(16):6549-55.
9836873	Korkhin Y, Kalb(Gilboa) AJ, Peretz M, Bogin O, Burstein Y, Frolow F: NADP-dependent bacterial alcohol dehydrogenases: crystal structure, cofactor-binding and cofactor specificity of the ADHs of Clostridium beijerinckii and Thermoanaerobacter brockii. J Mol Biol. 1998 May 22;278(5):967-81.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3446

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
37647

# Drug_Target_4_Name:
NADP-dependent alcohol dehydrogenase

# Drug_Target_4_Number_of_Residues:
352

# Drug_Target_4_PDB_ID:
1YKF

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_4_Protein_Sequence:
>NADP-dependent alcohol dehydrogenase
MKGFAMLSIGKVGWIEKEKPAPGPFDAIVRPLAVAPCTSDIHTVFEGAIGERHNMILGHE
AVGEVVEVGSEVKDFKPGDRVVVPAITPDWRTSEVQRGYHQHSGGMLAGWKFSNVKDGVF
GEFFHVNDADMNLAHLPKEIPLEAAVMIPDMMTTGFHGAELADIELGATVAVLGIGPVGL
MAVAGAKLRGAGRIIAVGSRPVCVDAAKYYGATDIVNYKDGPIESQIMNLTEGKGVDAAI
IAGGNADIMATAVKIVKPGGTIANVNYFGEGEVLPVPRLEWGCGMAHKTIKGGLCPGGRL
RMERLIDLVFYKRVDPSKLVTHVFRGFDNIEKAFMLMKDKPKDLIKPVVILA

# Drug_Target_4_Reaction:
an alcohol + NADP+ = an aldehyde + NADPH + H+

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
An alcohol + NADP(+) = an aldehyde + NADPH

# Drug_Target_4_SwissProt_ID:
P14941

# Drug_Target_4_SwissProt_Name:
ADH_THEBR

# Drug_Target_4_Synonyms:
EC 1.1.1.2

# Drug_Target_4_Theoretical_pI:
6.86

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_50_Cellular_Location:
Cellular thylakoid membrane

# Drug_Target_50_Chromosome_Location:
Not Available

# Drug_Target_50_Drug_References:
Not Available

# Drug_Target_50_Essentiality:
Non-Essential

# Drug_Target_50_GenAtlas_ID:
Not Available

# Drug_Target_50_GenBank_ID_Gene:
BA000019

# Drug_Target_50_GenBank_ID_Protein:
Not Available

# Drug_Target_50_GeneCard_ID:
Not Available

# Drug_Target_50_Gene_Name:
petH

# Drug_Target_50_Gene_Sequence:
>1323 bp
TTAGTATGTTTCTACGTGCCAGCGACCAGCTTTCTTGAGGTCTTTTTGGTAATCACTCCA
GGTAACACCTTCTTTCGCAGCCGCAGCACTTAAAGCAGCATCAATGCCCTCTTCCATACC
GCGCAAACCACAGATGTAGGTGTGGGTTTTTTCATTCTTGATTAATTGCCACAGTTCATC
AGCGTGTTCTGCCACACGGTCTTGGATGTACATTCTGCCACCTTGGGGATTCTTTTGCTC
CCGGCTGATAGCGTAAGTTAGGCGGAAGTTATCGGGATATTTTTGTTGGATTTCTTCCAG
TTCTTCTTTATAAAGAATGTTAGGAGTTGTAGGAACACCAAAGACTAACCAAGAGAATCC
TTTGAATTGATATTCTGGGTTAGCAGCTCTTTCTGCATCCTTGAACATCCGCCACAGGTA
AGTCCGCATAGGCGCAATACCAGTACCTGTTGCCAACATGATGACATTAGCTTCAGGATC
ATCGGGTAACAGCATTTCTTTACCCACAGGCCCAGTGATTTTCACTTCTGAACCTGGTTC
AATGTGAGTCAAGTAAGTAGAACAAACACCGTAAACTGTTTCGCCGCTTTCTGGATGTTT
GTACTCTAATTGACGGACGCACAGTGAGATGGTTTTATCATCCACATCATCGCCGTGACG
GGTCGAGGCAATGGAGTAGAGTCTCAATTTTTCCGGCTTGCCGTTCTTGTCCACTCCTGG
TGGAATGATACCAATACTTTGACCTTCGATGTACTTTAAGTTACCACCAGTTAGATCAAA
TTTAATGTGCTGAACAATACCTATCCCGCCTTCTTTTACCAGTGGTTCATTAGAGATTAC
CTTACCAATAAATGGAGCATTGGGACGGTAAAGATTAACAGGAACATCAGCGTGTTTGGC
TTTCGCTTGAGTCATGGTGTTGCCTTTGTTGTCTTTTTTCTTAAGCTGTTCTTCAGCTGG
TGGTTTAGCGAAGCCTTTAGCTCCACTATCAGTTTTTACAGGTGTGGCTTTACCATTCCC
CTCAGACTTAGCAATCTCACTAGACGCATCTGTTACTGTTGCAATGGTAGTTCTACCATT
GAGTTGTTGTAGTGCGCTTACTGTTTGAATGCTAACAATCTTGCCGCCTAGTCGAGTGAT
ACGCTGCATTTCTTGATTCATGCGGTTGTAAGGCACTCTAATGAACACACTGCCACTTTT
ACGAATTGGGTAGTTCGTTTGATCAGTTTCTTCGTTCTGACGCATACCCACCACTTCGTA
AACGAAGACGCGGCTACCTGATTCTACGTTGGCAGCACCATCAAAAGCACCTTGATTAGA
CAT

# Drug_Target_50_General_Function:
Involved in oxidoreductase activity

# Drug_Target_50_General_References:
11759840	Kaneko T, Nakamura Y, Wolk CP, Kuritz T, Sasamoto S, Watanabe A, Iriguchi M, Ishikawa A, Kawashima K, Kimura T, Kishida Y, Kohara M, Matsumoto M, Matsuno A, Muraki A, Nakazaki N, Shimpo S, Sugimoto M, Takazawa M, Yamada M, Yasuda M, Tabata S: Complete genomic sequence of the filamentous nitrogen-fixing cyanobacterium Anabaena sp. strain PCC 7120. DNA Res. 2001 Oct 31;8(5):205-13; 227-53.

# Drug_Target_50_HGNC_ID:
Not Available

# Drug_Target_50_HPRD_ID:
Not Available

# Drug_Target_50_ID:
5119

# Drug_Target_50_Locus:
Not Available

# Drug_Target_50_Molecular_Weight:
48839

# Drug_Target_50_Name:
Ferredoxin--NADP reductase

# Drug_Target_50_Number_of_Residues:
440

# Drug_Target_50_PDB_ID:
1GJR

# Drug_Target_50_Pathway:
Not Available

# Drug_Target_50_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00667	FAD_binding_1
PF01383	CpcD

# Drug_Target_50_Protein_Sequence:
>Ferredoxin--NADP reductase
MSNQGAFDGAANVESGSRVFVYEVVGMRQNEETDQTNYPIRKSGSVFIRVPYNRMNQEMQ
RITRLGGKIVSIQTVSALQQLNGRTTIATVTDASSEIAKSEGNGKATPVKTDSGAKGFAK
PPAEEQLKKKDNKGNTMTQAKAKHADVPVNLYRPNAPFIGKVISNEPLVKEGGIGIVQHI
KFDLTGGNLKYIEGQSIGIIPPGVDKNGKPEKLRLYSIASTRHGDDVDDKTISLCVRQLE
YKHPESGETVYGVCSTYLTHIEPGSEVKITGPVGKEMLLPDDPEANVIMLATGTGIAPMR
TYLWRMFKDAERAANPEYQFKGFSWLVFGVPTTPNILYKEELEEIQQKYPDNFRLTYAIS
REQKNPQGGRMYIQDRVAEHADELWQLIKNEKTHTYICGLRGMEEGIDAALSAAAAKEGV
TWSDYQKDLKKAGRWHVETY

# Drug_Target_50_Reaction:
Not Available

# Drug_Target_50_Signals:
None

# Drug_Target_50_Specific_Function:
Reduced ferredoxin + NADP(+) = oxidized ferredoxin + NADPH

# Drug_Target_50_SwissProt_ID:
P58558

# Drug_Target_50_SwissProt_Name:
FENR_NOSS1

# Drug_Target_50_Synonyms:
EC 1.18.1.2
FNR

# Drug_Target_50_Theoretical_pI:
8.05

# Drug_Target_50_Transmembrane_Regions:
None

# Drug_Target_51_Cellular_Location:
Cytoplasm

# Drug_Target_51_Chromosome_Location:
Not Available

# Drug_Target_51_Drug_References:
Not Available

# Drug_Target_51_Essentiality:
Non-Essential

# Drug_Target_51_GenAtlas_ID:
Not Available

# Drug_Target_51_GenBank_ID_Gene:
M12799

# Drug_Target_51_GenBank_ID_Protein:
Not Available

# Drug_Target_51_GeneCard_ID:
Not Available

# Drug_Target_51_Gene_Name:
dkgA

# Drug_Target_51_Gene_Sequence:
>837 bp
ATGACAGTTCCCAGCATCGTGCTCAACGACGGCAATTCCATTCCCCAGCTCGGGTACGGC
GTCTTCAAGGTGCCGCCGGCGGACACCCAGCGCGCCGTCGAGGAAGCGCTCGAAGTCGGC
TACCGGCACATCGACACCGCGGCGATCTACGGAAACGAAGAAGGCGTCGGCGCCGCGATC
GCGGCGAGCGGCATCGCGCGCGACGACCTGTTCATCACGACGAAGCTCTGGAACGATCGC
CACGACGGCGATGAGCCCGCTGCAGCGATCGCCGAGAGCCTCGCGAAGCTGGCACTCGAT
CAGGTCGACCTGTACCTCGTGCACTGGCCGACGCCCGCCGCCGACAACTACGTGCACGCG
TGGGAGAAGATGATCGAGCTTCGCGCAGCCGGTCTCACCCGCAGCATCGGCGTCTCGAAC
CACCTCGTGCCGCACCTCGAGCGCATCGTCGCCGCCACCGGCGTCGTGCCGGCGGTGAAC
CAGATCGAGCTGCACCCCGCCTACCAGCAGCGCGAGATCACCGACTGGGCCGCCGCCCAC
GACGTGAAGATCGAATCGTGGGGGCCGCTCGGTCAGGGCAAGTACGACCTCTTCGGCGCC
GAGCCCGTCACTGCGGCTGCCGCCGCCCACGGCAAGACCCCGGCGCAGGCCGTGCTCCGT
TGGCACCTGCAGAAGGGTTTCGTGGTCTTCCCGAAGTCGGTCCGCCGCGAGCGCCTCGAA
GAGAACCTCGACGTGTTCGACTTCGACCTCACCGACACCGAGATCGCCGCGATCGACGCG
ATGGATCCGGGCGACGGTTCGGGTCGCGTGAGCGCACACCCCGATGAGGTCGACTGA

# Drug_Target_51_General_Function:
Involved in oxidoreductase activity

# Drug_Target_51_General_References:
10737928	Khurana S, Sanli G, Powers DB, Anderson S, Blaber M: Molecular modeling of substrate binding in wild-type and mutant Corynebacteria 2,5-diketo-D-gluconate reductases. Proteins. 2000 Apr 1;39(1):68-75.
11399090	Sanli G, Blaber M: Structural assembly of the active site in an aldo-keto reductase by NADPH cofactor. J Mol Biol. 2001 Jun 22;309(5):1209-18.
3597405	Miller JV, Estell DA, Lazarus RA: Purification and characterization of 2,5-diketo-D-gluconate reductase from Corynebacterium sp. J Biol Chem. 1987 Jul 5;262(19):9016-20.
9618487	Khurana S, Powers DB, Anderson S, Blaber M: Crystal structure of 2,5-diketo-D-gluconic acid reductase A complexed with NADPH at 2.1-A resolution. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6768-73.

# Drug_Target_51_HGNC_ID:
Not Available

# Drug_Target_51_HPRD_ID:
Not Available

# Drug_Target_51_ID:
4484

# Drug_Target_51_Locus:
Not Available

# Drug_Target_51_Molecular_Weight:
30119

# Drug_Target_51_Name:
2,5-diketo-D-gluconic acid reductase A

# Drug_Target_51_Number_of_Residues:
278

# Drug_Target_51_PDB_ID:
1HW6

# Drug_Target_51_Pathway:
Not Available

# Drug_Target_51_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_51_Protein_Sequence:
>2,5-diketo-D-gluconic acid reductase A
MTVPSIVLNDGNSIPQLGYGVFKVPPADTQRAVEEALEVGYRHIDTAAIYGNEEGVGAAI
AASGIARDDLFITTKLWNDRHDGDEPAAAIAESLAKLALDQVDLYLVHWPTPAADNYVHA
WEKMIELRAAGLTRSIGVSNHLVPHLERIVAATGVVPAVNQIELHPAYQQREITDWAAAH
DVKIESWGPLGQGKYDLFGAEPVTAAAAAHGKTPAQAVLRWHLQKGFVVFPKSVRRERLE
ENLDVFDFDLTDTEIAAIDAMDPGDGSGRVSAHPDEVD

# Drug_Target_51_Reaction:
Not Available

# Drug_Target_51_Signals:
None

# Drug_Target_51_Specific_Function:
Catalyzes the reduction of 2,5-diketo-D-gluconic acid (25DKG) to 2-keto-L-gulonic acid (2KLG). 5-keto-D-fructose and dihydroxyacetone can also serve as substrates. 25DKGR-A exhibits a greater selectivity for the substrate and higher thermal stability than 25DKGR-B

# Drug_Target_51_SwissProt_ID:
P06632

# Drug_Target_51_SwissProt_Name:
DKGA_CORSC

# Drug_Target_51_Synonyms:
2,5-DKG reductase A
2,5-DKGR A
25DKGR-A
AKR5C
EC 1.1.1.274

# Drug_Target_51_Theoretical_pI:
4.56

# Drug_Target_51_Transmembrane_Regions:
None

# Drug_Target_52_Cellular_Location:
Not Available

# Drug_Target_52_Chromosome_Location:
Not Available

# Drug_Target_52_Drug_References:
Not Available

# Drug_Target_52_Essentiality:
Non-Essential

# Drug_Target_52_GenAtlas_ID:
Not Available

# Drug_Target_52_GenBank_ID_Gene:
AB005554

# Drug_Target_52_GenBank_ID_Protein:
Not Available

# Drug_Target_52_GeneCard_ID:
Not Available

# Drug_Target_52_Gene_Name:
iolS

# Drug_Target_52_Gene_Sequence:
>933 bp
TTATGCGAACAGCTTATCAATAAATGAAATATCCTCTTGAGAAAGCGTCACGTCAGCTGT
TTTGATGTTATCAATCAGCTGATCGGCACGTTTTGCTCCTGGGATTAAAATATCAATTTC
CGGTCTTGCTAAATACCAGGCCAATACGATGTGAGGGATATCCACGTTGTGTTTTTCGGC
AATCGGCGCAAGCTTGTTGACCTTTCTGATATTTTCTTTGAAACGCTCACCCTTGAAGTG
TTCCTGTTCGTTTCGCAGGTCGCCTTCTGGGAACGTTGTATCTTCTGTATACTTTCCTGC
CAATAAACCTGATACGAGAGGGAAGTAAGGGATAAATGAAATATTATGCTCCTTCGTATA
CGGGAAGAATGTTTTTTCCGCTTCACGGTTTAACAGGTTGTATTCGCCTTGCAATACATC
TACCAAACCGTCTTTGTTTGCTTCTTTCAATTGCTCTAAAGAGAAGTTGGATACACCGAT
GGAACGGATTTTTCCGGCTTTCTTCATCTCATTCAGCGCGTTAACGGCTTCATCCTTAGG
CGTATGTTCGTCAGGGAAGTGAATGTAGAACAAATCAATATAATCGGTATTCAAGCGCTT
CAGGCTTTCATCAACTGATTTTTTAAGAAAATCTGGTGAATTATCAAAGACAAAGTCATT
GCCTTGTTTTCTGTGAGCGGCTTTTGTCGCGATGACAACATCTTCACGGTTGAATTCACG
CAGCACTTCACCAATTAATTCTTCGGAACGGCCGATCCCGTAAATGTAAGCGGTGTCTAA
CATTGTCACGCCATTACGGATCGCCTCGCGCACCAATTCTTTTCCGGTTTCTTCATTTAG
GTTCGGGTAGAGGTTATGTCCTCCGACAGCATTTGTTCCTAATCCGATAGGGAATACCTG
CAAGTCTGATTTTCCGAGCTTCGCTTTTTTCAT

# Drug_Target_52_General_Function:
Energy production and conversion

# Drug_Target_52_General_References:
7584049	Yoshida K, Seki S, Fujimura M, Miwa Y, Fujita Y: Cloning and sequencing of a 36-kb region of the Bacillus subtilis genome between the gnt and iol operons. DNA Res. 1995;2(2):61-9.
9298659	Antelmann H, Bernhardt J, Schmid R, Mach H, Volker U, Hecker M: First steps from a two-dimensional protein index towards a response-regulation map for Bacillus subtilis. Electrophoresis. 1997 Aug;18(8):1451-63.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_52_HGNC_ID:
Not Available

# Drug_Target_52_HPRD_ID:
Not Available

# Drug_Target_52_ID:
4403

# Drug_Target_52_Locus:
Not Available

# Drug_Target_52_Molecular_Weight:
35168

# Drug_Target_52_Name:
Protein iolS

# Drug_Target_52_Number_of_Residues:
310

# Drug_Target_52_PDB_ID:
1PZ0

# Drug_Target_52_Pathway:
Not Available

# Drug_Target_52_Pfam_Domain_Function:
Not Available

# Drug_Target_52_Protein_Sequence:
>Protein iolS
MKKAKLGKSDLQVFPIGLGTNAVGGHNLYPNLNEETGKELVREAIRNGVTMLDTAYIYGI
GRSEELIGEVLREFNREDVVIATKAAHRKQGNDFVFDNSPDFLKKSVDESLKRLNTDYID
LFYIHFPDEHTPKDEAVNALNEMKKAGKIRSIGVSNFSLEQLKEANKDGLVDVLQGEYNL
LNREAEKTFFPYTKEHNISFIPYFPLVSGLLAGKYTEDTTFPEGDLRNEQEHFKGERFKE
NIRKVNKLAPIAEKHNVDIPHIVLAWYLARPEIDILIPGAKRADQLIDNIKTADVTLSQE
DISFIDKLFA

# Drug_Target_52_Reaction:
Not Available

# Drug_Target_52_Signals:
None

# Drug_Target_52_Specific_Function:
Not Available

# Drug_Target_52_SwissProt_ID:
P46336

# Drug_Target_52_SwissProt_Name:
IOLS_BACSU

# Drug_Target_52_Synonyms:
AKR11A
EC 1.1.1.-
VEG147
Vegetative protein 147

# Drug_Target_52_Theoretical_pI:
5.48

# Drug_Target_52_Transmembrane_Regions:
None

# Drug_Target_53_Cellular_Location:
Not Available

# Drug_Target_53_Chromosome_Location:
Not Available

# Drug_Target_53_Drug_References:
Not Available

# Drug_Target_53_Essentiality:
Non-Essential

# Drug_Target_53_GenAtlas_ID:
Not Available

# Drug_Target_53_GenBank_ID_Gene:
L38521

# Drug_Target_53_GenBank_ID_Protein:
Not Available

# Drug_Target_53_GeneCard_ID:
Not Available

# Drug_Target_53_Gene_Name:
gapN

# Drug_Target_53_Gene_Sequence:
>1428 bp
TTGACAAAACAATATAAAAATTATGTCAATGGCGAGTGGAAGCTTTCAGAAAATGAAATT
AAAATCTACGAACCAGCCAGTGGAGCTGAATTGGGTTCAGTTCCAGCAATGAGTACTGAA
GAAGTAGATTATGTTTATGCTTCAGCCAAGAAAGCTCAACCAGCTTGGCGAGCACTTTCA
TACATAGAACGTGCTGCCTACCTTCATAAGGTAGCAGATATTTTGATGCGTGATAAAGAA
AAAATAGGTGCTATTCTTTCCAAAGAGGTTGCTAAAGGTTATAAATCAGCAGTCAGCGAA
GTTGTTCGTACTGCAGAAATCATTAATTATGCAGCTGAAGAAGGTCTTCGTATGGAAGGT
GAAGTCCTTGAAGGCGGCAGTTTTGAAGCAGCCAGCAAGAAAAAAATTGCCGTTGTTCGT
CGTGAACCAGTAGGTCTTGTATTAGCTATTTCACCATTTAACTACCCTGTTAACTTGGCA
GGTTCGAAAATTGCACCGGCTCTTATTGCGGGAAATGTTATTGCTTTTAAACCACCGACG
CAAGGATCAATCTCAGGGCTCTTACTTGCTGAAGCATTTGCTGAAGCTGGACTTCCTGCA
GGTGTCTTTAATACCATTACAGGTCGTGGTTCTGAAATTGGAGACTATATTGTAGAACAT
CAAGCCGTTAACTTTATCAATTTCACTGGTTCAACAGGAATTGGCGAACGTATTGGCAAA
ATGGCTGGTATGCGTCCGATTATGCTTGAACTCGGTGGAAAAGATTCAGCCATCGTTCTT
GAAGATGCGGACCTTGAATTGACTGCTAAAAATATTATTGCAGGTGCTTTTGGTTATTCA
GGTCAACGCTGTACAGCAGTTAAACGTGTTCTTGTGATGGAAAGTGTTGCTGATGAACTG
GTCGAAAAAATCCGTGAAAAAGTTCTTGCATTAACAATTGGTAATCCAGAAGACGATGCA
GATATTACACCGTTGATTGATACAAAATCAGCTGATTATGTAGAAGGTCTTATTAATGAT
GCCAATGATAAAGGAGCCACTGCCCTTACTGAAATCAAACGTGAAGGTAATCTTATCTGT
CCAATCCTCTTTGATAAGGTAACGACAGATATGCGTCTTGCTTGGGAAGAACCATTTGGT
CCTGTTCTTCCGATCATTCGTGTGACATCTGTAGAAGAAGCCATTGAAATTTCTAACAAA
TCGGAATATGGACTTCAGGCTTCTATCTTTACAAATGATTTCCCACGCGCTTTTGGTATT
GCTGAGCAGCTTGAAGTTGGTACAGTTCATATCAATAATAAGACACAGCGCGGCACGGAC
AACTTCCCATTCTTAGGGGCTAAAAAATCAGGTGCAGGTATTCAAGGGGTAAAATATTCT
ATTGAAGCTATGACAACTGTTAAATCCGTCGTATTTGATATCAAATAA

# Drug_Target_53_General_Function:
Involved in oxidoreductase activity

# Drug_Target_53_General_References:
12397186	Ajdic D, McShan WM, McLaughlin RE, Savic G, Chang J, Carson MB, Primeaux C, Tian R, Kenton S, Jia H, Lin S, Qian Y, Li S, Zhu H, Najar F, Lai H, White J, Roe BA, Ferretti JJ: Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14434-9. Epub 2002 Oct 23.
7751269	Boyd DA, Cvitkovitch DG, Hamilton IR: Sequence, expression, and function of the gene for the nonphosphorylating, NADP-dependent glyceraldehyde-3-phosphate dehydrogenase of Streptococcus mutans. J Bacteriol. 1995 May;177(10):2622-7.

# Drug_Target_53_HGNC_ID:
Not Available

# Drug_Target_53_HPRD_ID:
Not Available

# Drug_Target_53_ID:
4628

# Drug_Target_53_Locus:
Not Available

# Drug_Target_53_Molecular_Weight:
51194

# Drug_Target_53_Name:
NADP-dependent glyceraldehyde-3-phosphate dehydrogenase

# Drug_Target_53_Number_of_Residues:
475

# Drug_Target_53_PDB_ID:
1QI6

# Drug_Target_53_Pathway:
Not Available

# Drug_Target_53_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_53_Protein_Sequence:
>NADP-dependent glyceraldehyde-3-phosphate dehydrogenase
MTKQYKNYVNGEWKLSENEIKIYEPASGAELGSVPAMSTEEVDYVYASAKKAQPAWRSLS
YIERAAYLHKVADILMRDKEKIGAVLSKEVAKGYKSAVSEVVRTAEIINYAAEEGLRMEG
EVLEGGSFEAASKKKIAVVRREPVGLVLAISPFNYPVNLAGSKIAPALIAGNVIAFKPPT
QGSISGLLLAEAFAEAGLPAGVFNTITGRGSEIGDYIVEHQAVNFINFTGSTGIGERIGK
MAGMRPIMLELGGKDSAIVLEDADLELTAKNIIAGAFGYSGQRCTAVKRVLVMESVADEL
VEKIREKVLALTIGNPEDDADITPLIDTKSADYVEGLINDANDKGAAALTEIKREGNLIC
PILFDKVTTDMRLAWEEPFGPVLPIIRVTSVEEAIEISNKSEYGLQASIFTNDFPRAFGI
AEQLEVGTVHINNKTQRGTDNFPFLGAKKSGAGIQGVKYSIEAMTTVKSVVFDIK

# Drug_Target_53_Reaction:
Not Available

# Drug_Target_53_Signals:
None

# Drug_Target_53_Specific_Function:
D-glyceraldehyde 3-phosphate + NADP(+) + H(2)O = 3-phospho-D-glycerate + NADPH

# Drug_Target_53_SwissProt_ID:
Q59931

# Drug_Target_53_SwissProt_Name:
GAPN_STRMU

# Drug_Target_53_Synonyms:
EC 1.2.1.9
Glyceraldehyde-3-phosphate dehydrogenase [NADP+]
Non-phosphorylating glyceraldehyde 3-phosphate dehydrogenase
Triosephosphate dehydrogenase

# Drug_Target_53_Theoretical_pI:
4.83

# Drug_Target_53_Transmembrane_Regions:
None

# Drug_Target_54_Cellular_Location:
Cytoplasm

# Drug_Target_54_Chromosome_Location:
9

# Drug_Target_54_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_54_Essentiality:
Non-Essential

# Drug_Target_54_GenAtlas_ID:
Not Available

# Drug_Target_54_GenBank_ID_Gene:
BC035228

# Drug_Target_54_GenBank_ID_Protein:
23271371

# Drug_Target_54_GeneCard_ID:
PTGR1

# Drug_Target_54_Gene_Name:
PTGR1

# Drug_Target_54_Gene_Sequence:
>990 bp
ATGGTTCGTACTAAGACATGGACCCTGAAGAAGCACTTTGTTGGCTATCCTACTAATAGT
GACTTTGAGTTGAAGACATCTGAGCTCCCACCCTTAAAAAATGGAGAGGTCCTGCTTGAA
GCTTTGTTCCTCACCGTGGATCCCTACATGAGAGTGGCAGCCAAAAGATTGAAGGAAGGT
GATACAATGATGGGGCAGCAAGTGGCCAAAGTTGTGGAAAGTAAAAATGTAGCCCTACCA
AAAGGAACTATTGTACTGGCTTCTCCAGGCTGGACAACGCACTCCATTTCTGATGGGAAA
GATCTGGAAAAGCTGCTGACAGAGTGGCCAGACACAATACCACTGTCTTTGGCTCTGGGG
ACAGTTGGCATGCCAGGCCTGACTGCCTACTTTGGCCTACTTGAAATCTGTGGTGTGAAG
GGTGGAGAAACAGTGATGGTTAATGCAGCAGCTGGAGCTGTGGGCTCAGTCGTGGGGCAG
ATTGCAAAGCTCAAGGGCTGCAAAGTTGTTGGAGCAGTAGGGTCTGATGAAAAGGTTGCC
TACCTTCAAAAGCTTGGATTTGATGTCGTCTTTAACTACAAGACGGTAGAGTCTTTGGAA
GAAACCTTGAAGAAAGCGTCTCCTGATGGTTATGATTGTTATTTTGATAATGTAGGTGGA
GAGTTTTCAAACACTGTTATCGGCCAGATGAAGAAATTTGGAAGGATTGCCATATGTGGA
GCCATCTCTACATATAACAGAACCGGCCCACTTCCCCCAGGCCCACCCCCAGAGATTGTT
ATCTATCAGGAGCTTCGCATGGAAGCTTTTGTCGTCTACCGCTGGCAAGGAGATGCCCGC
CAAAAAGCTCTGAAGGACTTGCTGAAATGGGTCTTAGAGGGTAAAATCCAGTACAAGGAA
TATATCATTGAAGGATTTGAAAACATGCCAGCCGCATTTATGGGAATGCTGAAAGGAGAT
AATTTGGGGAAGACAATAGTGAAAGCATGA

# Drug_Target_54_General_Function:
Involved in 15-oxoprostaglandin 13-oxidase activity

# Drug_Target_54_General_References:
15164053	Humphray SJ, Oliver K, Hunt AR, Plumb RW, Loveland JE, Howe KL, Andrews TD, Searle S, Hunt SE, Scott CE, Jones MC, Ainscough R, Almeida JP, Ambrose KD, Ashwell RI, Babbage AK, Babbage S, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beasley H, Beasley O, Bird CP, Bray-Allen S, Brown AJ, Brown JY, Burford D, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Chen Y, Clarke G, Clark SY, Clee CM, Clegg S, Collier RE, Corby N, Crosier M, Cummings AT, Davies J, Dhami P, Dunn M, Dutta I, Dyer LW, Earthrowl ME, Faulkner L, Fleming CJ, Frankish A, Frankland JA, French L, Fricker DG, Garner P, Garnett J, Ghori J, Gilbert JG, Glison C, Grafham DV, Gribble S, Griffiths C, Griffiths-Jones S, Grocock R, Guy J, Hall RE, Hammond S, Harley JL, Harrison ES, Hart EA, Heath PD, Henderson CD, Hopkins BL, Howard PJ, Howden PJ, Huckle E, Johnson C, Johnson D, Joy AA, Kay M, Keenan S, Kershaw JK, Kimberley AM, King A, Knights A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd C, Lloyd DM, Lovell J, Martin S, Mashreghi-Mohammadi M, Matthews L, McLaren S, McLay KE, McMurray A, Milne S, Nickerson T, Nisbett J, Nordsiek G, Pearce AV, Peck AI, Porter KM, Pandian R, Pelan S, Phillimore B, Povey S, Ramsey Y, Rand V, Scharfe M, Sehra HK, Shownkeen R, Sims SK, Skuce CD, Smith M, Steward CA, Swarbreck D, Sycamore N, Tester J, Thorpe A, Tracey A, Tromans A, Thomas DW, Wall M, Wallis JM, West AP, Whitehead SL, Willey DL, Williams SA, Wilming L, Wray PW, Young L, Ashurst JL, Coulson A, Blocker H, Durbin R, Sulston JE, Hubbard T, Jackson MJ, Bentley DR, Beck S, Rogers J, Dunham I: DNA sequence and analysis of human chromosome 9. Nature. 2004 May 27;429(6990):369-74.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
8576264	Yokomizo T, Ogawa Y, Uozumi N, Kume K, Izumi T, Shimizu T: cDNA cloning, expression, and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase. J Biol Chem. 1996 Feb 2;271(5):2844-50.

# Drug_Target_54_HGNC_ID:
GNC:18429

# Drug_Target_54_HPRD_ID:
Not Available

# Drug_Target_54_ID:
6297

# Drug_Target_54_Locus:
9q31.3

# Drug_Target_54_Molecular_Weight:
35869.6

# Drug_Target_54_Name:
Prostaglandin reductase 1

# Drug_Target_54_Number_of_Residues:
329

# Drug_Target_54_PDB_ID:
Not Available

# Drug_Target_54_Pathway:
Not Available

# Drug_Target_54_Pfam_Domain_Function:
PF00107	ADH_zinc_N

# Drug_Target_54_Protein_Sequence:
>Prostaglandin reductase 1
MVRTKTWTLKKHFVGYPTNSDFELKTAELPPLKNGEVLLEALFLTVDPYMRVAAKRLKEG
DTMMGQQVAKVVESKNVALPKGTIVLASPGWTTHSISDGKDLEKLLTEWPDTIPLSLALG
TVGMPGLTAYFGLLEICGVKGGETVMVNAAAGAVGSVVGQIAKLKGCKVVGAVGSDEKVA
YLQKLGFDVVFNYKTVESLEETLKKASPDGYDCYFDNVGGEFSNTVIGQMKKFGRIAICG
AISTYNRTGPLPPGPPPEIVIYQELRMEAFVVYRWQGDARQKALKDLLKWVLEGKIQYKE
YIIEGFENMPAAFMGMLKGDNLGKTIVKA

# Drug_Target_54_Reaction:
Not Available

# Drug_Target_54_Signals:
None

# Drug_Target_54_Specific_Function:
Functions as 15-oxo-prostaglandin 13-reductase and acts on 15-oxo-PGE1, 15-oxo-PGE2 and 15-oxo-PGE2-alpha. Has no activity towards PGE1, PGE2 and PGE2-alpha (By similarity). Catalyzes the conversion of leukotriene B4 into its biologically less active metabolite, 12-oxo-leukotriene B4. This is an initial and key step of metabolic inactivation of leukotriene B4

# Drug_Target_54_SwissProt_ID:
Q14914

# Drug_Target_54_SwissProt_Name:
PTGR1_HUMAN

# Drug_Target_54_Synonyms:
15-oxoprostaglandin 13-reductase
NADP-dependent leukotriene B4 12-hydroxydehydrogenase
PRG-1

# Drug_Target_54_Theoretical_pI:
8.53

# Drug_Target_54_Transmembrane_Regions:
None

# Drug_Target_55_Cellular_Location:
Not Available

# Drug_Target_55_Chromosome_Location:
Not Available

# Drug_Target_55_Drug_References:
Not Available

# Drug_Target_55_Essentiality:
Non-Essential

# Drug_Target_55_GenAtlas_ID:
Not Available

# Drug_Target_55_GenBank_ID_Gene:
M23008

# Drug_Target_55_GenBank_ID_Protein:
Not Available

# Drug_Target_55_GeneCard_ID:
Not Available

# Drug_Target_55_Gene_Name:
cysJ

# Drug_Target_55_Gene_Sequence:
>1800 bp
ATGACGACACAGGTCCCACCTTCCGCGTTGCTTCCGTTGAACCCGGAGCAACTGGCACGC
CTTCAGGCGGCCACGACCGATTTAACTCCCACCCAGCTTGCCTGGGTTTCTGGCTATTTC
TGGGGCGTACTCAATCAGCAGCCTGCTGCGCTTGCAGCAACGCCAGCGCCAGCTGCAGAA
ATGCCGGGTATAACTATTATCTCCGCCTCGCAAACCGGCAATGCGCGCCGGGTTGCTGAA
GCATTACGTGATGATTTATTAGCAGCAAAACTGAACGTTAAGCTGGTGAACGCGGGCGAC
TATAAATTCAAACAAATCGCCAGCGAAAAACTGCTCATCGTAGTGACGTCAACGCAAGGG
GAAGGGGAACCGCCGGAAGAAGCCGTCGCGCTGCATAAGTTCCTGTTCTCCAAAAAAGCG
CCAAAGCTGGAAAACACCGCGTTTGCCGTGTTTAGCCTCGGCGATACGTCTTATGAATTT
TTCTGCCAGTCCGGGAAAGATTTCGACAGCAAGCTGGCGGAACTGGGTGGTGAACGCCTG
CTCGACCGTGTCGATGCCGATGTTGAATACCAGGCTGCTGCCAGCGAGTGGCGCGCCCGC
GTGGTTGATGCGCTTAAATCGCGTGCGCCTGTCGCGGCACCTTCGCAATCCGTCGCTACT
GGCGCGGTAAATGAAATCCACACCAGCCCGTACAGCAAAGACGCGCCGCTGGTGGCTAGC
CTCTCTGTTAACCAGAAAATTACCGGGCGTAACTCTGAAAAAGACGTTCGCCATATCGAA
ATTGACTTAGGTGACTCGGGCCTGCGTTACCAGCCGGGTGACGCGCTGGGCGTCTGGTAT
CAGAACGATCCGGCACTGGTGAAAGAACTTGTCGAACTGCTGTGGCTGAAAGGCGATGAA
CCTGTCACCGTCGAGGGCAAAACGTTGCCTCTGAACGAAGCGCTACAGTGGCACTTCGAA
CTGACCGTCAACACCGCCAACATTGTTGAGAATTACGCCACGCTTACCCGCAGTGAAACA
CTGCTGCCGCTGGTGGGCGATAAAGCGAAGTTACAGCATTACGCCGCGACGACGCCGATT
GTTGACATGGTGCGTTTCTCCCCGGCACAGCTTGATGCCGAAGCGCTAATTAATCTGCTG
CGCCCGCTGACGCCGCGTCTCTATTCCATTGCCTCCTCGCAGGCGGAAGTCGAGAACGAA
GTACACGTCACCGTTGGTGTGGTGCGTTACGACGTGGAAGGCCGCGCCCGTGCCGGTGGT
GCCTCCAGCTTCCTCGCTGACCGCGTGGAAGAAGAGGGCGAAGTCCGCGTATTTATCGAA
CATAACGATAACTTCCGCCTGCCAGCCAATCCAGAAACCCCGGTGATTATGATTGGCCCA
GGCACCGGCATCGCGCCGTTCCGCGCCTTTATGCAGCAACGTGCTGCCGATGAAGCGCCG
GGAAAAAACTGGCTGTTCTTTGGCAACCCGCACTTTACGGAAGATTTCCTCTACCAGGTG
GAGTGGCAGCGCTACGTCAAAGAGGGTGTGCTGACGCGGATCGATCTCGCCTGGTCGCGC
GACCAAAAAGAAAAAGTTTACGTACAAGACAAACTGCGCGAACAGGGCGCGGAGCTGTGG
CGCTGGATCAATGACGGTGCCCACATTTATGTCTGCGGTGACGCTAATCGCATGGCGAAA
GACGTTGAGCAGGCACTTCTGGAAGTGATTGCCGAATTTGGTGGCATGGACACCGAAGCG
GCGGATGAATTTTTAAGTGAGCTGCGCGTAGAGCGCCGTTATCAGCGAGATGTCTACTAA

# Drug_Target_55_General_Function:
Involved in sulfite reductase (NADPH) activity

# Drug_Target_55_General_References:
10455035	Coves J, Lebrun C, Gervasi G, Dalbon P, Fontecave M: Overexpression of the FAD-binding domain of the sulphite reductase flavoprotein component from Escherichia coli and its inhibition by iodonium diphenyl chloride. Biochem J. 1999 Sep 1;342 ( Pt 2):465-72.
2550423	Ostrowski J, Barber MJ, Rueger DC, Miller BE, Siegel LM, Kredich NM: Characterization of the flavoprotein moieties of NADPH-sulfite reductase from Salmonella typhimurium and Escherichia coli. Physicochemical and catalytic properties, amino acid sequence deduced from DNA sequence of cysJ, and comparison with NADPH-cytochrome P-450 reductase. J Biol Chem. 1989 Sep 25;264(27):15796-808.
2670946	Ostrowski J, Wu JY, Rueger DC, Miller BE, Siegel LM, Kredich NM: Characterization of the cysJIH regions of Salmonella typhimurium and Escherichia coli B. DNA sequences of cysI and cysH and a model for the siroheme-Fe4S4 active center of sulfite reductase hemoprotein based on amino acid homology with spinach nitrite reductase. J Biol Chem. 1989 Sep 15;264(26):15726-37.
7589518	Eschenbrenner M, Coves J, Fontecave M: NADPH-sulfite reductase flavoprotein from Escherichia coli: contribution to the flavin content and subunit interaction. FEBS Lett. 1995 Oct 23;374(1):82-4.
7657631	Eschenbrenner M, Coves J, Fontecave M: The flavin reductase activity of the flavoprotein component of sulfite reductase from Escherichia coli. A new model for the protein structure. J Biol Chem. 1995 Sep 1;270(35):20550-5.
9153434	Coves J, Zeghouf M, Macherel D, Guigliarelli B, Asso M, Fontecave M: Flavin mononucleotide-binding domain of the flavoprotein component of the sulfite reductase from Escherichia coli. Biochemistry. 1997 May 13;36(19):5921-8.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9558350	Zeghouf M, Fontecave M, Macherel D, Coves J: The flavoprotein component of the Escherichia coli sulfite reductase: expression, purification, and spectral and catalytic properties of a monomeric form containing both the flavin adenine dinucleotide and the flavin mononucleotide cofactors. Biochemistry. 1998 Apr 28;37(17):6114-23.
9618257	Zeghouf M, Defaye G, Fontecave M, Coves J: The flavoprotein component of the Escherichia coli sulfite reductase can act as a cytochrome P450c17 reductase. Biochem Biophys Res Commun. 1998 May 29;246(3):602-5.

# Drug_Target_55_HGNC_ID:
Not Available

# Drug_Target_55_HPRD_ID:
Not Available

# Drug_Target_55_ID:
5075

# Drug_Target_55_Locus:
Not Available

# Drug_Target_55_Molecular_Weight:
66270

# Drug_Target_55_Name:
Sulfite reductase [NADPH] flavoprotein alpha-component

# Drug_Target_55_Number_of_Residues:
599

# Drug_Target_55_PDB_ID:
1DDI

# Drug_Target_55_Pathway:
Not Available

# Drug_Target_55_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00667	FAD_binding_1

# Drug_Target_55_Protein_Sequence:
>Sulfite reductase [NADPH] flavoprotein alpha-component
MTTQVPPSALLPLNPEQLARLQAATTDLTPTQLAWVSGYFWGVLNQQPAALAATPAPAAE
MPGITIISASQTGNARRVAEALRDDLLAAKLNVKLVNAGDYKFKQIASEKLLIVVTSTQG
EGEPPEEAVALHKFLFSKKAPKLENTAFAVFSLGDSSYEFFCQSGKDFDSKLAELGGERL
LDRVDADVEYQAAASEWRARVVDALKSRAPVAAPSQSVATGAVNEIHTSPYSKDAPLVAS
LSVNQKITGRNSEKDVRHIEIDLGDSGMRYQPGDALGVWYQNDPALVKELVELLWLKGDE
PVTVEGKTLPLNEALQWHFELTVNTANIVENYATLTRSETLLPLVGDKAKLQHYAATTPI
VDMVRFSPAQLDAEALINLLRPLTPRLYSIASSQAEVENEVHVTVGVVRYDVEGRARAGG
ASSFLADRVEEEGEVRVFIEHNDNFRLPANPETPVIMIGPGTGIAPFRAFMQQRAADEAP
GKNWLFFGNPHFTEDFLYQVEWQRYVKDGVLTRIDLAWSRDQKEKVYVQDKLREQGAELW
RWINDGAHIYVCGDANRMAKDVEQALLEVIAEFGGMDTEAADEFLSELRVERRYQRDVY

# Drug_Target_55_Reaction:
Not Available

# Drug_Target_55_Signals:
None

# Drug_Target_55_Specific_Function:
Catalyzes the 6-electron reduction of sulfite to sulfide. This is one of several activities required for the biosynthesis of L-cysteine from sulfate. The flavo-protein component catalyzes the electron flow from NADPH -> FAD -> FMN to the hemoprotein component

# Drug_Target_55_SwissProt_ID:
P38038

# Drug_Target_55_SwissProt_Name:
CYSJ_ECOLI

# Drug_Target_55_Synonyms:
EC 1.8.1.2
SIR-FP

# Drug_Target_55_Theoretical_pI:
4.66

# Drug_Target_55_Transmembrane_Regions:
None

# Drug_Target_56_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_56_Chromosome_Location:
7

# Drug_Target_56_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_56_Essentiality:
Non-Essential

# Drug_Target_56_GenAtlas_ID:
Not Available

# Drug_Target_56_GenBank_ID_Gene:
U37100

# Drug_Target_56_GenBank_ID_Protein:
3150035

# Drug_Target_56_GeneCard_ID:
AKR1B10

# Drug_Target_56_Gene_Name:
AKR1B10

# Drug_Target_56_Gene_Sequence:
>951 bp
ATGGCCACGTTTGTGGAGCTCAGTACCAAAGCCAAGATGCCCATTGTGGGCCTGGGCACT
TGGAAGTCTCCTCTCGGCAAAGTGAAAGAAGCAGTGAAGGTGGCCATTGATGCAGGATAT
CGGCACATTGACTGTGCCTATGTCTATCAGAATGAACATGAAGTGGGGGAAGCCATCCAA
GAGAAGATCCAAGAGAAGGCTGTGAAGCGGGAGGACCTGTTCATCGTCAGCAAGTTGTGG
CCCACTTTCTTTGAGAGACCCCTTGTGAGGAAAGCCTTTGAGAAGACCCTCAAGGACCTG
AAGCTGAGCTATCTGGACGTCTATCTTATTCACTGGCCACAGGGATTCAAGTCTGGGGAT
GACCTTTTCCCCAAAGATGATAAAGGTAATGCCATCGGTGGAAAAGCAACGTTCTTGGAT
GCCTGGGAGGCCATGGAGGAGCTGGTGGATGAGGGGCTGGTGAAAGCCCTTGGGGTCTCC
AATTTCAGCCACTTCCAGATCGAGAAGCTCTTGAACAAACCTGGACTGAAATATAAACCA
GTGACTAACCAGGTTGAGTGTCACCCATACCTCACGCAGGAGAAACTGATCCAGTACTGC
CACTCCAAGGGCATCACCGTTACGGCCTACAGCCCCCTGGGCTCTCCGGATAGACCTTGG
GCCAAGCCAGAAGACCCTTCCCTGCTGGAGGATCCCAAGATTAAGGAGATTGCTGCAAAG
CACAAAAAAACCGCAGCCCAGGTTCTGATCCGTTTCCATATCCAGAGGAATGTGATTGTC
ATCCCCAAGTCTGTGACACCAGCACGCATTGTTGAGAACATTCAGGTCTTTGACTTTAAA
TTGAGTGATGAGGAGATGGCAACCATACTCAGCTTCAACAGAAACTGGAGGGCCTGTAAC
GTGTTGCAATCCTCTCATTTGGAAGACTATCCCTTCGATGCAGAATATTGA

# Drug_Target_56_General_Function:
Involved in aldo-keto reductase activity

# Drug_Target_56_General_References:
12690205	Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, Carson AR, Parker-Katiraee L, Skaug J, Khaja R, Zhang J, Hudek AK, Li M, Haddad M, Duggan GE, Fernandez BA, Kanematsu E, Gentles S, Christopoulos CC, Choufani S, Kwasnicka D, Zheng XH, Lai Z, Nusskern D, Zhang Q, Gu Z, Lu F, Zeesman S, Nowaczyk MJ, Teshima I, Chitayat D, Shuman C, Weksberg R, Zackai EH, Grebe TA, Cox SR, Kirkpatrick SJ, Rahman N, Friedman JM, Heng HH, Pelicci PG, Lo-Coco F, Belloni E, Shaffer LG, Pober B, Morton CC, Gusella JF, Bruns GA, Korf BR, Quade BJ, Ligon AH, Ferguson H, Higgins AW, Leach NT, Herrick SR, Lemyre E, Farra CG, Kim HG, Summers AM, Gripp KW, Roberts W, Szatmari P, Winsor EJ, Grzeschik KH, Teebi A, Minassian BA, Kere J, Armengol L, Pujana MA, Estivill X, Wilson MD, Koop BF, Tosi S, Moore GE, Boright AP, Zlotorynski E, Kerem B, Kroisel PM, Petek E, Oscier DG, Mould SJ, Dohner H, Dohner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC: Human chromosome 7: DNA sequence and biology. Science. 2003 May 2;300(5620):767-72. Epub 2003 Apr 10.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
18087047	Gallego O, Ruiz FX, Ardevol A, Dominguez M, Alvarez R, de Lera AR, Rovira C, Farres J, Fita I, Pares X: Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20764-9. Epub 2007 Dec 17.
9537432	Scuric Z, Stain SC, Anderson WF, Hwang JJ: New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology. 1998 Apr;27(4):943-50.
9565553	Cao D, Fan ST, Chung SS: Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem. 1998 May 8;273(19):11429-35.
9765596	Hyndman DJ, Flynn TG: Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim Biophys Acta. 1998 Aug 20;1399(2-3):198-202.

# Drug_Target_56_HGNC_ID:
GNC:382

# Drug_Target_56_HPRD_ID:
Not Available

# Drug_Target_56_ID:
6862

# Drug_Target_56_Locus:
7q33

# Drug_Target_56_Molecular_Weight:
36020.3

# Drug_Target_56_Name:
Aldo-keto reductase family 1 member B10

# Drug_Target_56_Number_of_Residues:
316

# Drug_Target_56_PDB_ID:
Not Available

# Drug_Target_56_Pathway:
Not Available

# Drug_Target_56_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_56_Protein_Sequence:
>Aldo-keto reductase family 1 member B10
MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEVGEAIQ
EKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWPQGFKSGD
DLFPKDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEKLLNKPGLKYKP
VTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDPSLLEDPKIKEIAAK
HKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEMATILSFNRNWRACN
VLQSSHLEDYPFDAEY

# Drug_Target_56_Reaction:
Not Available

# Drug_Target_56_Signals:
None

# Drug_Target_56_Specific_Function:
Acts as all-trans-retinaldehyde reductase. Can efficiently reduce aliphatic and aromatic aldehydes, and is less active on hexoses (in vitro). May be responsible for detoxification of reactive aldehydes in the digested food before the nutrients are passed on to other organs

# Drug_Target_56_SwissProt_ID:
O60218

# Drug_Target_56_SwissProt_Name:
AK1BA_HUMAN

# Drug_Target_56_Synonyms:
ARL-1
ARP
Aldose reductase-like
Aldose reductase-related protein
SI reductase
Small intestine reductase
hARP

# Drug_Target_56_Theoretical_pI:
7.63

# Drug_Target_56_Transmembrane_Regions:
None

# Drug_Target_57_Cellular_Location:
Not Available

# Drug_Target_57_Chromosome_Location:
Not Available

# Drug_Target_57_Drug_References:
Not Available

# Drug_Target_57_Essentiality:
Non-Essential

# Drug_Target_57_GenAtlas_ID:
Not Available

# Drug_Target_57_GenBank_ID_Gene:
AE000512

# Drug_Target_57_GenBank_ID_Protein:
Not Available

# Drug_Target_57_GeneCard_ID:
Not Available

# Drug_Target_57_Gene_Name:
TM_0820

# Drug_Target_57_Gene_Sequence:
>1188 bp
ATGGAGAACTTCGTCTTCCACAATCCCACGAAGATCGTCTTTGGAAGAGGAACGATTCCA
AAAATAGGAGAAGAGATAAAGAACGCGGGAATCAGAAAGGTGCTGTTCCTATACGGTGGT
GGATCGATAAAGAAAAATGGCGTTTATGATCAGGTTGTCGATTCACTGAAAAAGCACGGA
ATAGAGTGGGTAGAAGTATCTGGTGTCAAGCCGAATCCAGTCCTTTCCAAGGTCCACGAA
GCCGTCGAGGTGGCGAAAAAAGAAAAGGTGGAGGCTGTTCTTGGTGTTGGTGGAGGAAGC
GTTGTGGATTCTGCAAAAGCAGTAGCGGCTGGTGCTCTCTACGAGGGCGACATATGGGAT
GCTTTTATCGGTAAATACCAGATCGAGAAAGCCCTTCCTATTTTCGACGTGCTCACAATC
TCGGCGACAGGAACGGAGATGAACGGTAACGCTGTGATAACGAACGAGAAAACGAAGGAA
AAATATGGAGTGAGTTCGAAGGCTCTCTATCCAAAAGTATCCATAATCGATCCTTCTGTT
CAATTCACTCTTCCAAAAGAACAAACAGTTTATGGAGCGGTGGATGCGATCTCACACATC
CTCGAGTACTATTTCGATGGGAGCAGTCCTGAGATCTCCAACGAAATAGCGGAAGGTACT
ATCAGAACGATCATGAAAATGACAGAAAGGTTGATAGAAAAACCGGATGACTACGAAGCA
AGGGCAAATCTCGCGTGGTCTGCAACGATCGCTCTCAATGGAACGATGGCAGTCGGAAGA
AGGGGCGGAGAGTGGGCTTGTCACAGGATCGAGCACTCCCTCAGCGCTCTTTACGATATT
GCACACGGAGCGGGTCTCGCCATTGTGTTTCCGGCGTGGATGAAGTATGTGTACAGAAAG
AATCCTGCGCAGTTCGAAAGGTTTGCGAAAAAAATCTTCGGATTTGAGGGTGAGGGAGAG
GAACTGATTCTGAAAGGGATAGAAGCTTTCAAAAACTGGCTGAAGAAGGTAGGAGCTCCT
GTGTCCCTCAAAGATGCGGGAATCCCAGAAGAAGACATAGACAAGATCGTGGACAACGTC
ATGCTTCTTGTGGAAAAGAATCTGAAACCTAAAGGAGCGAGTTTGGGAAGAATAATGGTG
CTCGAAAGAGAAGACGTTCGTGAAATATTGAAATTAGCGGCGAAATGA

# Drug_Target_57_General_Function:
Involved in oxidoreductase activity

# Drug_Target_57_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_57_HGNC_ID:
Not Available

# Drug_Target_57_HPRD_ID:
Not Available

# Drug_Target_57_ID:
5342

# Drug_Target_57_Locus:
Not Available

# Drug_Target_57_Molecular_Weight:
43356

# Drug_Target_57_Name:
NADH-dependent butanol dehydrogenase, putative

# Drug_Target_57_Number_of_Residues:
395

# Drug_Target_57_PDB_ID:
1VLJ

# Drug_Target_57_Pathway:
Not Available

# Drug_Target_57_Pfam_Domain_Function:
PF00465	Fe-ADH

# Drug_Target_57_Protein_Sequence:
>NADH-dependent butanol dehydrogenase, putative
MENFVFHNPTKIVFGRGTIPKIGEEIKNAGIRKVLFLYGGGSIKKNGVYDQVVDSLKKHG
IEWVEVSGVKPNPVLSKVHEAVEVAKKEKVEAVLGVGGGSVVDSAKAVAAGALYEGDIWD
AFIGKYQIEKALPIFDVLTISATGTEMNGNAVITNEKTKEKYGVSSKALYPKVSIIDPSV
QFTLPKEQTVYGAVDAISHILEYYFDGSSPEISNEIAEGTIRTIMKMTERLIEKPDDYEA
RANLAWSATIALNGTMAVGRRGGEWACHRIEHSLSALYDIAHGAGLAIVFPAWMKYVYRK
NPAQFERFAKKIFGFEGEGEELILKGIEAFKNWLKKVGAPVSLKDAGIPEEDIDKIVDNV
MLLVEKNLKPKGASLGRIMVLEREDVREILKLAAK

# Drug_Target_57_Reaction:
Not Available

# Drug_Target_57_Signals:
None

# Drug_Target_57_Specific_Function:
Not Available

# Drug_Target_57_SwissProt_ID:
Q9WZS7

# Drug_Target_57_SwissProt_Name:
Q9WZS7_THEMA

# Drug_Target_57_Synonyms:
Not Available

# Drug_Target_57_Theoretical_pI:
7.23

# Drug_Target_57_Transmembrane_Regions:
None

# Drug_Target_58_Cellular_Location:
Not Available

# Drug_Target_58_Chromosome_Location:
Not Available

# Drug_Target_58_Drug_References:
Not Available

# Drug_Target_58_Essentiality:
Non-Essential

# Drug_Target_58_GenAtlas_ID:
Not Available

# Drug_Target_58_GenBank_ID_Gene:
U39638

# Drug_Target_58_GenBank_ID_Protein:
Not Available

# Drug_Target_58_GeneCard_ID:
Not Available

# Drug_Target_58_Gene_Name:
aldH

# Drug_Target_58_Gene_Sequence:
>1533 bp
ATGAACCCGCAAACCGACAACGTTTTTTACGCTACTAACGCCTTTACCGGTGAGGCGCTC
CCTTTAGCTTTTCCTGTTCATACGGAAGTTGAGGTCAATCAAGCCGCAACTGCTGCTGCA
AAAGTCGCACGCGATTTTCGCCGCTTAAATAACAGTAAGCGCGCTAGTCTGCTTCGCACG
ATTGCCAGTGAATTAGAGGCAAGAAGTGATGACATTATCGCCCGAGCCCATTTAGAAACG
GCGCTTCCCGAAGTACGCCTGACAGGAGAAATCGCTCGTACAGCGAATCAACTTCGCTTA
TTCGCTGACGTAGTCAATTCTGGCAGTTATCACCAAGCCATTCTTGATACGCCAAACCCA
ACTCGCGCCCCACTACCTAAGCCAGATATTCGTCGCCAACAAATTGCGCTGGGTCCTGTC
GCGGTATTTGGAGCATCCAACTTTCCGTTGGCTTTCTCTGCTGCTGGTGGAGATACTGCT
TCTGCCCTCGCAGCGGGTTGCCCGGTGATTGTAAAAGGTCATACTGCGCACCCAGGTACA
AGCCAAATCGTTGCAGAGTGTATCGAGCAAGCGCTGAAACAAGAGCAACTACCACAAGCG
ATTTTCACCTTGCTGCAAGGAAATCAGCGTGCTTTAGGACAAGCTCTAGTCAGCCATCCT
GAAATAAAAGCGGTGGGCTTTACTGGATCGGTTGGTGGTGGACGCGCCCTGTTCAACCTA
GCGCACGAGCGACCTGAGCCAATCCCGTTCTATGGTGAACTTGGTGCGATTAACCCGACG
TTTATTTTCCCTTCTGCAATGAGAGCCAAAGCAGATTTAGCGGATCAATTTGTTGCCTCA
ATGACCATGGGATGTGGGCAATTTTGTACAAAACCTGGCGTAGTGTTCGCGCTTAACACA
CCGGAAACACAAGCGTTTATTGAAACCGCGCAATCCCTCATTCGCCAACAATCCCCTTCT
ACTCTACTTACTCCCGGAATCCGTGATAGTTACCAATCACAGGTCGTCAGCCGAGGTTCT
GACGACGGAATTGACGTCACTTTTTCTCAAGCGGAGTCCCCTTGTGTTGCCTCGGCTCTC
TTTGTTACAAGCAGTGAAAATTGGCGCAAACATCCTGCGTGGGAAGAAGAGATTTTTGGT
CCACAATCGTTGATCGTCGTTTGTGAAAATGTGGCTGATATGCTTTCGCTCAGTGAAATG
CTAGCAGGATCGCTAACCGCGACAATTCATGCAACGGAAGAAGATTACCCACAAGTATCG
CAGCTCATCCCTCGTTTGGAAGAGATTGCCGGACGACTGGTATTTAATGGTTGGCCGACA
GGCGTAGAAGTTGGTTATGCCATGGTGCATGGCGGTCCATATCCCGCATCAACCCATTCG
GCTTCGACTTCTGTTGGTGCCGAAGCCATTCATCGTTGGCTACGTCCGGTGGCTTATCAA
GCGTTACCAGAAAGCTTACTGCCCGATTCGTTAAAAGCAGAAAATCCATTGGAGATCGCG
CGCGCAGTAGATGGCAAAGCAGCTCACAGTTAA

# Drug_Target_58_General_Function:
Involved in oxidoreductase activity

# Drug_Target_58_General_References:
10903148	Ahvazi B, Coulombe R, Delarge M, Vedadi M, Zhang L, Meighen E, Vrielink A: Crystal structure of the NADP+-dependent aldehyde dehydrogenase from Vibrio harveyi: structural implications for cofactor specificity and affinity. Biochem J. 2000 Aug 1;349 Pt 3:853-61.
8527447	Vedadi M, Szittner R, Smillie L, Meighen E: Involvement of cysteine 289 in the catalytic activity of an NADP(+)-specific fatty aldehyde dehydrogenase from Vibrio harveyi. Biochemistry. 1995 Dec 26;34(51):16725-32.

# Drug_Target_58_HGNC_ID:
Not Available

# Drug_Target_58_HPRD_ID:
Not Available

# Drug_Target_58_ID:
5343

# Drug_Target_58_Locus:
Not Available

# Drug_Target_58_Molecular_Weight:
54460

# Drug_Target_58_Name:
NADP-dependent fatty aldehyde dehydrogenase

# Drug_Target_58_Number_of_Residues:
510

# Drug_Target_58_PDB_ID:
1EZ0

# Drug_Target_58_Pathway:
Not Available

# Drug_Target_58_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_58_Protein_Sequence:
>NADP-dependent fatty aldehyde dehydrogenase
MNPQTDNVFYATNAFTGEALPLAFPVHTEVEVNQAATAAAKVARDFRRLNNSKRASLLRT
IASELEARSDDIIARAHLETALPEVRLTGEIARTANQLRLFADVVNSGSYHQAILDTPNP
TRAPLPKPDIRRQQIALGPVAVFGASNFPLAFSAAGGDTASALAAGCPVIVKGHTAHPGT
SQIVAECIEQALKQEQLPQAIFTLLQGNQRALGQALVSHPEIKAVGFTGSVGGGRALFNL
AHERPEPIPFYGELGAINPTFIFPSAMRAKADLADQFVASMTMGCGQFCTKPGVVFALNT
PETQAFIETAQSLIRQQSPSTLLTPGIRDSYQSQVVSRGSDDGIDVTFSQAESPCVASAL
FVTSSENWRKHPAWEEEIFGPQSLIVVCENVADMLSLSEMLAGSLTATIHATEEDYPQVS
QLIPRLEEIAGRLVFNGWPTGVEVGYAMVHGGPYPASTHSASTSVGAEAIHRWLRPVAYQ
ALPESLLPDSLKAENPLEIARAVDGKAAHS

# Drug_Target_58_Reaction:
Not Available

# Drug_Target_58_Signals:
None

# Drug_Target_58_Specific_Function:
Catalyzes the oxidation of long-chain aliphatic aldehydes to acids. May be implicated in controlling luminescence as it catalyzes the oxidation of the fatty aldehyde substrate for the light-emitting reaction

# Drug_Target_58_SwissProt_ID:
Q56694

# Drug_Target_58_SwissProt_Name:
ALDH_VIBHA

# Drug_Target_58_Synonyms:
EC 1.2.1.4

# Drug_Target_58_Theoretical_pI:
5.43

# Drug_Target_58_Transmembrane_Regions:
None

# Drug_Target_59_Cellular_Location:
Not Available

# Drug_Target_59_Chromosome_Location:
Not Available

# Drug_Target_59_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_59_Essentiality:
Non-Essential

# Drug_Target_59_GenAtlas_ID:
Not Available

# Drug_Target_59_GenBank_ID_Gene:
Not Available

# Drug_Target_59_GenBank_ID_Protein:
Not Available

# Drug_Target_59_GeneCard_ID:
Not Available

# Drug_Target_59_Gene_Name:
DHRS4L1

# Drug_Target_59_Gene_Sequence:
Not Available

# Drug_Target_59_General_Function:
Not Available

# Drug_Target_59_General_References:
Not Available

# Drug_Target_59_HGNC_ID:
Not Available

# Drug_Target_59_HPRD_ID:
Not Available

# Drug_Target_59_ID:
6486

# Drug_Target_59_Locus:
Not Available

# Drug_Target_59_Molecular_Weight:
Not Available

# Drug_Target_59_Name:
Putative dehydrogenase/reductase SDR family member 4-like 2

# Drug_Target_59_Number_of_Residues:
0

# Drug_Target_59_PDB_ID:
Not Available

# Drug_Target_59_Pathway:
Not Available

# Drug_Target_59_Pfam_Domain_Function:
Not Available

# Drug_Target_59_Protein_Sequence:
Not Available

# Drug_Target_59_Reaction:
Not Available

# Drug_Target_59_Signals:
Not Available

# Drug_Target_59_Specific_Function:
Not Available

# Drug_Target_59_SwissProt_ID:
P0CG22

# Drug_Target_59_SwissProt_Name:
DR4L1_HUMAN

# Drug_Target_59_Synonyms:
Not Available

# Drug_Target_59_Theoretical_pI:
Not Available

# Drug_Target_59_Transmembrane_Regions:
Not Available

# Drug_Target_5_Cellular_Location:
Cytoplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
U38473

# Drug_Target_5_GenBank_ID_Protein:
1407613

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
fcl

# Drug_Target_5_Gene_Sequence:
>966 bp
ATGAGTAAACAACGAGTTTTTATTGCTGGTCATCGCGGGATGGTCGGTTCCGCCATCAGG
CGGCAGCTCGAACAGCGCGGTGATGTGGAACTGGTATTACGCACCCGCGACGAGCTGAAC
CTGCTGGACAGCCGCGCCGTGCATGATTTCTTTGCCAGCGAACGTATTGACCAGGTCTAT
CTGGCGGCGGCGAAAGTGGGCGGCATTGTTGCCAACAACACCTATCCGGCGGATTTCATC
TACCAGAACATGATGATTGAGAGCAACATCATTCACGCCGCGCATCAGAACGACGTGAAC
AAACTGCTGTTTCTCGGATCGTCCTGCATCTACCCGAAACTGGCAAAACAGCCGATGGCA
GAAAGCGAGTTGTTGCAGGGCACGCTGGAGCCGACTAACGAGCCTTATGCTATTGCCAAA
ATCGCCGGGATCAAACTGTGCGAATCATACAACCGCCAGTACGGACGCGATTACCGCTCA
GTCATGCCGACCAACCTGTACGGGCCACACGACAACTTCCACCCGAGTAATTCGCATGTG
ATCCCAGCATTGCTGCGTCGCTTCCACGAGGCGACGGCACAGAATGCGCCGGACGTGGTG
GTATGGGGCAGCGGTACACCGATGCGCGAATTTCTGCACGTCGATGATATGGCGGCGGCG
AGCATTCATGTCATGGAGCTGGCGCATGAAGTCTGGCTGGAGAACACCCAGCCGATGTTG
TCGCACATTAACGTCGGCACGGGCGTTGACTGCACTATCCGCGACGTGGCGCAAACCATC
GCCAAAGTGGTGGGTTACAAAGGCCGGGTGGTTTTTGATGCCAGCAAACCGGATGGCACG
CCGCGCAAACTGCTGGATGTGACGCGCCTGCATCAGCTTGGCTGGTATCACGAAATCTCA
CTGGAAGCGGGGCTTGCCAGCACTTACCAGTGGTTCCTTGAGAATCAAGACCGCTTTCGG
GGGTAA

# Drug_Target_5_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_5_General_References:
7815923	Aoyama K, Haase AM, Reeves PR: Evidence for effect of random genetic drift on G+C content after lateral transfer of fucose pathway genes to Escherichia coli K-12. Mol Biol Evol. 1994 Nov;11(6):829-38.
8759852	Stevenson G, Andrianopoulos K, Hobbs M, Reeves PR: Organization of the Escherichia coli K-12 gene cluster responsible for production of the extracellular polysaccharide colanic acid. J Bacteriol. 1996 Aug;178(16):4885-93.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9473059	Andrianopoulos K, Wang L, Reeves PR: Identification of the fucose synthetase gene in the colanic acid gene cluster of Escherichia coli K-12. J Bacteriol. 1998 Feb;180(4):998-1001.
9862812	Somers WS, Stahl ML, Sullivan FX: GDP-fucose synthetase from Escherichia coli: structure of a unique member of the short-chain dehydrogenase/reductase family that catalyzes two distinct reactions at the same active site. Structure. 1998 Dec 15;6(12):1601-12.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
3463

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
36142

# Drug_Target_5_Name:
GDP-L-fucose synthetase

# Drug_Target_5_Number_of_Residues:
321

# Drug_Target_5_PDB_ID:
1FXS

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_5_Protein_Sequence:
>GDP-L-fucose synthetase
MSKQRVFIAGHRGMVGSAIRRQLEQRGDVELVLRTRDELNLLDSRAVHDFFASERIDQVY
LAAAKVGGIVANNTYPADFIYQNMMIESNIIHAAHQNDVNKLLFLGSSCIYPKLAKQPMA
ESELLQGTLEPTNEPYAIAKIAGIKLCESYNRQYGRDYRSVMPTNLYGPHDNFHPSNSHV
IPALLRRFHEATAQNAPDVVVWGSGTPMREFLHVDDMAAASIHVMELAHEVWLENTQPML
SHINVGTGVDCTIRELAQTIAKVVGYKGRVVFDASKPDGTPRKLLDVTRLHQLGWYHEIS
LEAGLASTYQWFLENQDRFRG

# Drug_Target_5_Reaction:
GDP-L-fucose + NADP+ = GDP-4-dehydro-6-deoxy-D-mannose + NADPH + H+

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Two step NADP-dependent conversion of GDP-4-dehydro-6- deoxy-D-mannose to GDP-fucose, involving an epimerase and a reductase reaction

# Drug_Target_5_SwissProt_ID:
P32055

# Drug_Target_5_SwissProt_Name:
FCL_ECOLI

# Drug_Target_5_Synonyms:
EC 1.1.1.271
GDP-4-keto-6-deoxy-D-mannose- 3,5-epimerase-4-reductase

# Drug_Target_5_Theoretical_pI:
6.89

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_60_Cellular_Location:
Not Available

# Drug_Target_60_Chromosome_Location:
Not Available

# Drug_Target_60_Drug_References:
Not Available

# Drug_Target_60_Essentiality:
Non-Essential

# Drug_Target_60_GenAtlas_ID:
Not Available

# Drug_Target_60_GenBank_ID_Gene:
AE000512

# Drug_Target_60_GenBank_ID_Protein:
Not Available

# Drug_Target_60_GeneCard_ID:
Not Available

# Drug_Target_60_Gene_Name:
TM_1009

# Drug_Target_60_Gene_Sequence:
>861 bp
ATGCAGGTTCCAAAAGTTACTTTGAACAACGGTGTAGAAATGCCTATTCTGGGATACGGA
GTTTTCCAGATACCACCAGAAAAGACGGAAGAATGTGTCTATGAGGCTATAAAGGTGGGA
TACAGACTCATCGACACAGCAGCATCGTACATGAACGAAGAGGGAGTGGGAAGAGCGATA
AAACGCGCGATTGACGAAGGAATTGTCAGAAGAGAGGAGCTCTTCGTCACGACCAAACTG
TGGGTGTCGGATGTTGGTTACGAATCCACAAAGAAGGCTTTTGAAAAGTCTTTGAAGAAA
CTGCAACTCGAATACATAGATCTCTATCTAATTCATCAACCTTTTGGAGATGTACACTGT
GCCTGGAAAGCTATGGAAGAAATGTACAAAGATGGATTGGTAAGAGCCATAGGTGTGAGC
AACTTCTACCCTGATCGGTTGATGGATCTAATGGTTCATCACGAAATTGTTCCCGCGGTG
AACCAGATCGAGATACATCCGTTTTATCAGAGACAAGAGGAGATCGAATTCATGAGAAAT
TACAACATCCAACCTGAAGCTTGGGGTCCTTTCGCTGAGGGAAGAAAAAACATTTTCCAG
AACGGAGTGCTCAGATCGATCGCGGAAAAGTACGGCAAAACGGTTGCACAGGTCATTCTG
AGATGGCTCACTCAGAAAGGAATCGTTGCCATTCCCAAAACTGTGAGAAGAGAGAGGATG
AAAGAAAACATCAGCATCTTCGATTTTGAACTCACACAGGAAGACATGGAAAAGATTGCA
ACGCTCGATGAAGGGCAGAGTGCGTTCTTCTCCCACAGGGATCCCGAGGTTGTCAAGTGG
ATTTGTTCACTGAAAAGATGA

# Drug_Target_60_General_Function:
Involved in oxidoreductase activity

# Drug_Target_60_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_60_HGNC_ID:
Not Available

# Drug_Target_60_HPRD_ID:
Not Available

# Drug_Target_60_ID:
5346

# Drug_Target_60_Locus:
Not Available

# Drug_Target_60_Molecular_Weight:
33245

# Drug_Target_60_Name:
Oxidoreductase, aldo/keto reductase family

# Drug_Target_60_Number_of_Residues:
286

# Drug_Target_60_PDB_ID:
1VP5

# Drug_Target_60_Pathway:
Not Available

# Drug_Target_60_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_60_Protein_Sequence:
>Oxidoreductase, aldo/keto reductase family
MQVPKVTLNNGVEMPILGYGVFQIPPEKTEECVYEAIKVGYRLIDTAASYMNEEGVGRAI
KRAIDEGIVRREELFVTTKLWVSDVGYESTKKAFEKSLKKLQLEYIDLYLIHQPFGDVHC
AWKAMEEMYKDGLVRAIGVSNFYPDRLMDLMVHHEIVPAVNQIEIHPFYQRQEEIEFMRN
YNIQPEAWGPFAEGRKNIFQNGVLRSIAEKYGKTVAQVILRWLTQKGIVAIPKTVRRERM
KENISIFDFELTQEDMEKIATLDEGQSAFFSHRDPEVVKWICSLKR

# Drug_Target_60_Reaction:
Not Available

# Drug_Target_60_Signals:
None

# Drug_Target_60_Specific_Function:
Not Available

# Drug_Target_60_SwissProt_ID:
Q9X0A2

# Drug_Target_60_SwissProt_Name:
Q9X0A2_THEMA

# Drug_Target_60_Synonyms:
Not Available

# Drug_Target_60_Theoretical_pI:
6.27

# Drug_Target_60_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
L42023

# Drug_Target_6_GenBank_ID_Protein:
1573644

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
asd

# Drug_Target_6_Gene_Sequence:
>1116 bp
TTATGCCACTAATTGTTTTAAAATACGGCGAACTGGCTCTGCCGCACCCCATAATAATTG
GTCGCCCACGGTAAAAGCTGCCAAATATTCAGGCCCCATAGCCAATTTACGTAAACGCCC
CACTGGCACGCTTAATGTACCTGTTACTTTCGCTGGCGTTAATTCACGCAATGTGATTTC
TTTGTCGTTTGGAATCACTTTTACCCATTCATTATGTGATGCAATAATTTGTTCGATTTC
TTCTAATGGTAAGTCTTTTTTCAGTTTGATGGTAAACGCTTGGCTATGGCAACGTAATGC
ACCGATACGCACACATAAACCATCAACAGGAATTGGATTGTCGCTTAAACCTAAAATTTT
ATTGGTTTCTGCATAACCTTTCCATTCTTCTTTAGTTTGCCCTGTTTCAGGAAGAAGTTT
GTCAATCCAAGGGATTAAGCTACCACCTAATGCCGCGCCAAAGTTATCCGTTGGGAAATT
ATCAGCACGCATTTTTGCAGTCACTTTACGTTCAATATCTAAAATAGATGAAGCAGGGTC
TTTTAATTCACTCGAAACTGCTTGTTCTAATAAACCCATTTGTGAAAGTAATTCACGCAT
ATTTTTTGCGCCAGCACCTGAAGCCGCTTGATAAGTTGCCACAGAAATCCATTCCACCAA
ATCTTTTTCAAATAGACCGCCGATAGCCATTAACATTAAGCTTACGGTACAGTTACCGCC
CACGAAAGTTTTAATGCCTTTTTTCAAACCTTCAGAAATCACGTGTTGGTTTACTGGATC
AAGCACGATAATTGCATCATCTTTCATACGCAACGCAGAAGCGGCATCAACCCAATAACC
ATCCCAACCTGTTGCTTTTAATTTTGGATAGACTTCATTGGTGTAATCGCCACCTTGGCA
AGTCACGATAATGTCTAATTTTTTAAGTTCTTCAATATCGAATGCACTTTTCAGGTCGCC
TGCATCCTTGCCACCAAAAACAGGTGCTTTTTGACCTGCTTGTGAAGTTGTAAAAAATAC
GGGATTAAGATTTTCAAAATCATTTTCCTGCGACATACGATCCATTAATACGGAACCCAC
CATTCCGCGCCAGCCGATAAAGCCTACATTTTTCAT

# Drug_Target_6_General_Function:
Amino acid transport and metabolism

# Drug_Target_6_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
3062

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
40539

# Drug_Target_6_Name:
Aspartate-semialdehyde dehydrogenase

# Drug_Target_6_Number_of_Residues:
371

# Drug_Target_6_PDB_ID:
1NWC

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF01118	Semialdhyde_dh
PF02774	Semialdhyde_dhC

# Drug_Target_6_Protein_Sequence:
>Aspartate-semialdehyde dehydrogenase
MKNVGFIGWRGMVGSVLMDRMSQENDFENLNPVFFTTSQAGQKAPVFGGKDAGDLKSAFD
IEELKKLDIIVTCQGGDYTNEVYPKLKATGWDGYWVDAASALRMKDDAIIVLDPVNQHVI
SEGLKKGIKTFVGGNCTVSLMLMAIGGLFEKDLVEWISVATYQAASGAGAKNMRELLSQM
GLLEQAVSSELKDPASSILDIERKVTAKMRADNFPTDNFGAALGGSLIPWIDKLLPETGQ
TKEEWKGYAETNKILGLSDNPIPVDGLCVRIGALRCHSQAFTIKLKKDLPLEEIEQIIAS
HNEWVKVIPNDKEITLRELTPAKVTGTLSVPVGRLRKLAMGPEYLAAFTVGDQLLWGAAE
PVRRILKQLVA

# Drug_Target_6_Reaction:
L-aspartate 4-semialdehyde + phosphate + NADP+ = L-4-aspartyl phosphate + NADPH + H+

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
L-aspartate 4-semialdehyde + phosphate + NADP(+) = L-4-aspartyl phosphate + NADPH

# Drug_Target_6_SwissProt_ID:
P44801

# Drug_Target_6_SwissProt_Name:
DHAS_HAEIN

# Drug_Target_6_Synonyms:
ASA dehydrogenase
ASADH
EC 1.2.1.11

# Drug_Target_6_Theoretical_pI:
5.33

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
U93405

# Drug_Target_7_GenBank_ID_Protein:
2584857

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
fadH

# Drug_Target_7_Gene_Sequence:
>2019 bp
ATGAGCTACCCGTCGCTGTTCGCCCCGCTGGATTTAGGTTTTACCACGTTAAAAAACCGC
GTGTTGATGGGCTCAATGCACACCGGGCTGGAGGAATACCCGGACGGTGCCGAGCGGCTG
GCAGCGTTTTATGCCGAACGCGCCCGTCACGGCGTGGCGCTGATTGTCAGCGGCGGCATT
GCACCAGATTTAACAGGCGTTGGCATGGAAGGTGGCGCAATGCTCAACGACGCCAGCCAG
ATCCCACACCATCGCACCATTACCGAAGCGGTACATCAGGAAGGCGGCAAAATAGCCCTG
CAAATTTTGCATACCGGGCGCTACAGCTACCAACCGCATCTGGTCGCCCCGTCCGCATTG
CAGGCCCCCATCAACCGTTTCGTGCCCCATGAGTTAAGCCATGAAGAGATCCTGCAACTG
ATCGACAATTTCGCCCGCTGCGCGCAACTGGCGCGGGAGGCAGGATACGACGGTGTAGAG
GTGATGGGTTCCGAAGGGTATTTGATCAACGAATTTCTGACGCTGCGCACCAATCAGCGT
AGTGACCAGTGGGGCGGCGATTACCGCAACCGGATGCGATTTGCCGTAGAAGTAGTGCGT
GCGGTGCGCGAACGCGTCGGCAACGACTTCATTATTATCTACCGACTGTCGATGCTCGAC
CTGGTCGAAGACGGCGGGACTTTTGCCGAAACGGTAGAGCTGGCGCAGGCCATTGAAGCG
GCGGGCGCGACCATTATCAACACCGGCATTGGCTGGCATGAAGCACGTATTCCGACCATT
GCCACGCCCGTGCCGCGCGGCGCATTTAGCTGGGTCACGCGCAAACTGAAAGGCCACGTC
TCGCTGCCGCTGGTAACCACCAACCGGATTAACGATCCGCAGGTTGCCGACGATATTCTC
TCGCGCGGCGATGCCGATATGGTATCGATGGCGCGACCGTTTCTTGCTGATGCGGAGCTG
CTGTCAAAAGCGCAATCGGGACGAGCCGATGAGATCAACACTTGTATTGGCTGCAATCAG
GCCTGTCTCGATCAAATCTTCGTTGGCAAAGTCACCTCGTGCCTGGTGAATCCTCGCGCC
TGCCACGAAACCAAAATGCCAATCCTTCCCGCCGTGCAGAAAAAAAATCTGGCGGTGGTC
GGTGCGGGACCTGCTGGGCTGGCGTTTGCCATTAACGCGGCGGCGCGTGGGCATCAGGTA
ACATTGTTTGACGCTCATAGCGAGATTGGCGGGCAGTTTAATATCGCCAAACAGATCCCC
GGCAAAGAGGAGTTTTACGAAACGCTGCGCTATTACCGCCGGATGATCGAAGTGACGGGC
GTGACGCTAAAACTCAATCACACCGTGACGGCGGATCAGTTACAGGCTTTCGATGAAACG
ATCCTCGCCAGTGGGATCGTGCCGCGCACTCCGCCCATCGACGGGATCGATCATCCGAAG
GTATTGAGTTATCTCGATGTACTGCGCGACAAAGCGCCGGTTGGCAACAAAGTTGCCATC
ATCGGTTGTGGCGGGATTGGTTTTGATACGGCGATGTATTTAAGTCAGCCGGGCGAATCC
ACCAGCCAGAATATCGCCGGGTTCTGTAATGAATGGGGGATCGACAGTAGCCTACAACAG
GCTGGTGGCTTAAGCCCGCAGGGAATGCAGATCCCCCGTAGCCCACGGCAGATTGTGATG
CTCCAGCGCAAAGCCAGCAAACCAGGACAGGGGTTAGGCAAAACCACCGGCTGGATCCAT
CGCACCACCCTGCTCTCGCGGGGTGTGAAAATGATCCCAGGCGTAAGTTATCAGAAGATT
GACGATGACGGGCTGCATGTGGTGATCAACGGCGAAACGCAGGTATTAGCAGTGGACAAT
GTGGTGATCTGCGCAGGGCAAGAGCCAAACCGCGCGCTGGCGCAACCGCTGATTGATAGC
GGGAAAACGGTGCATTTAATTGGCGGCTGCGATGTGGCTATGGAGCTGGACGCACGACGG
GCAATTGCCCAGGGAACACGGCTGGCGCTGGAGATTTAA

# Drug_Target_7_General_Function:
Energy production and conversion

# Drug_Target_7_General_References:
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9346310	He XY, Yang SY, Schulz H: Cloning and expression of the fadH gene and characterization of the gene product 2,4-dienoyl coenzyme A reductase from Escherichia coli. Eur J Biochem. 1997 Sep 1;248(2):516-20.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
3573

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
72679

# Drug_Target_7_Name:
2,4-dienoyl-CoA reductase [NADPH]

# Drug_Target_7_Number_of_Residues:
672

# Drug_Target_7_PDB_ID:
1PS9

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00070	Pyr_redox
PF00724	Oxidored_FMN
PF07992	Pyr_redox_2

# Drug_Target_7_Protein_Sequence:
>2,4-dienoyl-CoA reductase [NADPH]
MSYPSLFAPLDLGFTTLKNRVLMGSMHTGLEEYPDGAERLAAFYAERARHGVALIVSGGI
APDLTGVGMEGGAMLNDASQIPHHRTITEAVHQEGGKIALQILHTGRYSYQPHLVAPSAL
QAPINRFVPHELSHEEILQLIDNFARCAQLAREAGYDGVEVMGSEGYLINEFLTLRTNQR
SDQWGGDYRNRMRFAVEVVRAVRERVGNDFIIIYRLSMLDLVEDGGTFAETVELAQAIEA
AGATIINTGIGWHEARIPTIATPVPRGAFSWVTRKLKGHVSLPLVTTNRINDPQVADDIL
SRGDADMVSMARPFLADAELLSKAQSGRADEINTCIGCNQACLDQIFVGKVTSCLVNPRA
CHETKMPILPAVQKKNLAVVGAGPAGLAFAINAAARGHQVTLFDAHSEIGGQFNIAKQIP
GKEEFYETLRYYRRMIEVTGVTLKLNHTVTADQLQAFDETILASGIVPRTPPIDGIDHPK
VLSYLDVLRDKAPVGNKVAIIGCGGIGFDTAMYLSQPGESTSQNIAGFCNEWGIDSSLQQ
AGGLSPQGMQIPRSPRQIVMLQRKASKPGQGLGKTTGWIHRTTLLSRGVKMIPGVSYQKI
DDDGLHVVINGETQVLAVDNVVICAGQEPNRALAQPLIDSGKTVHLIGGCDVAMELDARR
AIAQGTRLALEI

# Drug_Target_7_Reaction:
trans-2,3-didehydroacyl-CoA + NADP+ = trans,trans-2,3,4,5-tetradehydroacyl-CoA + NADPH + H+

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Catalyzes the NADP-dependent reduction of 2,4-dienoyl- CoA to yield trans-2- enoyl-CoA

# Drug_Target_7_SwissProt_ID:
P42593

# Drug_Target_7_SwissProt_Name:
FADH_ECOLI

# Drug_Target_7_Synonyms:
2,4-dienoyl coenzyme A reductase
EC 1.3.1.34

# Drug_Target_7_Theoretical_pI:
6.55

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cytoplasm

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
ME1

# Drug_Target_8_GenBank_ID_Gene:
X77244

# Drug_Target_8_GenBank_ID_Protein:
495123

# Drug_Target_8_GeneCard_ID:
ME1

# Drug_Target_8_Gene_Name:
ME1

# Drug_Target_8_Gene_Sequence:
>1719 bp
ATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACCTGCTGACACGG
AACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAGACAGCAATTGAACATT
CATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTTCTTAGAGTAGTAAAA
AATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCTTAATGGATCTCCAAGAT
AGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACATTGAGAAATTCATGCCTATT
GTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATATAGTTTGGTGTTTCGGAAGCCA
AGAGGTCTCTTTATTACTATCCACGATCGAGGGCATATTGCTTCAGTTCTCAATGCATGG
CCAGAAGATGTCATCAAGGCCATTGTGGTGACTGATGGAGAGCGTATTCTTGGCTTGGGA
GACCTTGGCTGTAATGGAATGGGCATCCCTGTGGGTAAATTGGCTCTATATACAGCTTGC
GGAGGGATGAATCCTCAAGAATGTCTGCCTGTCATTCTGGATGTGGGAACCGAAAATGAG
GAGTTACTTAAAGATCCACTCTACATTGGACTACGGCAGAGAAGAGTAAGAGGTTCTGAA
TATGATGATTTTTTGGACGAATTCATGGAGGCAGTTTCTTCCAAGTATGGCATGAATTGC
CTTATTCAGTTTGAAGATTTTGCCAATGTGAATGCATTTCGTCTCCTGAACAAGTATCGA
AACCAGTATTGCACATTCAATGATGATATTCAAGGAACAGCATCTGTTGCAGTTGCAGGT
CTCCTTGCAGCTCTTCGAATAACCAAGAACAAACTGTCTGATCAAACAATACTATTCCAA
GGAGCTGGAGAGGCTGCCCTAGGGATTGCACACCTGATTGTGATGGCCTTGGAAAAAGAA
GGTTTACCAAAAGAGAAAGCCATCAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATA
GTTAAGGGACGTGCTTCCTTAACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAA
ATGAAGAACCTAGAAGCCATTGTTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCT
GCAATTGGTGGTGCATTCTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGG
CCTATTATTTTTGCTTTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGC
TACAAAATAACCAAGGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACT
CTTCCAAATGGACAGACCCTATATCCTGGCCAAGGCAACAATTCCTACGTGTTCCCTGGA
GTTGCTCTTGGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACT
ACTGCTGAGGTTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTAT
CCTCCTTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAAGAT
GCATACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCATTTGTC
CGCTCCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTCTTGGCCT
GAAGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAG

# Drug_Target_8_General_Function:
Energy production and conversion

# Drug_Target_8_General_References:
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
7622060	Gonzalez-Manchon C, Ferrer M, Ayuso MS, Parrilla R: Cloning, sequencing and functional expression of a cDNA encoding a NADP-dependent malic enzyme from human liver. Gene. 1995 Jul 4;159(2):255-60.
8187880	Loeber G, Dworkin MB, Infante A, Ahorn H: Characterization of cytosolic malic enzyme in human tumor cells. FEBS Lett. 1994 May 16;344(2-3):181-6.
8804575	Chou WY, Huang SM, Chang GG: Nonidentity of the cDNA sequence of human breast cancer cell malic enzyme to that from the normal human cell. J Protein Chem. 1996 Apr;15(3):273-9.

# Drug_Target_8_HGNC_ID:
HGNC:6983

# Drug_Target_8_HPRD_ID:
01102

# Drug_Target_8_ID:
666

# Drug_Target_8_Locus:
6q12

# Drug_Target_8_Molecular_Weight:
64150

# Drug_Target_8_Name:
NADP-dependent malic enzyme

# Drug_Target_8_Number_of_Residues:
572

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00390	malic
PF03949	Malic_M

# Drug_Target_8_Protein_Sequence:
>NADP-dependent malic enzyme
MEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLRVVK
NFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSLVFRKP
RGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGIPVGKLALYTAC
GGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEAVSSKYGMNC
LIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITKNKLSDQTILFQ
GAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASLTQEKEKFAHEHEE
MKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIFALSNPTSKAECSAEQC
YKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGVALGVVACGLRQITDNIFLT
TAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVKDAYQEKTATVYPEPQNKEAFV
RSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ

# Drug_Target_8_Reaction:
(S)-malate + NADP+ = pyruvate + CO2 + NADPH

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
P48163

# Drug_Target_8_SwissProt_Name:
MAOX_HUMAN

# Drug_Target_8_Synonyms:
EC 1.1.1.40
Malic enzyme 1
NADP-ME

# Drug_Target_8_Theoretical_pI:
6.01

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cell inner membrane
multi-pass membrane protein

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
U01158

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
pntB

# Drug_Target_9_Gene_Sequence:
Not Available

# Drug_Target_9_General_Function:
Energy production and conversion

# Drug_Target_9_General_References:
11004437	Jeeves M, Smith KJ, Quirk PG, Cotton NP, Jackson JB: Solution structure of the NADP(H)-binding component (dIII) of proton-translocating transhydrogenase from Rhodospirillum rubrum. Biochim Biophys Acta. 2000 Aug 15;1459(2-3):248-57.
11250201	Cotton NP, White SA, Peake SJ, McSweeney S, Jackson JB: The crystal structure of an asymmetric complex of the two nucleotide binding components of proton-translocating transhydrogenase. Structure. 2001 Feb 7;9(2):165-76.
7844118	Yamaguchi M, Hatefi Y: Energy-transducing nicotinamide nucleotide transhydrogenase: nucleotide sequences of the genes and predicted amino acid sequences of the subunits of the enzyme from Rhodospirillum rubrum. J Bioenerg Biomembr. 1994 Aug;26(4):435-45.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
3778

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
47809

# Drug_Target_9_Name:
NAD(P) transhydrogenase subunit beta

# Drug_Target_9_Number_of_Residues:
464

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF02233	PNTB

# Drug_Target_9_Protein_Sequence:
>NAD(P) transhydrogenase subunit beta
MTHSLTMAAYIVAGVLFILALRGLSNPESARNGNRMGMVGMAIAILTTLLSPSVQAYAWI
VLAIAIGGAIGTVIAKKVLMTALPQLVAAFHSLVGMAAVLVATGALLNPEAYGIGSAGAI
HAGSLVEMSLGLAVGAITFSGSVIAFGKLQGLIAGKPVTFPMQHPLNAVLGILLVVLLVV
FAATESHTAYFALMILAFALGFLLIIPIGGADMPVVISMLNSYSGWAAAGIGFTLGNPLL
IIAGALVGSSGAILSYIMCKGMNRSIFNVILGGFGSEGGVAAAGGAAGDRSVKAGSAEDA
AFIMKNASKVIIVPGYGMAVAQAQHALREMADVLKKEGVEVSYAIHPVAGRMPGHMNVLL
AEANVPYDEVFELEEINSSFQTADVAFVIGANDVTNPAAKTDPSSPIYGMPILDVEKAGT
VLFIKRSMASGYAGVENELFFRNNTMMLFGDAKKMTEQIVQAMN

# Drug_Target_9_Reaction:
NADPH + NAD+ = NADP+ + NADH

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane

# Drug_Target_9_SwissProt_ID:
P0C188

# Drug_Target_9_SwissProt_Name:
PNTB_RHORU

# Drug_Target_9_Synonyms:
EC 1.6.1.2
Nicotinamide nucleotide transhydrogenase subunit beta
Proton-translocating transhydrogenase NADP(H-binding component
Pyridine nucleotide transhydrogenase subunit beta
dIII

# Drug_Target_9_Theoretical_pI:
6.52

# Drug_Target_9_Transmembrane_Regions:
54-74
86-106
126-146
164-184
191-211
227-247

#END_DRUGCARD DB03461
